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ABSTRACT 
 Bladder cancer, the most common urinary tract malignancy, has environmental 
toxicant exposure as one of its biggest risk factors. This lab examines potential 
biomarkers employing an in vitro model of urothelial carcinoma using a normal bladder 
cell line and its malignantly transformed cells transformed counterpart, transformed by 
exposure to long term, low doses of cadmium (Cd2+). Initial microarray analysis 
determined that Secreted Protein Acidic and Rich in Cysteine (SPARC) was the most 
repressed gene across all transformed cell lines compared to its normal counterpart 
(Garrett et al., 2014, Larson et al., 2010).  
SPARC, an extracellular matrix glycoprotein, functions by regulating cell-matrix 
interactions. It has both oncogene and tumor suppressor actions depending upon the 
cancer with its role in bladder carcinoma remaining unclear. Previous lab results 
identified three key findings regarding the role of SPARC: 1) SPARC was significantly 
repressed following short term, low dose cadmium exposure; 2) SPARC is expressed at 
moderate levels in the normal transitional epithelium, however, in urothelial carcinomas, 
SPARC expression is drastically repressed; and 3) when SPARC was transfected into 
Cd2+ transformed cells with expression being ‘forced’ via a CMV promoter, 
heterotransplant tumors again had very little, if any, SPARC expression (Larson et al., 
2010; Slusser et al., 2016). 
The current study is based on 3 overarching hypotheses: 1) SPARC plays a 
critical role in urothelial cell proliferation, migration, attachment, and spreading; 2)
 xviii 
 
Cadmium transformation significantly decreases SPARC expression by silencing the 
promoter early in the malignant transformation process; and 3) that in urothelial tumors 
generated from Cd2+-transformed cell lines, SPARC is prohibitive to tumor initiation. 
The results of this study advance the understanding of SPARC in transformed 
cells by showing that SPARC promotes cell spreading which may be inhibitory to tumor 
initiation, necessitating its repression; preferential transcription factor binding of SOX5 
compared to Sp1/Sp3 contributing to SPARC repression; and that in serial 
heterotransplant tumors, repression of human tumor SPARC continues along with an 
increase in mouse stromal SPARC. Overall, the conclusion from this research is that 
SPARC acts as a tumor suppressor in the UROtsa model system requiring repression for 
malignant transformation and tumor initiation.
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CHAPTER I 
INTRODUCTION 
The bladder is an organ located in the bowl of the pelvis and is part of the urinary 
tract. The urinary tract is comprised of the kidneys, ureters, bladder, and urethra. The 
kidneys function to filter waste products from cellular processes into urine that then 
travels down to the bladder through the ureters. The bladder is a muscular organ that 
distends acting as a reservoir for urine, and contracts to expel the urine out through the 
urethra. 
Histologically, the urinary tract, from the renal pelvis of the bladder to the 
proximal urethra, is lined with transitional epithelium, called urothelium. The urothelium 
contains umbrella-like cells on the apical surface that are in direct contact with the urine 
(Anderson, 2018; Pawlina, 2016). They are flexible cells that flatten when the bladder 
distends in order to keep the epithelial barrier intact and maintain separation between the 
urine and vulnerable underlying tissue. The urothelial plaques and hinges help to make 
the urothelium on of the most flexible and impermeable membranes in the human body 
(Wu et al., 2009, Negrete et al., 1996). Urothelial plaques are aggregates of uroplakin 
proteins interrupted by small plasma membrane hinge regions that cover nearly 90% of 
the apical surface of the urothelium (Lewis, 2000, Wu et al., 2009). The N-terminal 
luminal regions of the uroplakin proteins are heavily glycosylated creating a “sticky” 
glycocalyx that is important for the physical and chemical barrier between concentrated 
waste products and the underlying tissue (Kątnik-Prastowska et al., 2014). The lamina 
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propria is the layer of connective tissue situated below the epithelial layer and superficial 
to the muscularis layer. This layer contains necessary immune cells and the vasculature 
that supplies the superficial epithelial layer with important nutrients. The muscle of the 
bladder is termed the Detrusor muscle and is comprised of three alternating layers of 
muscle. This layering of muscle increases the contractile strength of the bladder to 
adequately expel urine. The outer most surface of the bladder is surrounded by a 
connective tissue capsule that helps to preserve the integrity of the layers of the bladder 
and protect it from physical injury. Figure I-1 depicts the thickness of the bladder at the 
cellular and molecular level emphasizing the importance of isolating the waste products 
from the rest of the body and properly expelling the toxic waste. 
 
Figure I-1. Histology of the Urinary Bladder. Histological layers of the bladder 
illustrating: the transitional epithelia, lamina propria (LP), thick Detrusor muscle, and 
 3 
 
adventia. (A) 1x overview of the bladder, (B) 20x magnification of transitional 
epithelium (TE) and lamina propria, (C) 5x magnification of Detrusor muscle, (D) 5x 
magnification of outer muscle layer, and adventitia (AD). [UND SMHS Virtual Slide 
Collection] 
 
The bladder, like the majority of organs in the body, is not immune to the 
devastating disease of cancer. Bladder cancer is the most commonly diagnosed cancer of 
the urinary tract (Anderson, 2018). It is diagnosed in approximately 400,000 new patients 
each year around the world making it one of the most prevalent types of cancer (Inamura, 
2018). In 2019 it is estimated that over 80,000 new cases of bladder cancer will be 
diagnosed in the United States with over 17,000 patients succumbing to this disease. Men 
are approximately three to four times more likely to be diagnosed with bladder cancer 
than are women (ACS Facts and Figures 2019). However, women are older, on average, 
at the time of diagnosis, present in the clinic with more advanced disease, and tend to 
have a poorer survival rate than men (Anderson, 2018). It is the most expensive cancer to 
treat per patient lifetime due to a high rate of recurrence that requires long-term treatment 
and monitoring (Kaffenberger et al., 2018, Jung et al., 2018). 
There are multiple types of bladder cancer with urothelial carcinoma or 
transitional cell carcinoma being the most common type, affecting the transitional 
epithelial layer of cells in direct contact with the urine (Jacobs et al., 2010, Kamat et al. 
2016). Like other cancers, the specific type of bladder cancer determines the form of 
treatment needed to manage the disease as best as possible (Kamat et al., 2016). 75% of 
bladder cancer diagnoses are urothelial carcinomas which are non-muscle invasive 
tumors (Kamat et al., 2016, Kaffenberger et al., 2018). The majority of the non-muscle 
invasive bladder cancers (NMIBC) are low-grade papillary tumors that do not have a 
high rate of progression (10-30%) but they have an alarmingly high rate of recurrence at 
 4 
 
50-70% (Kamat et al, 2016, Anderson, 2018, Inamura, 2018). The low- and intermediate-
risk papillary NMIBC tumor type protrudes into the lumen of the bladder compared to the 
high-risk NMIBC carcinoma in situ (CIS) that is flat within the urothelium as seen in 
Figure I-2. CIS is considered high-risk because it has been shown to progress to muscle-
invasive bladder cancer (MIBC) in many cases (Barth et al., 2018). MIBCs progressively 
invade through the thick Detrusor muscle and into adjacent organs as well as the 
peritoneal cavity, ultimately increasing the chances of metastasis (Knowles and Hurst, 
2015). 
 
Figure I-2. Urothelial Tumor Progression. Urothelial tumor progression from 
carcinoma in situ to T4 metastatic tumor and associated grading represented by the 1973 
WHO grading system as well as the updated 2004 WHO/ISUP system. [Reprinted from 
Knowles and Hurst, 2015, with © permission from Springer Nature Publishing] 
 
The most common and most correlated symptom of bladder cancer that presents 
in the clinic is haematuria which warrants further diagnostic testing (Kamat et al., 2016). 
In these patients, various forms of imaging are used to evaluate the urinary tract. The 
upper urinary tract is examined using computed tomography (CT) urography and the 
lower urinary tract is examined using cystoscopy (Kamat et al., 2016). CIS is inherently 
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difficult to detect via cystoscopy because it is flat and incorporated into the urothelium 
presenting a disadvantage to this imaging technique (Jacobs et al., 2010). 
Once diagnosed, the standard of care is to remove the tumor via TransUrethral 
Resection of the Bladder Tumor (TURBT) (Kamat et al, 2016, Anderson, 2018, 
Kaffenberger et al., 2018). However, there are issues that arise from this procedure 
including increased recurrence rates, in part, due to tumor cells breaking off during 
resection increasing the possibility of cells implanting elsewhere in the bladder and 
establishing a potential recurrence site (Anderson, 2018). 
Currently, intravesical chemotherapy or immunotherapy treatments are in place to 
help reduce recurrence attributed to TURBT to slightly less than 40% (Kaffenberger et 
al., 2018). For low- and intermediate-risk non-muscle invasive bladder carcinomas it is 
recommended to administer a chemotherapeutic agent, most commonly mitomycin-C, 
directly into the bladder immediately following a TURBT procedure. This treatment 
appears more beneficial for intermediate-risk NMIBC patients when administering 
follow-up maintenance doses for one year (Kamat et al., 2016). Although proven 
efficacious, treatment of bladder cancer with mitomycin-C has been slow to be 
incorporated into the clinic due to its expense, its availability, and most importantly, its 
potential toxicity (Kaffenberger et al., 2018). High-risk non-muscle invasive bladder 
cancer has been shown to respond better to intravesical immunotherapy compared to 
chemotherapy. Most commonly, Bacillus Calmete-Guerin (BCG) is used in these cases 
(Kamat et al., 2016). It is a live strain of mycobacterium that recruits and activates the 
patient’s own immune cells to attack the tumor (American Cancer Society, 2016, 
Anderson, 2018). As with chemotherapy treatment, BCG immunotherapy has been 
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shown to be most effective when followed up with maintenance treatment for one to three 
years (Kamat et al., 2016, Anderson, 2018). Due to the high recurrence rate of bladder 
tumors, surveillance cystoscopy is recommended four times per year for one to two years 
followed by annual scans (Jacobs et al., 2010). Although the majority of bladder cancer 
diagnoses will not progress to muscle-invasive bladder cancers, studies show that 
repeated scans, procedures, and treatments have a substantial impact on patient quality of 
life (Jung et al., 2018). This illustrates the desperate need for a therapeutic target to help 
decrease the high recurrence rate and increase patient quality of life. 
Biomarkers are researched and used for many conditions and diseases, including 
cancer. Generally, a biomarker is defined as a substance that is measureable and able to 
be used to indicate normal function as well as the potential and/or presence of disease 
(Strimbu and Tavel, 2010). There are numerous categories of biomarkers utilized by 
researchers and clinicians to further understand: disease risk, prediction, diagnosis, 
treatment, and even safety of a medical therapeutic or environmental agent (FDA-NIH, 
2016, Mayeux, 2004). Traditionally, clinical condition or disease has allowed researchers 
to better identify a key missing or over-active component of a biological process, as well 
as the safety of a substance (Mayeux, 2004). Therefore, a majority of known biomarkers 
when absent or present, functional or non-functional can result/predict a range of 
abnormalities. These biomarkers can then be used to: implement preventative strategies 
to minimize disease, determine the best course of treatment, as well as create laws for 
public safety (FDA-NIH, 2016). Researchers are continually aimed at identifying and 
developing new therapeutic targets or biomarkers to advance medicine. However, a 
complicating factor emerges when a lab-based biomarker does not succeed in clinical 
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settings (Strimbu and Tavel, 2010). There is extensive and necessary testing to be done 
prior to a biomarker reaching the clinical setting to minimize failure and better predict 
success; but, the true potential therapeutic benefit can only be determined in the clinic 
(FDA-NIH, 2016). The ultimate end goal of biomedical research is to positively impact 
human health, making biomarker research important to the scientific community as well 
as the general public. 
Numerous cancer types have at least one biomarker associated with them; 
however, some are more well-known than others. BRCA 1/2 gene mutations can be used 
as susceptibility biomarkers to predict a patient’s risk of developing breast or ovarian 
cancer; which, can be followed by preventative intervention to reduce or minimize 
clinical outcome (FDA-NIH, 2016). Estrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor 2 (HER2) status can be used as predictive 
biomarkers to determine the best course of treatment for breast cancer patients (Clark et 
al., 2019). Many molecules have been studied as potential biomarkers for transitional cell 
carcinoma, including: p53 status, ERCC2 and other DNA damage response genes, 
programmed death ligand-1 (PD-L1), fibroblast growth factor receptor 3 (FGFR3), as 
well as alterations in epidermal growth factor receptor (EGFR) and human epidermal 
growth factor receptor 2 and 3 (HER2 and 3). Unfortunately, there remains to be a 
reliable biomarker utilized in the clinic for bladder cancer (Cheng and Iyer, 2018, 
Miremami and Kyprianou, 2014, Tabayoyong and Kamat, 2018). Invasive cystoscopy 
and non-invasive cytology are the recognized diagnosis tools for bladder cancer; 
however, both have limitations in regards to accurate visualization and sensitivity, 
respectively (Tabayoyong and Kamat, 2018). The FDA has approved a select few 
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markers to be used in conjunction with, not in place of, cystoscopy and cytology due to 
lower sensitivity (Tabayoyong and Kamat, 2018). However, there are no biomarkers 
approved for standard of care guided urinary bladder cancer treatment (Cheng and Iyer, 
2018). Therefore, there is a desperate need for bladder cancer biomarkers to decrease 
recurrence rates and increase patient quality of life by providing less invasive long-term 
monitoring. 
Bladder cancer has a number of known risk factors, including age and 
environmental exposure to toxicants (Anderson, 2018, Inamura, 2018, Kaffenberger, et 
al., 2018). It has a strong link to environmental toxicant exposure; in part, due to the body 
filtering toxicants into the urine that is then stored and concentrated in the bladder. 
Toxicant exposure has also been proposed to address the increased frequency of bladder 
cancer in men; stating that men held occupations in industrial settings and were more 
likely to smoke increasing exposure to toxicants (Dobruch et al., 2016, Kirkali et al., 
2005). Animal research by Reid et al. (1984), also suggests a role for sex-specific 
hormones in either promoting, or not inhibiting, oncogenesis (androgen), and conversely, 
inhibiting, or not promoting, oncogenesis (estrogen) (Dobruch et al., 2016, Kirkali et al., 
2005). However, this does not fully address the disparity between men and women in 
regards to bladder cancer and should be further researched.  
A particular environmental toxicant studied in our lab is cadmium. Cadmium is a 
heavy metal element that is naturally occurring in the Earth’s crust (Bernhoft, 2013). In 
the periodic table it falls near zinc (Zn) and mercury (Hg) and takes on chemical 
similarities to zinc (Bernhoft, 2013). Humans can be exposed to cadmium through a 
variety of different mechanisms. Non-smokers are mainly exposed to cadmium through 
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ingestion of contaminated food and water, either naturally from the soil or from industrial 
pollutants; and, inhalation of cigarette smoke is the major source of cadmium exposure in 
smokers (Bernhoft, 2013, Bertin and Averbeck, 2006, Rani et al., 2014, Satarug et al., 
2010). Although it exists in the Earth’s crust at low levels of 0.1 ppm, certain areas can 
have higher concentrations of cadmium in the soil (Bernhoft, 2013). This becomes 
important when the areas containing higher levels of cadmium are agricultural farmlands 
in the upper Midwest that can be further contaminated with cadmium from fertilizers 
(Page et al., 1987, Vacchi-Suzzi et al., 2016). Cadmium can be readily taken up and 
bioaccumulated by plants and subsequently ingested as food or inhaled as tobacco smoke 
leading to human exposure of higher concentrations of cadmium (Bernhoft, 2013, Rani et 
al., 2014).  
Higher concentrations of cadmium exposure are concerning because of its 
extremely long biological half-life of greater than 20 years; as well as, its deposition and 
accumulation within tissues of the body (Bernhoft, 2013, Rani et al., 2014). Cadmium has 
been studied for its ability to cause or contribute to various diseases as early as the late 
1800’s and early 1900’s (Nordberg, 2009, Rani et al., 2014). Most notably, 
environmental contamination of cadmium was described to be a major contributing factor 
to Itai-Itai disease, or ouch-ouch disease, that affected Japanese people (Bernhoft, 2013, 
Nordberg et al., 2009, Rani et al., 2014). The rice fields irrigated using the Jinzu River 
became contaminated when cadmium was released from a mine into the river (Nordberg 
et al., 2009). Following this described strong link between environmental cadmium 
exposure and disease, cadmium became a main area of research resulting in its 
classification as a priority pollutant by the Environmental Protection Agency (EPA) and 
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Type I human carcinogen by the International Agency for Cancer Research (IARC) (Rani 
et al., 2014, Waisberg et al., 2003, EPA, 2014, IARC, 1993). 
Cadmium can enter cells and various tissues using different mechanisms and 
ultimately elicit an adverse effect on multiple cellular processes. Several studies have 
shown that the main organs for deposition and potential subsequent toxicity are the liver 
and kidney in part due to metallothionein synthesis in these tissues (Bernard, 2008, 
Bernhoft, 2013, Rani et al., 2014, Yang and Shu, 2015). Under normal conditions, 
mechanisms are in place to mediate the toxic effect of metals by binding to the metal and 
reducing the reactivity of free cadmium. Following exposure, cadmium in the circulation 
is bound by albumin and readily endocytosed into hepatocytes, inducing metallothionein 
expression and production (Yang and Shu, 2015). Metallothioneins are small proteins 
with high affinity for metal ions resulting in sequestration of cadmium and other 
potentially toxic metals (Nordberg, 2009, Waisberg et al., 2003, Yang and Shu, 2015). 
This small metallothionein-cadmium complex is then released back into the circulation to 
the kidney where it is readily filtered through the glomerulus and endocytosed into the 
proximal tubule (Yang and Shu, 2015). The complex is quickly dissociated and the free 
cadmium induces metallothionein expression within renal cells and is taken up to reduce 
toxicity (Waisberg et al., 2003, Yang and Shu, 2015). However, cadmium deposition has 
been shown to be cumulative, resulting in high concentrations of cadmium and a 
saturation of metallothionein-cadmium complex formation leading to potential toxicity 
from reactive cadmium (Bernard, 2008, Waisberg et al., 2003, Yang and Shu, 2015). 
There are other transport mechanisms cadmium has been shown to utilize to gain 
entry into the cell; however, these are mainly in vitro studies and are not as fully 
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understood. All of the transport mechanisms hypothesize the use of mimicry by cadmium 
to take the place of a similar molecule, as cadmium has no known benefit within human 
cells (Zalups and Ahmad, 2003). Cadmium has been described to utilize: zinc 
transporters (ZIP8 and ZIP14) and calcium transient receptor potential channels (TRP) 
competing with zinc and calcium, respectively, for binding, organic-anion, -cation, and 
amino acid transporters shielded by thiol-containing molecules; as well as, divalent metal 
transporters and metal transport proteins (Zalups and Ahmad, 2003, Yang and Shu, 
2015). Figure I-3 illustrates potential cadmium transport mechanisms into the cell. As 
with metallothionein sequestration, these transport mechanisms can also contribute to 
cadmium accumulation within the cell and subsequent potential toxicity. 
 
Figure I-3. Cadmium Cellular Transport. Proposed receptors and transporters utilized 
by cadmium (Cd2+) to gain entry into the cell. Also illustrates the flow of cadmium from 
the circulation to the liver, leaving the liver, re-entering the circulation and being filtered 
through the glomerulus, ultimately being endocytosed and accumulating in the kidney 
tubules. P-glycoprotein (P-gp) has been shown to aid in cellular excretion of cadmium 
and multidrug and toxin extrusion proteins (MATE) have been proposed to aid in this 
process as well. Metallothionein (MT), L-Cysteine (Cys), Glutathione (GSH), Zinc/iron-
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regulated transporter (ZIP), Divalent metal-ion transporter (DMT), Organic cation 
transporter (OCT), Voltage-dependent calcium channel (VDCC), Transient receptor 
potential vanilloid (TRVP), Proximal tubular cells segment 1, 2, or 3 (PT S1, S2, S3), 
Distal convoluted tubular cells (DCT), Connected tubular cells (CT). [with © permission 
under Creative Commons Attribution License from Yang and Shu, 2015] 
 
 Free cadmium within the cell can have severely detrimental effects on numerous 
cellular processes including: proliferation, DNA replication and repair, cell cycle 
progression, and has been shown to induce malignant transformation of different cell 
types (Bertin and Averbeck, 2006, Chen and Costa, 2017, Luevano and Damodaran, 
2014, Sens et al., 2004). Several studies have investigated potential mechanisms behind 
cadmium’s negative effect on the cells, showing that cadmium can directly mimic similar 
metals resulting in protein distortion and inhibited function; and, that cadmium indirectly 
causes genomic instability via oxidative stress (Bertin and Averbeck, 2006, Rani et al., 
2014, Waisberg et al., 2003) Cadmium’s high affinity for thiol groups such as those in 
cysteine residues result in cadmium’s ability to replace zinc in zinc-finger motifs 
rendering the protein inactive (Bertin and Averbeck, 2006). Although cadmium itself 
cannot elicit oxidative stress in the cell, its presence decreases availability of detoxifying 
enzymes such as glutathione and indirectly generates several types of reactive oxygen 
species (ROS) (Rani et al., 2014). This results in oxidative stress in the form of lipid 
peroxidation, DNA damage, chromosomal abnormalities, and potentially carcinogenesis 
(Bertin and Averbeck, 2006, Luevano and Damodaran, 2014, Rani et al., 2014). 
Oxidative stress may play a central role; however, it most probably is a complex, 
combinatorial effect of multiple mechanisms resulting in cadmium toxicity. Prolonged 
exposure to oxidative stress, such as chronic cadmium exposure, can lead to cell 
adaptation and redox homeostasis shift along with priming the activation of signaling 
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molecules important for redox reactions (Luevano and Damodaran, 2014). Making cells 
more sensitive to stress could potentially abnormally initiate signaling pathways and 
ultimately promote carcinogenesis. Interestingly, cadmium has been associated with 
multiple types of cancers (Bertin and Averbeck, 2006, Luevano and Damodaran, 2014, 
Waisberg et al., 2003). 
 The majority of cadmium is retained in the cells of the body. As mentioned 
earlier, the liver and kidney have been shown to have the highest cadmium accumulation 
(Bernard, 2008, Bernhoft, 2013, Rani et al., 2014, Yang and Shu, 2015). However, when 
cadmium is excreted, it is in small amounts in the urine relative to the total cadmium in 
the body (Vacchi-Suzzi et al., 2016). Excreted cadmium could potentially have negative 
effects on downstream organs, including the bladder. Studies have shown that even 
chronic small amounts of cadmium can result in adverse biological effects (Rani et al., 
2014). The bladder does express low levels of three functional isoform genes important 
for encoding metallothioneins 1 and 2 with two of the three showing upregulation in 
bladder cancers (Somji et al., 2001). ZIP8 has also been shown to be expressed on 
bladder and bladder cancer cells (Ajjimaporn et al., 2012). Ajjimaporn et al. (2012) also 
showed that ZIP8 could be internally localized near the nucleus of these cells. This, 
coupled with a strong association between environmental toxicant exposure and bladder 
cancer; as well as, numerous carcinogenesis research studies, support cadmium as a 
potential carcinogenic factor for transitional cell carcinoma of the bladder. 
 This lab exploits the strong link between environmental toxicant exposure, 
specifically cadmium, and bladder cancer to study potential biomarkers. This system uses 
urothelial cells from the lining of the ureter that were immortalized using the Simian 
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Virus-40 (SV-40) Large-T antigen (Petzoldt et al., 1994 and 1995). They maintain their 
normal morphology and basal epithelial cell characteristics as well as contact-inhibited 
growth when grown in serum containing media, and are non-tumorigenic (Sens et al., 
2004). They are known as UROtsa cells and represent an adequate in vitro system to 
study the human bladder (Rossi et al, 2001). 
 Malignant transformation of the UROtsa cells by exposure to cadmium took place 
over several weeks. The cells were exposed to 1µM cadmium and showed minimal signs 
of toxicity in the first 30 days of exposure (Sens et al., 2004). However, more than 95% 
cell death occurred between 30-48 days after showing short-term signs of toxicity in the 
preceding 96 hours (Sens et al., 2004). Exposure to cadmium was continued and multiple 
clones of proliferating cells were observed 15-30 days later (Sens et al., 2004). After 
several passages, again, 95% cell death was observed; however, this time, proliferating 
clones appeared and subsequent confluency quickly developed (Sens et al., 2004). Once 
it was determined there was no further toxicity after several subsequent passages, it 
appeared the cells had been transformed, showing: increased growth rates, colony 
formation in soft agar, and heterotransplant tumor formation in nude mice (Sens et al., 
2004). The heterotransplant tumors were similar to human transitional cell carcinoma 
tumors (Sens et al., 2004), providing further evidence as to cadmium’s carcinogenic 
potential as well as increasing the value of this model system. Further testing of these 
transformed cells showed increased resistance to cadmium-induced cell death compared 
to non-transformed UROtsa parent cells (Somji et al., 2006). 
Following the initial cadmium malignant transformation of UROtsa cells, Somji 
et al. (2010) wanted to determine if independent cadmium exposure resulted in 
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transformed cell lines with similar phenotypic characteristics. Another goal of the study 
was to address the disparity in the investigation of reproducible transformation of a cell 
line via exposure to a single environmental toxicant; thereby, further validating the model 
system (Somji et al., 2010). Eight identical UROtsa cell cultures were exposed to 1μM 
Cd2+ and the protocol from the initial transformation was followed (Somji et al., 2010). 
Results were similar to the initial transformation showing an initial round of cell death 
followed by regrowth in 6 of the 8 subcultures (Somji et al., 2010). These cells did not 
form colonies in soft agar; however, after a second round of cell death, the cultures 
reached confluency and did form colonies on soft agar (Somji et al., 2010). These 6 
subcultures were combined with the initial transformed cell line resulting in 7 
independent Cd2+-transformed cell lines to be studied for phenotypic characteristics 
(Somji et al., 2010). 
Doubling times were measured for the transformed cell lines to assess cell 
growth. Results showed decreased doubling times for 5 of the 7 transformed lines 
portraying increased growth rates compared to the non-transformed UROtsa parent cell 
line (Somji et al., 2010). A hallmark characteristic of a malignant cell is increased 
proliferation, which is observed in the majority of these cell lines providing evidence of 
malignant transformation. Additionally, light microscopy revealed similar epithelial 
morphology across all cell lines with continued contact-inhibited growth of the 
monolayers (Somji et al., 2010). Furthermore, subcutaneous injections of the transformed 
cell lines into nude athymic mice resulted in tumor formation in at least 2 of 5 mice for 
every cell line compared to no tumor formation after inoculation with non-transformed 
UROtsa parent cells (Somji et al., 2010). Overall histological analysis showed the 
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heterotransplants were similar to the initial transformation study and to human invasive 
transitional cell carcinoma (Somji et al., 2010). Subsequent characterization studies, 
using gene expression analysis, determined heterotransplant tumors generated from the 
transformed cell lines display more basal-like characteristics, similar to those observed in 
human muscle invasive urothelial carcinomas (Hoggarth et al., 2018). 
The ability of these cell lines to colonize organs within the peritoneal cavity was 
investigated to determine metastatic potential of these transformed cell lines. 
Intraperitoneal tumor formation results showed only 1 of the 7 transformed cell lines 
formed tumor nodules with no nodules seen in the non-transformed UROtsa parent 
inoculated mice (Somji et al., 2010). In the Cd #1 group that did form peritoneal tumors, 
4 of 6 mice had extensive tumor nodules on several organs throughout the peritoneum 
(Somji et al., 2010). Therefore, although all transformed cell lines developed 
subcutaneous tumors, variation was observed in the ability of the transformed cell lines to 
colonize organs within the peritoneal cavity (Somji et al., 2010). Overall, results from 
this study provided further evidence in support of cadmium’s potential as a transitional 
cell carcinoma carcinogen. Following establishment of this Cd2+transformed UROtsa 
model system, displaying minimal phenotypic variation, later studies used microarray 
analysis to determine a number of candidate genes to further investigate as potential 
biomarkers for transitional cell carcinoma (Garrett et al., 2014). 
 One gene of considerable interest was Secreted Protein Acidic and Rich in 
Cysteine (SPARC). It is a secreted matricellular glycoprotein acting in the extracellular 
matrix environment (Yan and Sage, 1999). Matricellular proteins are a family of proteins 
that were first studied in the mid-1990’s by Paul Bornstein, PhD and his lab at the 
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University of Washington (Murphy-Ullrich and Sage, 2014). He defined matricellular 
proteins as, “modular, extracellular proteins whose functions are achieved by binding to 
matrix proteins as well as to cell surface receptors, or to other molecules such as 
cytokines and proteases that interact, in turn, with the cell surface” (Bornstein, 1995). He 
went on to describe a non-structural role for matricellular proteins in the extracellular 
matrix as opposed to the structural roles described for: fibrillar collagens, laminin, 
fibronectin, and vitronectin (Bornstein, 1995, Chiodoni et al., 2010, Murphy-Ullrich and 
Sage, 2014, Yan and Sage, 1999). This seminal research has resulted in several 
subsequent studies, performed in multiple labs, leading to a family of matricellular 
proteins that has expanded from the original: SPARC, thrombospondin, and tenascin 
members. Currently, the matricellular family of proteins includes: SPARC, hevin 
(SPARC-like Protein 1), testicans (SPOCK) 1-3, follistatin-like protein 1 (fstl-1), and 
secreted modular calcium binding protein (SMOC) 1 and 2 (Bradshaw, 2012). 
Interestingly, SPARC is the most well-known and well-characterized matricellular 
protein, in part due to its relatively simple structure (Murphy-Ullrich and Sage, 2014, 
Yan and Sage, 1999).  
Most protein families are comprised of members with similar structure and 
somewhat similar function. Matricellular proteins are unique in that they are biologically 
non-homologous in structure; showing a high degree of structural divergence in the N-
terminal acidic domain (Bradshaw, 2012). However, each member retains a conserved 
EF-hand motif, important for calcium-binding protein activity (Bradshaw, 2012, Murphy-
Ullrich and Sage, 2014). Murphy-Ullrich and Sage (2014) reviewed the matricellular 
unifying characteristics, classifying them as secreted proteins, associated with, but not 
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necessarily part of, structural extracellular matrix. It was further stated that they display 
de-adhesive properties and are highly expressed during tissue remodeling events as well 
as mammalian and avian development. These proteins are highly expressed during 
development; however, in the adult, expression is much more regulated and limited to 
wound healing and tissue remodeling events (Chiodoni et al., 2010). 
Matricellular proteins are important for cell-matrix interactions, either directly or 
indirectly, leading to potential influence of multiple downstream signaling pathways 
responsible for: cell proliferation, adhesion and migration, survival, cell death, cell 
senescence and extracellular matrix deposition, among others (Chiodoni et al., 2010, 
Murphy-Ullrich and Sage, 2014). Potential influence of several signaling pathways 
requires heavy regulation to keep homeostatic biological processes functioning correctly. 
When these processes are needed, such as in wound healing, matricellular protein 
expression increases to aid in successful wound closure (Chiodoni et al., 2010). 
Interestingly, knockout of a matricellular protein in mice is not lethal; but rather, results 
in subtle phenotype changes, namely alterations in wound response, as observed with 
SPARC (Bornstein and Sage, 2002). Furthermore, the variation in the alteration of wound 
responses suggests diverse biological functions for this family of proteins (Kyriakides 
and Bornstein, 2003). Consequently, dysregulation of matricellular proteins has been 
described for several diseases, including cancer (Murphy-Ullrich and Sage, 2014). 
SPARC is a prototype matricellular protein and although it was not the first 
discovered, it is fairly well characterized, in part, due to its relatively simplistic structure 
as seen in Figure I-4 (Murphy-Ullrich and Sage, 2014, Yan and Sage, 1999). It is also 
known as osteonectin or basement membrane protein 40 (BM-40) (Bradshaw and Sage, 
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2001). Osteonectin was first described to be a bone-specific, 32kD protein that bound 
collagen, calcium, and hydroxyapatite, and was chemically distinct from other bone-
proteins, as well as immunologically different from serum proteins (Termine et al., 1981). 
Helene Sage, in Paul Bornstein’s, laboratory described a similar glycoprotein with a 
molecular weight of 43kD, due to carbohydrate addition, that was secreted from 
endothelial cells (Sage et al., 1984). In 1986, a glycoprotein termed SPARC was 
described to be “structurally and antigenically closely related to” the glycoprotein 
described by Sage et al. (1984) determined by amino acid sequence and structure 
homology (Mason et al., 1986). It was also determined that removal of the carbohydrate 
from SPARC resulted in migration of a 32kD molecular weight protein under non-
reducing conditions (Mason et al., 1986). Buttgereit et al. (1988) used partial sequence 
analysis, and determined a common identity between BM-40 and the newly described 
SPARC matricellular protein. Interestingly, BM-40 sequence had also been shown to 
have high homology to osteonectin (Buttgereit et al., 1988). It was concluded, in this 
publication, that SPARC, osteonectin, and BM-40 characterized the same protein 
(Buttgereit et al., 1988). 
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Figure I-4. SPARC Ribbon Structure and Proposed Cellular Functions. SPARC 
ribbon structure illustrating the three domains: Acidic, Follistatin-like, and Extracellular 
Ca2+-binding, along with the cellular functions that have been attributed to each domain. 
[Reprinted from Brekken, R. A., & Sage, E. H. (2001). SPARC, a matricellular protein: 
At the crossroads of cell-matrix communication. Matrix Biology, 19(8), 815-827, which 
was modified from Hohenester et al. (1997) and the Brookhaven Protein Database, with 
© permission from Elsevier] 
 
The human SPARC gene is located on chromosome 5q31-33 and contains 9 
coding exons (Brekken and Sage, 2001, UCSC Genome Browser [Kent et al., 2002]). The 
first exon remains untranslated and contains CCTG sequence repeats resulting in 
expression of a reporter gene while the 3’ untranslated region resides entirely in exon 10 
along with at least two functional polyadenylation sites (Lane and Sage, 1994). Synthesis 
of full length SPARC results in a protein that is 303 amino acids in length with the 
addition of the signaling sequence; which, is removed prior to secretion, resulting in a 
functional protein of 286 amino acids (Brekken and Sage, 2001, UCSC Genome Browser 
[Kent et al., 2002], Yan and Sage, 1999). SPARC shows a high degree of evolutionary 
conservation between species. Murine and human SPARC share 92% amino acid 
sequence homology, and bovine and human share 99% sequence homology (Brekken and 
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Sage, 2001). There are small differences; however, the substantial sequence homology 
observed indicates a necessary functional role for this protein for species to survive.  
SPARC protein has been described to have three functional domains including: 
the acidic N-terminal domain, a follistatin-like domain, and an extracellular Ca2+-binding 
C-terminal domain (Brekken and Sage, 2001, Clark and Sage, 2008). Proposed cellular 
functions have been described for each domain resulting in roles for SPARC in several 
biological processes such as: impeding cell adhesion, growth factor activity modulation, 
and inhibiting cell proliferation (Brekken and Sage, 2001). Several reviews summarize 
structure and proposed functions for each domain of the SPARC protein, in a succinct but 
descriptive manner, describing key findings that lead to the characterization of this 
protein (Brekken and Sage, 2001, Clark and Sage, 2008, Yan and Sage, 1999).  
The acidic N-terminal domain I, comprised of amino acids 1-52, has low calcium-
binding affinity and its structure is sensitive to Ca2+ changes in the environment (Brekken 
and Sage, 2001, Yan and Sage, 1999). Along with Ca2+-binding, it has also been 
proposed as the interaction site with hydroxyapatite as well as contributing to collagen 
binding (Romberg et al., 1985). The major immunological epitopes to the SPARC protein 
can be found in the N-terminal domain (Brekken and Sage, 2001, Yan and Sage, 1999). 
This, in combination with structural diversity among family members, results in little, if 
any, antibody cross-reactivity between family members (Yan and Sage, 1999). There are 
also differences between human and nematode SPARC within this domain. Nematode 
SPARC lacks exon 3; however, studies showed functional SPARC protein with no effect 
on Ca2+-binding nor collagen-binding due to the lack of exon 3 (Maurer et al., 1997, 
Schwarzbauer et al., 1994). An important post-translational modification affecting protein 
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function within this domain is disulfide crosslinking between SPARC and cysteine-rich 
proteins. For example, Aechlimann et al. (1995) described transglutaminase-mediated 
SPARC complexes in cartilage that were thought to contribute to extracellular matrix 
stability. Crosslinking with a variety of proteins in different tissues may support tissue-
specific roles for SPARC. Some of the roles that the N-terminal domain has been 
proposed to participate in are cell spreading inhibition and preventing chemotaxis 
(Hohenester et al., 1997, Lane and Sage, 1994). Mechanistically, SPARC may be directly 
sequestering growth factors and chemokines away from cell surface receptors; or, it may 
be participating by competitively binding or blocking interaction with cell surface 
receptors and subsequent signaling. 
The second domain of SPARC is the follistatin-like domain II, comprised of 
amino acids 53-137 (Yan and Sage, 1999). This is a cysteine-rich domain, containing 
disulfide bonds, and showing sequence and structure similar to follistatin (Patthy, 1991). 
One similarity within this domain is the potential for copper-binding. KGHK copper 
binding sites, at residues 119-122, have been proposed for SPARC in promoting cell 
proliferation and angiogenesis of endothelial cells (Funk and Sage, 1993, Lane et al., 
1994). This is thought to act through a bioactive peptide created by proteolysis of this 
cationic region (Funk and Sage, 1993). A peptide comprising amino acids 113-130 and 
containing the KGHK copper-binding site as well as part of the Kazal protease inhibitor-
like region stimulated endothelial cell proliferation and angiogenesis in vitro (Funk and 
Sage, 1993, Brekken and Sage, 2001). This study described a functional cell biological 
role for this region of the SPARC protein; although, the complete mechanism remains 
unknown. Another bioactive peptide comprised of amino acids 55-74 and containing a 
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portion of the EGF-like β hairpin, was found by Funk and Sage (1993) to bind copper 
with high affinity and inhibit endothelial cell proliferation but had no effect on 
angiogenesis. 
Additionally, the follistatin-like domain contains the single glycosylation site of 
the SPARC protein at asparagine (Asn)99 (Yan and Sage, 1999). In endothelial cells this 
has been shown to be an N-linked oligosaccharide; however, in bone SPARC is 
glycosylated with a high mannose-type oligosaccharide (Yan and Sage, 1999). This 
contributes to the molecular weight difference observed in SDS-PAGE analysis between 
endothelial cells (43kD) and bone (32kD). It has also been proposed to contribute to 
tissue-specific SPARC protein function as well as collagen binding specificity (Kelm and 
Mann, 1991). Overall, the follistatin-like domain contains binding motifs for a variety of 
molecules, as well as post-translational modifications, important for SPARC function 
(Yan and Sage, 1999). 
The final domain of the SPARC protein is the extracellular calcium binding 
domain III, comprised of amino acids 138-286 (Yan and Sage, 1999). It is largely 
composed of an α-helical structure with a canonical pair of EF-hands showing high 
affinity for calcium (Hohenester et al., 1996). This domain was originally defined as two 
separate domains; however, Pottgiesser et al. (1994) determined it to be a single domain 
with propensity for both extracellular calcium and collagen binding. Maurer et al. (1995) 
and (1997) determined that SPARC binds to basement membrane associated collagen IV 
with moderate affinity, as well as fibrillar collagens. It was discovered that interaction 
with the follistatin-like domain II stabilizes calcium-binding to domain III (Hohenester et 
al., 1997). It was also shown that SPARC binding to fibrillar collagens I, III, and VI and 
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basement membrane associated collagen IV is a Ca2+dependent event (Sasaki et al., 
1998). Crystal structure and site-directed mutagenesis studies determined the residues 
necessary for collagen binding and found that proteolytic cleavage at lysine (Lys)197 and 
Lys198 increased collagen affinity by 10-fold (Sasaki et al., 1998). These studies showed 
that protein cleavage by matrix metalloproteinases may be a regulatory mechanism 
utilized to increase SPARC activity (Sasaki et al., 1998). Matrix metalloproteinases are 
highly expressed in tissue injury and remodeling events, as is SPARC, making this a 
significant interaction for normal biological function (Tardáguila-García, et al., 2019). 
Other cell processes domain III has been proposed to impact are: deterring cell spreading, 
disrupting focal adhesions, and inhibiting cell proliferation (Brekken and Sage, 2001, 
Lane and Sage, 1994, Murphy-Ullrich et al., 1991). The exact mechanism behind the 
majority of SPARC’s roles are not well understood; however, SPARC’s interaction with 
collagens have been extensively studied and as a result is fairly well characterized. 
Once SPARC-collagen binding was understood, studies began to identify SPARC 
binding sites on fibrillar collagens I, III, and VI as well as non-fibrillar collagen IV. The 
structure of collagen is important for its binding to various extracellular matrix molecules 
as well as to cells. It has a triple helical structure that is comprised of three α chains 
(Giudici et al., 2008). The α chains contain Glycine (Gly)-X-Y sequence repeats with X 
most often representing proline and Y most often representing hydroxyproline (Giudici et 
al., 2008). Although the X and Y repeat positions can vary, glycine is imperative at every 
third residue to allow for proper α chain interaction due to a lack of hindering side chains 
on glycine (Giudici et al., 2008). The X and Y residues contain side chains that are 
exposed on the triple helical structure providing potential binding epitopes for various 
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molecules and proteins (Giudici et al., 2008). Giudici et al. (2008) mapped SPARC 
binding sites on fibrillar collagens using a synthetic SPARC peptide and rotary 
shadowing. A conserved SPARC binding site on collagens I, II, and III at around 180nm 
from the C terminus was found (Giudici et al., 2008). Interestingly, there is some overlap 
of cell surface receptor binding and SPARC binding to collagen within this region 
(Giudici et al., 2008).  
Collagens have been determined to bind to cells via integrin cell surface receptors 
α1β1, α2β1, and α11β1 as well as discoidin domain receptors (Agarwal, et al., 2002, Giudici 
et al., 2008, Xu et al., 2000, Zhang et al., 2003). Synthetic peptides have been important 
for mapping active binding sites on both SPARC and its collagen binding partners 
resulting in a better understanding and characterization of SPARC. The mapping of 
SPARC binding sites on fibrillar collagens revealed a potential role for SPARC in 
collagen fibrillogenesis, further evidenced by later studies finding decreased collagen 
fibril diameter as well as a reduction in fibril size uniformity (Bradshaw et al., 2003, 
Giudici et al., 2008). Earlier studies, observing early onset cataractogenesis along with 
increased lens capsule basement membrane permeability in SPARC-null mice, implicated 
a role for SPARC in basement membrane formation and stability; potentially, via 
modulation of collagen IV transport and deposition into the basement membrane matrix 
(Chioran et al., 2017, Gilmour et al., 1998, Martinek et al., 2007, Norose et al., 1998, Yan 
et al., 2002). Additionally, SPARC binding to collagen may act to inhibit or block cell 
surface binding to collagen affecting downstream signaling pathways important for cell 
adhesion, proliferation, and survival, as well as modulating growth factor activity with 
the cell surface (Giudici et al., 2008). 
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Among the many roles described for SPARC, modulation of growth factor 
activity can result in significant alterations in cellular function. SPARC has been shown 
to modulate the activity of several growth factors and cytokines including: platelet 
decrived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), and transforming growth factor (TGF)-β (Brekken and 
Bradshaw, 2010). Raines et al. (1992) found that SPARC domain III, separate from Ca2+-
dependent collagen-binding epitope (Göhring et al., 1998), bound to specific variants of 
PDGF (-AB and –BB) and prevented interaction with cell surface receptors, ultimately 
inhibiting proliferation of fibroblasts. Similarly, Kupprion et al. (1999) determined that 
the EC domain III of SPARC bound to VEGF, inhibiting its interaction with cell surface 
receptors on endothelial cells. This reduced cell proliferation via a proposed decrease in 
tyrosine phosphorylation of mitogen-activated protein kinases (MAPKs) (Kupprion et al., 
1998). Another growth factor determined to be affected by SPARC is bFGF. Hasselaar 
and Sage (1992) showed a reduction in migration and proliferation of bovine endothelial 
cells in the presence of exogenous SPARC; however, SPARC’s role did not appear to be 
direct and required a subsequent serum component. Additional mechanistic studies are 
needed to better understand the interaction between SPARC and bFGF.  
TGF-β has several known homeostatic biological functions. TGF-β was shown by 
Lane and Sage (1994) to act as a regulator of SPARC expression in fibroblasts 
stimulating its expression. Both TGF-β and SPARC are expressed during wound healing 
and in tissue remodeling events providing a basis for investigation into potential 
interactions. Later studies using mesangial cells isolated from SPARC-null mice 
indicated decreased levels of TGF-β that could be increased by exposure to exogenous 
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SPARC (Francki et al., 1999). Therefore, these two studies indicate a potential positive 
feedback loop between SPARC and TGF-β; however, more research is needed to 
determine the mechanism and if the interaction is direct or indirect. Growth factor 
interactions have the potential to affect several downstream signaling pathways resulting 
in aberrant cellular function. However, tight regulation including: tissue- and time-
specific expression, proteolytic activation, transcription factor binding, miRNA, and 
feedback loops, among others, maintain the homeostatic activity of matricellular proteins 
such as SPARC (Murphy-Ullrich and Sage, 2014). 
The regulated expression and function of SPARC and other matricellular proteins 
makes them ideal targets for disease. These proteins are critical for proper wound healing 
and tissue remodeling; however, dysregulation resulting in aberrant protein expression 
and function can have severely detrimental effects (Murphy-Ullrich and Sage, 2014). For 
the purpose of this study, cancer will be the disease of focus. Tumors have been 
described as, “wounds that do not heal” (Dvorak, 1986). SPARC plays an integral role in 
wound healing and therefore has been implicated in various types of cancer. However, as 
reviewed by several researchers, its expression and role is not consistent between cancers 
but instead is tissue-specific (Arnold and Brekken, 2009, Nagaraju et al., 2014, Said and 
Theodorescu, 2013). In general, SPARC has been described to act in an oncogene-like 
fashion promoting tumor progression in melanomas, and gliomas; however, it has been 
described to act in a tumor-suppressor-like fashion inhibiting tumor progression in many 
epithelial cancers such as lung, prostate, ovarian and colorectal (Arnold and Brekken, 
2009, Brekken and Bradshaw, 2010, Said and Theodorescu, 2013). There are also cancers 
that have varying SPARC expression depending on the subtype and/or tumor grade 
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(Nagaraju et al., 2014, Said and Theodorescu, 2013). As seen in Figure I-5, SPARC’s 
contradictory roles in either promoting cellular processes or inhibiting cellular processes 
through proposed mechanisms, along with tissue-specific expression of proteolytic 
molecules such as matrix metalloproteinases, could explain its dysregulation in particular 
cancer types (Nagaraju et al., 2014). The mechanisms behind SPARC’s function in 
cancer are overwhelmingly thought to occur through modulation of signaling factors and 
interruptions in signaling pathways resulting in aberrant cellular function and, more 
recently, through weakening of the extracellular matrix via collagen IV interactions 
(Arnold and Brekken, 2009, Morrissey et al., 2016, Nagaraju et al., 2014). This is 
complicated by SPARC being a secreted protein making it necessary to consider SPARC 
expression by the tumor as well as the surrounding stromal environment. 
 
Figure I-5. Various Roles for SPARC in Cancer. Diagram depicting SPARC’s 
contradictory roles in promoting cancer as well as inhibiting cancer. Mechanistic details 
determined from numerous studies describe tissue and cancer-specific functions for 
SPARC. [Nagaraju et al., 2014, by © permission of Oxford University Press] 
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Harold Dvorak (1986) explained the necessary, complex interplay between tumor 
and stroma, along with the potential role for aberrant wound healing in cancer. Tumor 
associated stroma is an environment conducive to: aberrant matricellular protein 
expression and function, inappropriate wound healing events, and ultimately tumor 
progression. It is important to consider that both tumor cells and supporting cancer-
associated stromal cells can secrete matricellular proteins (Chiodoni et al., 2010). It has 
not been fully determined if the source of secreted matricellular proteins contributes 
differently to the overall outcome; however, this is of considerable interest as it may lead 
to potential therapeutic targets. 
SPARC expression and function in urothelial carcinoma is limited; however, 
studies show expression appears to be negatively correlated with disease progression 
(Said et al., 2013, Said, 2016). SPARC is expressed in normal urothelium in the basal and 
luminal cells of the epithelial layer (Said et al., 2013). However, in urothelial carcinoma 
tumors, SPARC expression within the tumor cells is decreased while expression is 
maintained or increased in the supporting stromal cells (Larson et al., 2010, Said et al., 
2013). The downregulation of SPARC within tumor cells was shown to promote 
carcinogenesis and tumor progression through ROS accumulation, increased cell 
proliferation, and increased carcinogen-induced inflammation (Said et al., 2013). Ovarian 
cancer studies report similar findings of increased stromal SPARC expression with 
decreased tumor cell expression (Brown et al., 1999). In this case, SPARC is thought to 
elicit its tumor suppressor functions through inhibition of cell adhesion, suppression of 
mitogen-activated protein kinase (MAPK) cell survival signaling, as well as tumor 
microenvironment neutralization (Said et al., 2007a, Said et al., 2007b). This, along with 
 30 
 
tumor cell heterogeneity and the complex tumor-stroma cross-talk, further exemplify the 
importance of studying the origin of SPARC expression in regards to cancer and future 
therapeutics. SPARC’s tissue-specific expression and function make it a difficult 
therapeutic option due to off-target side-effects; however, understanding the mechanisms 
underlying SPARC function may lead to cancer-specific downstream effector molecules 
that can be targeted or monitored. 
Microarray analysis of our lab’s in vitro model system of heavy metal cadmium-
induced urothelial carcinoma reported SPARC as the most repressed gene across all 
transformed cell lines (Garrett et al., 2014). Larson et al. (2010) observed SPARC mRNA 
and protein levels below detectable limits in all of the transformed cell lines compared to 
the non-transformed UROtsa parent cell line and normal human urothelium. Fluorescence 
imaging found vesicular expression of SPARC in the cytoplasm of the non-transformed 
UROtsa parent cells; however, no SPARC expression was observed in the transformed 
cell lines (Larson et al., 2010). Immunohistochemical analysis compared SPARC 
expression in human non-cancerous and cancerous urothelial tissue. Results showed a 
decrease in urothelial cell SPARC expression but an increase in stromal SPARC 
expression from normal to cancerous urothelium as well as Cd2+-transformed 
heterotransplant tumors. There appeared to be differences in the stromal SPARC 
expression between tissues in regards to the inflammatory status; with inflammatory and 
desmoplastic (densely fibrotic) areas of low and high grade urothelial carcinomas, 
respectively, showing strong stromal SPARC expression (Larson et al., 2010). Therefore, 
it is possible that stromal SPARC is playing a role in creating or sustaining an 
inflammatory microenvironment to promote tumor progression.  
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Interestingly, exposure of UROtsa parent cells to cadmium resulted in a rapid 
decrease in SPARC expression clearly indicating a role, either direct or indirect, for 
cadmium in the repression of SPARC (Larson et al., 2010). Repression of SPARC in 
many epithelial tumors has been reported due to hypermethylation of the promoter 
(Arnold and Brekken, 2009, Chen et al., 2014, Gao et al., 2010, Socha et al., 2009). 
Therefore, Larson et al. (2010) treated Cd2+-transformed cells with either MS-275 histone 
deacetylase inhibitor or 5-AZC methyltransferase inhibitor but determined that SPARC 
repression following malignant transformation did not appear to be due to changes in 
common promoter methylation or histone acetylation. These results indicate an 
alternative regulatory mechanism resulting in SPARC repression in the heavy metal-
induced urothelial carcinoma model system. 
Further studies, performed to better understand the expression and function of 
SPARC in this model system, led to stable transfection of SPARC under a CMV 
promoter in two Cd2+-transformed cell lines (Slusser et al., 2016). Tumorigenesis 
experiments showed that stable transfection did not affect the ability of these cells to 
form colonies on soft agar, nor ability to form tumors in nude athymic mice (Slusser et 
al., 2016). Additional results indicated no difference in: epithelial cell morphology, 
intracellular location of SPARC, proliferation rates, migration, nor invasion capabilities. 
Interestingly, the heterotransplant tumors formed from the stably SPARC-transfected 
Cd2+-transformed cell lines completely lacked detectable SPARC expression (Slusser et 
al., 2016). However, heterotransplant tumors formed from the proposed cancer-initiating 
cell subpopulation or, UROsphere population, of the SPARC-transfected, transformed 
cells lines showed 10-20% focal SPARC expression compared to the SPARC-transfected, 
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transformed cell lines (Slusser et al., 2016). This increase in focal SPARC protein 
expression could indicate a potential subset of cells expressing SPARC that may 
contribute to tumorigenesis, tumor progression, and/or tumor metastasis. 
The previous results from our lab, in conjunction with the overall desperate need 
for biomarkers for bladder cancer, led to this proposed research study to further analyze 
SPARC expression and function in an in vitro model of heavy metal Cd2+-induced 
urothelial carcinoma. Literature suggests tissue-specific biological roles for SPARC 
(Brekken and Sage, 2001). Additionally, a well-defined role for SPARC in the bladder 
and bladder cancer remains to be fully determined. Therefore, one hypothesis of this 
study is that SPARC plays a critical role in cell proliferation, migration, attachment, or 
spreading of urothelial cells. Our model system presents an ideal opportunity to 
determine a role for SPARC in non-tumorigenic SPARC+ UROtsa parent cells that is 
affected in non-SPARC expressing Cd #1 transformed cells.  
Furthermore, the SPARC promoter has been shown to be hypermethylated in 
several cancer types (Brekken and Bradshaw, 2010). However, that does not appear to be 
occurring in our system. Additionally, SPARC was repressed in UROtsa parent cells 
following short term exposure to cadmium (Larson et al., 2010). Therefore, the goal of 
this study is to examine an alternative regulatory mechanism that may be contributing to 
SPARC repression in transformed urothelial cells, namely transcription factor binding to 
the SPARC promoter. The second hypothesis of this study is that cadmium significantly 
decreases SPARC expression by silencing the promoter early in the malignant 
transformation process. Finally, the significant repression of tumor cell SPARC in 
heterotransplant tumors generated from SPARC-transfected transformed cells (Slusser et 
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al., 2016), motivated further examination of SPARC and tumor initiation. The goal of this 
study, described in Chapter IV, is to determine SPARC expression in serially transplanted 
bladder heterotransplant tumors. Previous heterotransplant tumor results led to the third 
hypothesis that in urothelial tumors generated from the Cd2+-transformed cell lines, 
SPARC is prohibitive to tumor initiation.
 34 
 
CHAPTER II 
SPARC AND BLADDER UROTHELIAL CARCINOMA CELL ATTACHMENT, 
SPREADING, AND MIGRATION 
 
Introduction 
 SPARC is a matricellular glycoprotein that has both tissue specific expression and 
function (Nagaraju et al., 2014, Yan and Sage, 1999). It has been shown to play a tissue 
dependent role in contradictory biological processes (Nagaraju et al., 2014). This has led 
to SPARC being described as both oncogene-like and tumor suppressor-like depending 
on the cancer of interest (Nagaraju et al., 2014). However, its role in bladder cancer is yet 
to be fully elucidated. One goal of this research is to determine a role for SPARC in our 
model system of heavy metal induced bladder urothelial carcinoma. 
 This study focuses on the cell biological processes of growth, migration, 
attachment, and spreading; all of which are necessary for normal cell survival. However, 
these processes and others have also been shown to be altered in regards to tumor 
initiation and progression (Hanahan and Weinberg. 2000, Hannahan and Weinberg, 2011, 
Pickup et al., 2014). SPARC has been shown to play a role in all of these processes; 
therefore, it is plausible SPARC functions in one or more of them in our model system 
(Bradshaw and Sage, 2001, Nagarju et al., 2014, Yan and Sage, 1999). 
 Cell growth and migration are both integral components of wound healing 
(Midwood et al., 2004). Normally, there are phases of tissue injury repair encompassing 
migration of immune cells and clotting factors into the wound followed by migration and 
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proliferation of epithelial cells and finally maturation of cells and extracellular matrix 
molecules to heal the wound (Midwood et al., 2004). SPARC has been described to play 
a role in extracellular matrix molecule deposition as well as cell-matrix de-adhesion 
promoting tissue injury repair and regeneration (Arnold and Brekken, 2009, Bradshaw 
and Sage, 2001). In a sense, a cancerous lesion is a wound in need of repair so these same 
processes are occurring but may be altered to promote tumor growth and progression 
(Dvorak, 1986, Dillekås, et al., 2019). The experiments in this study will focus on 
epithelial cell migration and proliferation in the presence or absence of SPARC in the 
first 24 hours following injury. 
 Two other important biological processes studied in this research are cell 
attachment and cell spreading. Studies have shown that these processes are separate but 
both are needed for adherent-dependent cell survival (Chen et al., 1997). As shown in 
Figure II-1, Christopher Chen and colleagues used an extracellular substrate of 
fibronectin. They plated a specified amount in one spot at 20µm in diameter, and in 
another location, the same amount of fibronectin was distributed over multiple spots at 3-
5µm in diameter to mimic focal adhesion size (Chen et al., 1997). It was found that the 
cell that attached to the 20μm spot of fibronectin could not spread and died via apoptosis. 
However, the cell that attached onto the same amount of fibronectin spread out over 
multiple spots totaling 50μm could spread, allowing it to survive and grow (Chen et al., 
1997). 
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Figure II-1. Attachment and Spreading of Adherent Cells. Specified amount of 
fibronectin placed in single location or distributed over multiple locations illustrates both 
cell attachment and cell spreading are necessary for cell survival and growth. (Reprinted 
from Chen et al., 1997 with © permission from AAAS.) 
 
These experiments were pivotal in determining the importance of both cell 
attachment and cell spreading for normal cell function and survival. There have been 
several studies assessing cell attachment and spreading using a variety of methods 
(Khalili and Ahmad, 2015). The most simple assay is the wash assay in which unattached 
cells are washed away; however, this method does not allow for real-time quantification 
so further analysis is needed (Khalili and Ahmad, 2015). This is the basic method that 
will be utilized to examine attachment and spreading in this study. Lane and Sage (1990) 
developed a method to quantitate categorized cells via observation using a rounding 
index (RI), with the formula RI = (1a + 2b + 3c) / (a + b + c), where (a) is fully spread, 
(b) is spreading, and (c) is rounded. As the cells in each image become more fully spread, 
the RI gets closer to a value of 1. This method has been used in several subsequent 
studies analyzing cell spreading; however, percent attached is also commonly utilized for 
attachment and spreading data representation (Everitt and Sage, 1992, Motamed and 
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Sage, 1998, Hudson et al., 2005, Delostrinos et al., 2006, Humphries, 2009). Intriguingly, 
cell spreading quantitation has become more automated with computer-based 
classification systems using trainable classifiers to categorize cells based on morphology 
(Costa and Yang, 2009, Dehlinger et al., 2013, Ambühl et al., 2012, Carpenter et al., 
2006, Garvey et al., 2016, Jaccard et al., 2014b). This automation reduces a level of 
human bias and makes analysis more consistent. Furthermore, this study is an ideal 
opportunity for its utilization in examining SPARC’s role in urothelial cell attachment 
and spreading. 
SPARC has been shown to have de-adhesive properties thereby decreasing cell 
attachment and subsequent spreading in the systems studied (Bradshaw and Sage, 2001). 
Interestingly, this was shown in human urothelial cells to occur via SPARC’s C-terminal 
Ca2+-binding domain (Delostrinos et al., 2006). One interaction that has been extensively 
studied and shown to be important for many functions is SPARC’s interaction with 
fibrillary collagens and basement membrane collagen IV (Bradshaw, 2009). Mechanistic 
studies describe this as a calcium-dependent interaction involving the C-terminal domain 
of the SPARC protein containing two high-affinity calcium-binding EF Hands 
(Bradshaw, 2009). The affinity of SPARC binding to collagen can be tissue specific due 
to the tissue-specific glycosylation of SPARC (Bradshaw, 2009). SPARC binding sites 
on collagen I have been described by two different lab groups. Both groups found two 
similar binding sites; however, Guidici et al. (2008) found another potential site that was 
not described by Wang et al. (2005) (Bradshaw, 2009). Overall, both groups identified 
binding sites that coincide with the integrin cell adhesion receptor and/or Discoidin 
Domain Receptor (DDR) family binding sites which could result in altered cell 
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attachment and subsequent spreading. However, these processes have not been studied in 
the context of heavy metal induced bladder urothelial carcinoma warranting investigation 
in our system. Our model system of cadmium transformed urothelial carcinoma cells 
lacking SPARC expression presents an opportunity to explore cell attachment and 
spreading, as well as cell growth and migration, in regards to SPARC. 
Materials and Methods 
Cell Culture 
 SPARC+ UROtsa parent cells were maintained in 25cm2 tissue culture flasks 
containing Dulbecco’s Modified Eagle’s Medium (DMEM) [Sigma-Aldrich, St. Louis, 
MO] supplemented with 5% v/v fetal calf serum (Gibco, Waltham, MA) as described in 
Rossi et al. (2001). Cadmium malignantly transformed cells, their respective SPARC-
transfected cells, and associated destination vector-transfected control cells were also 
maintained in 25cm2 tissue culture flasks containing DMEM supplemented with 5% v/v 
fetal calf serum with the addition of 1% v/v glucose . Cells were grown in a 37°C, 5% 
CO2 tissue culture incubator and fed fresh media every 2 days. Confluent flasks were 
passaged at a 1:8 (UROtsa) and 1:10 (Cd2+) ratio after dislodging cells using 0.25% 
Trypsin-EDTA (Gibco). Cells were passaged approximately 20 times; after which, fresh 
vials were thawed and grown in culture. 
Wound Closure Assay 
 Cells were plated and grown to confluency in 6-well tissue culture plates. Once 
confluent, wells were wounded with a plus sign mark using the pointed end of a sterile 
200µL pipette tip. Wells were washed with 1xPBS and fresh growth media was added. 
Phase contrast images were taken at 10x magnification above and below the cross-point 
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at 0h, 4h, 8h, 12h, and 24h time points, using a Zeiss Axiovert 35 microscope (Carl Zeiss 
AG, Oberkochen, Germany) fitted with an Olympus DP72 camera (Olympus, Tokyo, 
Japan). Wound closure was analyzed using Olympus cellSens Standard software 
measuring distance between wound edges. Each well was measured in triplicate with the 
experiment performed in triplicate. Percent wound closure graphed using GraphPad 
PRISM version 5.01 (GraphPad Software, San Diego, CA). 
Cell Attachment and Spreading Under Normal Tissue Culture Conditions 
 
 Cells were grown to confluency in 25cm2 tissue culture flasks and passaged using 
0.25% Trypsin-EDTA (Gibco). All cells were passaged using a 1:6 ratio into 25cm2 
tissue culture flasks. The flasks were then allowed to incubate at 37°C, 5% CO2 in a 
tissue culture incubator. At 30 minutes, 60 minutes, and 120 minutes flasks were 
removed and imaged using phase-contrast microscopy on a Zeiss Axiovert 35 microscope 
(Carl Zeiss AG) at 10x magnification. Because only one flask was used for each cell line, 
one representative image was taken of each flask, after which the flask was placed back 
in the incubator. Data was graphed using Graphpad PRISM v5.01. 
Fiji and PHANTAST Image Pre-Processing 
 
 Fiji is just ImageJ (Fiji) software (FIJI/ImageJ version 1.52i) freely available from 
the National Institutes of Health (NIH) was downloaded to aid in image pre-processing 
steps. A specific plugin, PHANTAST, (v0.2, www.github.com/nicjac/PHANTAST-
FIJI/releases/tag/v0.2) was then downloaded to further aid in pre-processing. This plugin 
was developed by Jaccard et al. (2014a) to correct for the halo artifact in phase contrast 
microscopy images. Briefly, an algorithm was used to determine which pixels matched 
the cell and which matched the background using a gradient determined by multiple 
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Kirsch filters (Jaccard et al., 2014a). A list of potential halo locations is made and pixel 
by pixel each location is determined to be cell or halo/background until the list is 
completed (Jaccard et al., 2014a). How much each pixel analyzed is affected by or affects 
its nearest neighbors is determined using the sigma and epsilon values within the 
PHANTAST plugin which will be described later (Jaccard et al., 2014a).  
Images were opened in Fiji and converted from an 8-bit image to a 32-bit image 
in order to run the PHANTAST plugin. Phase contrast images are greyscale resulting in a 
lack of contrast between the cells and the background. This required the contrast to be 
modified for each image to get optimal clarity. Subsequently, the PHANTAST plugin 
was launched and sigma and epsilon parameters were set. Sigma determines the influence 
of a pixel on its neighbors; therefore, increasing sigma results in more neighboring pixels 
that “look” like that pixel (Jaccard et al., 2014a). Epsilon determines the amount of pixels 
that will be recognized as cell or background. Therefore, based on the algorithm, 
decreasing epsilon results in an increase in the amount of pixels that will be recognized as 
a cell (Jaccard et al., 2014a). After the proper values are determined a binary (0 or 1) 
output image is created. This image shows black cells (1) on a white background (0). 
Following the PHANTAST segmentation, the binary image is overlayed on the original 
image. The result of this is an image of cells without a halo on a black background. This 
image is then converted back to an 8-bit image and can be analyzed using the Leica 
LASX software package. The overlay image helps to visualize the cell and allows for 
proper exclusion of non-cell debris and falsely selected background. This pre-processing 
was optimized for the majority of the cells in each image.  
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Once these steps were optimized this process was written into a macro to make 
this process more efficient. The macro incorporated interactive elements to further 
optimize these steps to achieve the best results. Briefly, all images from a single well 
were analyzed together using the macro. The first step is to manually modify the contrast 
for each image to get optimal clarity as stated previously. Subsequently a range of sigma 
and epsilon values were entered and each image was run through the program. Once the 
program finished the output image with the best border definition was chosen to be 
analyzed. From each well of 20-30 images, 10 images were chosen for analysis with the 
Leica LASX program. 
Leica LASX Image Analysis 
Leica LASX program version 3.0.1 (Leica Microsystems, Inc., Buffalo Grove, IL) 
has the ability to classify cells within an image based on morphology. Similar versions of 
this software have been utilized in Ristic et al. (2014) and Zorgetto et al. (2013) to assess 
morphology as well as count blood vessels, respectively. This software tool was 
important for this study, allowing for a reduction in human bias associated with cell 
classification. Because this program is part of a confocal microscopy system it was not 
designed to recognize phase contrast images. Therefore, the pre-processing through Fiji, 
using the PHANTAST plugin, was imperative to use the Leica LASX software. The 
overlay images with the black background were able to be recognized by the LASX 
software; therefore, this program could be used moving forward to analyze attachment 
and spreading images via LASX computer software. 
The image was uploaded into the software and the analysis panel within the 
LASX program was opened. Once opened, a series of pre-filters can be utilized to 
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process the image as needed. One pre-filter utilized for these images was the binary pre-
processing filter to size exclude small debris from selection. Another filter used was the 
binary image editing filter. Within this filter, cells that were touching could be manually 
split and cells touching the edge could be excluded. This filter also allowed for removal 
of larger non-cell debris as well as adjustment of any incorrect cell borders. As stated 
earlier, the pre-processing in Fiji was optimized for the majority of cells in each image. 
This resulted in manual border selection of some cells due to a lack of contrast that was 
unable to be corrected in the pre-processing steps. Once the pre-filter steps were finished 
the image was subjected to the classifier and each cell in the image was categorized based 
on several parameters. 
The classifier feature of the Leica LASX software had to be manually trained to 
correctly categorize cells based on morphology. Therefore, a control image was used to 
train the classifier. Classes for rounded, spreading, and flattened were created. Then, 
several cells for each class were manually selected and the classifier was trained to 
categorize subsequent cells based on those cells manually selected. Initially, only two 
classes were created, rounded and flattened; however, the classifier could not accurately 
categorize cells into the two classes and needed a third to “catch” those cells in between 
rounded and flattened. Once optimized, the classifier measured several parameters 
including: surface area, length, perimeter, roundness, and shape, among others. How each 
parameter was weighted in the classification is proprietary information; however, once 
optimized, the classifier was saved and each image was classified using the same 
classifier. Modification of the attachment and spreading assay required modification of 
the classifier; but, once modified, each image was analyzed with the same classifier. The 
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classification resulted in a report that was exported to Excel where the number of cells in 
each category was calculated using the “countif” function. The percent of total cells in 
each category was determined by dividing the number of cells in each class by the total 
number of cells and multiplying that value by 100. The relative surface area was also 
calculated for all cells as well as for cells in each class. 
Cell Attachment and Spreading Assay on a Collagen I Matrix 
 
 Cells were grown to confluency as described previously. Cells were then counted 
using a hemacytometer and diluted to 50,000cells/well concentration and plated in 12 
well tissue culture plates. Tissue culture plates were coated with PureCol Collagen I 
(Advanced BioMatrix, San Diego, CA) one day prior to the experiment. 12 well plates 
were coated with 750µL PureCol Collagen I and allowed to dry for 2-4h. 1mL of Bovine 
Serum Albumin (BSA) blocking buffer (3% in PBS) [Alfa Aesar, Haverhill, MA] diluted 
to 1% was added to each collagen coated well and plates were incubated in a 37°C, 5% 
CO2 tissue culture incubator overnight. Collagen coated wells were washed three times 
with 1xPBS prior to cell plating. Cells were plated in triplicate on both normal tissue 
culture wells and collagen I coated wells. Cells were placed in a 37°C, 5% CO2 tissue 
culture incubator and allowed to attach for 30min, 60min, or 120min. Once removed, 
cells were washed quickly 3 times with 1xPBS and methanol fixed in the freezer for 3 
minutes using ice-cold methanol. Cells were then quick rinsed with 1xPBS- followed by 
three 5 minute washes with 1xPBS- and one 5 minute wash with 1xPBS+. Cells were 
stored in 1x PBS+ at 4°C until imaged. Phase contrast images were taken of each well 
using a Zeiss Axiovert 35 microscope (Carl Zeiss AG) at 10x magnification. Initial cell 
attachment and spreading analyzed by manually counting rounded versus non-rounded 
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cells in 5 images. The same images were then pre-processed using Fiji and PHANTAST 
and analyzed using Leica LASX software (Leica Microsystems, Inc.) as described 
previously. Results were graphed and statistical analysis performed using GraphPad 
PRISM v5.01. Manual data was compared to software data to validate software analysis.  
Modified Cell Attachment and Spreading Assay on a Collagen I Matrix 
 Cells were grown to confluency as previously described. Cells were counted using 
a hemacytometer, diluted to 30,000cells/well concentration, and plated in 12 well plates. 
Cells were plated in triplicate on both normal tissue culture wells and collagen I coated 
wells prepared as described previously. Cells were placed in a 37°C, 5% CO2 tissue 
culture incubator and allowed to attach for 15min, 30min, 45min, and 60 min. Based on 
preliminary results, this experiment was carried out to 60 minutes in order to analyze the 
active process of cell attachment and spreading. Additionally, the cells become too 
confluent and too flattened for accurate analysis at later time points. Once removed, cells 
were methanol fixed, washed, and stored as previously described. Phase contrast images 
were taken of each well using a Zeiss Axioervert 35 microscope (Carl Zeiss AG) at 20x 
magnification. Images were pre-processed using Fiji and PHANTAST and analyzed 
using Leica LASX software (Leica Microsystems, Inc.) as described previously. Results 
were graphed and statistical analysis performed using GraphPad PRISM v5.01. 
Immunofluorescent Microscopy during Cell Spreading 
 Cells were grown to confluency as previously described. Cells were then counted 
using a hemacytometer and diluted to 30,000cells/well concentration and plated in 12 
well plates containing collagen I coated glass coverslips (Fisherbrand #1.5) [Fisher 
Scientific, Hampton, NH] prepared as described in the attachment and spreading assay on 
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a collagen I matrix. Cells were placed in a 37°C, 5% CO2 tissue culture incubator for 45 
minutes. Cells were washed twice with DMEM-F12-no phenol red (Gibco #11039-021) 
and fixed using 3.7% methanol-free formaldehyde (Polysciences, Inc., #18814-10) 
[Warrington, PA] for 10 minutes at room temperature. Free aldehyde groups were 
quenched using 0.1M NH4Cl (Sigma-Aldrich) for 15 minutes at room temperature and 
cells were permeabilized using 0.1% Igepal (Sigma-Aldrich) for 10 minutes at room 
temperature. Coverslips were incubated with Alexa Fluor 488 Phalloidin antibody, 
6.6µM (Cell Signaling #8878) [Danvers, MA] at a 1:100 dilution for 45 minutes at 37°C. 
Coverslips were mounted using ProLong Diamond Antifade mounting medium with 
DAPI (Life Technologies #P36971) [Carlsbad, CA] for nuclear staining. Cell spreading 
was visualized using the Leica Laser Scanning SP8 Confocal microscope (Leica 
Microsystems, Inc.) at 63x magnification. Maximum projection images were subjected to 
deconvolution using Leica LASX software. SPARC+ UROtsa parent cells were used as a 
control for cell spreading. 
SPARC siRNA Transfection in the Cd #1-SPARC Transfected Cell Line 
 Cells were grown to confluency in 12 well plates. TransIT-siQUEST (Mirus 
#MIR2114) [Mirus Bio LLC,Madison, WI] transfection reagent was added to OptiMem 
(Gibco) and incubated for 15 minutes at room temperature. SPARC siRNA (Dharmacon 
#J-003710-07-002) [Dharmacon Inc., Lafayette, CO], Non-targeting Scrambled siRNA 
(Dharmacon #D-001810-01-05), or siGLO Lamin A/C control siRNA (Dharmacon #D-
001620-02-05) were reconstituted in sterile 1xPBS. siRNA was diluted in OptiMem at 
1:20 creating a 1µM working solution. siRNA was then added to microfuge tubes 
containing TransIT-siQUEST and OptiMem and incubated for 15 minutes at room 
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temperature. siRNA/transfection complexes were added in dropwise manner to respective 
wells containing fresh growth medium. Cells were incubated with siRNA/transfection 
complexes for 24 hours in a 37°C, 5% CO2 tissue culture incubator. Cells were then 
harvested for RNA and protein analysis. Treatments were performed in duplicate with 
one well for RNA analysis and one well for protein analysis. 
RNA and Protein Isolation from the Cd #1-SPARC Transfected Cell Line 
 Total RNA was isolated from siRNA treated cells using TRI REAGENTTM 
(Molecular Research Center, Inc., Cincinnati, OH). Cells were washed with cell culture 
PBS and 500μL TRI REAGENT was added to each well. Cell suspension was transferred 
to microfuge tube and incubated at room temperature for 10 minutes. 50μL 1-Bromo-3-
Chloropropane (BCP) [MRC #BP151] was then added and each sample was vortexed to 
mix. Samples were incubated for 5 minutes at room temperature then centrifuged at 
12,000g for 15 minutes at 4°C to separate sample. Aqueous phase was transferred to a 
fresh RNase/DNase free microfuge tube and 250µL 100% Isopropanol was added to each 
sample. Samples were incubated for 10 minutes at room temperature then centrifuged at 
12,000g for 7 minutes at 4°C to precipitate RNA. Supernatant was removed, pellet was 
washed with 75% EtOH, and centrifuged at 12,000g for 7 minutes at 4°C. Again, 
supernatant was removed and pellet was allowed to air dry for 3-10 minutes. Pellet was 
reconstituted in 30µL nuclease free water (Mo Bio Laboratories, Carlsbad, CA). RNA 
concentration was determined using the Nanodrop One (Thermo Fisher Scientific, 
Waltham, MA) and a portion of each sample was diluted to 20ng/µl concentration for 
subsequent RT-qPCR analysis. 
 47 
 
 Total protein was isolated from siRNA treated cells using phosphate buffered 
saline (PBS)-based lysis buffer, comprised of: 10x PBS, 100mM magnesium chloride 
(MgCl2), 100mM ethylene glycol tetraacetic acid (EGTA, pH 8.0), 100mM sodium 
pyrophosphate (NaPpi), 100mM sodium orthovanadate (Na3VO4), 1M sodium fluoride 
(NaF), protease inhibitor cocktail tablets (cOmplete Mini Ref# 11836153001) [Roche 
Diagnostics, Mannheim, Germany], 2% w/v sodium dodecyl sulfate (SDS). Cells were 
washed with cell culture PBS and 125µL PBS lysis buffer with protease inhibitors was 
added to each well. Cells were scraped to the bottom of each well and transferred to 
microfuge tube. Samples were incubated at room temperature for 5 minutes then 
sonicated using the 60 sonic dismembrator (Fisher Scientific) to shear the DNA. Protein 
concentration was determined using a BCA Assay. Albumin standards were made 
(Thermo Fisher Scientific) and each protein sample was diluted 5-fold. Standards and 
protein samples were plated in triplicate in a 96-well flat-bottom plate. Working reagent 
was added to each well with water and working reagent only as controls. The plate was 
incubated at 37°C for 30 minutes. Color change was quantified using a 
spectrophotometer at a 570nm wavelength. Protein concentration was further determined 
using Excel for subsequent use in western blot analysis.   
RT-qPCR Analysis of SPARC siRNA Transfected Cd #1-SPARC Cells 
 
 SPARC mRNA expression in siRNA treated cells was determined using real-time 
reverse transcription polymerase chain reaction (RT-qPCR). 100ng of total RNA was 
used in a 20µL reaction volume for cDNA synthesis using the iScriptTM cDNA Synthesis 
Kit (#1708891) [Bio-Rad Laboratories, Hercules, CA]. Each sample was run on a 
thermocycler using the following protocol: priming – 5 min. at 25°C, reverse 
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transcription – 20 min. at 46°C, and RT inactivation – 1 min. at 95°C. cDNA samples 
were then used for subsequent RT-qPCR. 
 2µL of cDNA was amplified using 20µM SPARC specific primers (Qiagen 
#QT00018620) [Qiagen, Valenica, CA] and recorded using SYBR green fluorescence in 
a total reaction volume of 20µL. Samples were run on a CFX960 Thermocycler (Bio-Rad 
Laboratories) using the following cycling parameters: 5 min. at 95°C, Denaturation – 
15sec. at 95°C, Annealing – 45sec. at 62°C, repeat denaturation and annealing steps x39, 
and the melt curve was collected. SPARC expression was determined relative to the 
untreated control using a standard curve generated from qualitative SPARC standards. 
SPARC mRNA expression was normalized to β-actin amplified using an Invitrogen 
primer set with the following sequences, sense: CGACAACGGCTCCGGCATGT, anti-
sense: TGCCGTGCTCGATGGGGTACT. [Invitrogen, Carlsbad, CA] under the same 
cycling parameters. β-actin expression was determined relative to the untreated control 
using a standard curve generated using β-actin standards. Expression data was graphed 
and statistical analysis performed using GraphPad PRISM v5.01.   
Western Blot Analysis of SPARC siRNA Transfected Cd #1-SPARC Cells 
 
 SPARC protein expression in siRNA treated cells was determined using Western 
Blot analysis. 20µg of total protein was separated on a pre-cast Any kD polyacrylamide 
gel (Bio-Rad #4568123). Bands were transferred from the gel onto a membrane using the 
TransBlot Turbo Transfer System (Bio-Rad) for 7 minutes. The membrane was blocked 
using 5% powdered milk in TBS-T (Tris-Buffered Saline with 0.1% Tween) blocking 
buffer for 1.5h at room temperature. The membrane was then incubated with mouse anti-
Osteonectin antibody (NovocastraTM, Cat # NCL-O-NECTIN) [Leica Biosystems Inc., 
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Buffalo Grove, IL] at a 1:200 dilution in 1% milk in TBS-T overnight at 4°C. Membrane 
was washed three times with TBS-T and incubated with anti-mouse IgG, HRP-linked 
antibody (Cell-Signaling Technology, #7076S) at 1:3,000 and anti-biotin, HRP-linked 
antibody (Cell-Signaling Technology, #7075S) at 1:1,500 in 1% powdered milk in TBS-
T for 1h at room temperature. The membrane was washed three times using TBS-T and 
incubated with developing solution (1:1 luminol solution:peroxide solution) (Bio-Rad) 
for 5min. at room temperature. The ChemiDoc MP Imaging System (Bio-Rad) was used 
to visualize SPARC protein expression. 
The membrane used for SPARC protein expression was stripped and re-probed 
for β-actin by incubating in stripping buffer (Bio-Rad) for 1h at room temperature. The 
membrane was washed three times with TBS-T and placed in 5% BSA blocking buffer 
(5% w/v Bovine Serum Albumin in TBS-T) for 1.5h at room temperature. Following 
blocking, the blot was incubated with mouse monoclonal anti-β-actin antibody (Abcam, 
#ab8226) [Abcam, Cambridge, MA] at 1mg/mL using a 1:2,000 dilution in 1% BSA in 
TBS-T overnight at 4°C. The blot was washed three times with TBS-T and incubated 
with anti-mouse secondary antibody anti-mouse IgG, HRP-linked antibody (Cell-
Signaling Technology, #7076S) at 1:3,000 and anti-biotin, HRP-linked antibody (Cell-
Signaling Technology, #7075S) at 1:1,500 in 5% powdered milk in TBS-T for 1h at room 
temperature. Membrane was washed and developed as described above. 
Statistics 
 All data was analyzed using GraphPad PRISM v5.01 software (GraphPad 
Software). Statistical analysis for cell attachment and spreading was performed using a 
one-way ANOVA and Tukey’s Multiple Comparison post hoc testing. Statistical analysis 
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for mRNA expression was performed using a one-way ANOVA and Dunnett’s Multiple 
Comparison post hoc test. Statistical significance was determined for all results using 
p<0.05. 
Results 
Wound Closure of SPARC+ UROtsa Parent, Cd #1, and the Respective Cd #1-
SPARC Transfected Cell Lines 
 
 SPARC+ UROtsa parent control cells, a cadmium transformed UROtsa cell line 
(Cd #1) and its respective stably transfected SPARC cell line (Cd #1-SPARC) were used 
to assess SPARC’s role in wound closure. Previous studies analyzed wound closure in the 
presence of mitomycin C, to prevent cell growth, at 24 hours and 48 hours (Larson et al., 
2010). This study aimed to assess wound closure at earlier time points to determine if 
there was a difference in wound closure between SPARC expressing and non-SPARC 
expressing cells up to 24 hours post-wound. Figure II-2 shows representative phase-
contrast images of the wounded area in the SPARC+ control, Cd #1, and the Cd #1-
SPARC cell lines at 0hr., 4hr., 8hr., 12hr, and 24hr. post-wound. Three locations along 
the wound front were analyzed in each image at each time point.  
Results in figure II-3 show the percent wound closure with regard to SPARC 
expression. It appears there is no difference in wound closure at any time points except 
24 hours post-wound. At 24 hours, both the Cd #1 and Cd #1-SPARC cell lines had a 
larger percent of the wound open than the SPARC+ control cells. It does appear there is a 
slight increase in wound closure of the cell lines expressing SPARC at the 8 hour and 12 
hour time points; however, the results were not significant. At the 24h time point the Cd 
#1-SPARC shows a significant decrease in wound closure compared to the SPARC+ 
control cell line. The Cd #1 cell line continued to show a delay in wound closure 
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becoming significant at 24 hours. This significance may be indicative of a shift in the 
biological process occurring in the transformed cells. When a cell is proliferating it is not 
migrating and vice versa. Therefore, cell migration may still be the dominant process in 
the non-transformed cells while cell proliferation has become the dominant process in the 
cadmium transformed cells at 24 hours. Previous results show Cd #1 and Cd #1-SPARC 
have decreased doubling times compared to the SPARC+ control UROtsa cells indicating 
that they proliferate more quickly than the SPARC+ control cells (Larson, 2012). 
Previous results also show variation between malignantly transformed isolates in growth, 
migration, and invasion (Slusser et al., 2016). Therefore, although we are assessing the 
same biological process of wound healing overall, the cells in this experiment were not 
treated to inhibit cell proliferation so both proliferation and migration are a part of this 
wounding assay.  
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Figure II-2. Phase Contrast Images of Wound Closure. SPARC+ cell line, Cd #1 cell 
line, and Cd #1-SPARC cell lines at 0 hours, 4 hours, 8 hours, 12 hours, and 24 hours 
post-wound. Percent wound closure determined by measuring the distance between 
wound edges divided by the initial wound distance. 
 
 53 
 
 
Figure II-3. Percent Wound Closure and SPARC Expression. Wound closure 
measured over 24 hours of SPARC+ control, Cd #1, and Cd #1-SPARC cell lines. Data 
represents the mean ±SEM of 20 measurements. Statistical significance determined using 
two-way ANOVA with Bonferroni post hoc test. * (p≤0.05) and ** (p≤0.01). 
 
Cell Attachment and Spreading Under Normal Tissue Culture Conditions 
 To assess SPARC’s role in cellular attachment and spreading in our lab model 
system, SPARC expressing control cells (UROtsa parent), non-SPARC expressing 
cadmium transformed cells (Cd #1), and the respective SPARC-transfected cells (Cd #1-
SPARC) were used. These cells were plated under normal cell culture conditions to 
initially determine if SPARC had a potential role in these cell biological processes. 
Figure II-4 depicts the percentage of total cells that are rounded (not spreading) at 30 
minutes, 60 minutes, and 120 minutes. The SPARC expressing control UROtsa parent 
cells are not shown; however, Cd #1-SPARC cells show a decrease in the percentage of 
rounded cells compared to their respective non-transfected Cd #1 parental cell lines. 
Interestingly, this difference appeared to decrease with time. These preliminary results 
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provided confidence in moving forward to assess SPARC’s role in attachment and 
spreading on a collagen I matrix. 
 
Figure II-4. Preliminary Cell Attachment and Spreading Assay under Normal 
Tissue Culture Conditions. Data represents the rounded percent of total cells counted in 
one field at 10x magnification at 30 minutes, 60 minutes, and 120 minutes. The Cd #1 
cells have nearly lost all SPARC expression following heavy metal malignant 
transformation. The Cd #1-SPARC cells have been malignantly transformed and 
transfected to express SPARC under a CMV promoter. 
 
FIJI PHANTAST Cell Attachment and Spreading Image Processing 
 Cellular attachment and spreading was initially analyzed via observation and 
manual counting of cells in each group. This process was long and tedious, introduced an 
element of human bias, and was generally not feasible for a larger number of conditions. 
Therefore, it was necessary to evaluate a software analysis process. After an extensive 
literature search, it was determined that Leica had developed a program, within its LASX 
microscope software, with a classifier that could be used to categorize cells based on 
morphology. However, this was initially designed to work with fluorescent images. The 
images from the attachment and spreading assay were grey-scale phase-contrast images 
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and the Leica LASX software program was not able to distinguish the cells from the 
background. In order to get the LASX software to classify cells from a phase-contrast 
image it was necessary to process the image in FIJI prior to analyzing it with the LASX 
software. 
 
Figure II-5. Cell Attachment and Spreading Assay Image Processing. Images show 
the progression of processing used in FIJI. The PHANTAST plugin was used to reduce 
the halo-effect from phase-contrast imaging and more precisely define cell borders. The 
resulting overlay image can then be used in the LASX software from Leica to categorize 
the cells based on morphology. 
 
 Figure II-5 illustrates the image processing performed in FIJI using the 
PHANTAST plugin. The initial phase-contrast image is changed from an 8-bit image to a 
32-bit image making it clearer. Then, this image is processed using the PHANTAST 
plugin. This process uses an algorithm to reduce the halo-effect seen in phase-contrast 
images and improve edge detection. It is necessary to have accurate edge detection when 
measuring surface area and categorizing cells based on morphology. The output from this 
processing is a black and white binary image. This is then overlaid onto the original 
image to create an overlay image. The overlay image shows the cells, with the edge 
detection determined using the PHANTAST plugin, on a black background. The overlay 
image is recognized by the Leica LASX software and can be analyzed. This FIJI image 
processing enables the use of software to analyze images, reducing human bias and 
increasing classification precision between images. 
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Leica LASX Cell Attachment and Spreading Image Analysis 
 Once the attachment and spreading images have been processed through FIJI they 
could be analyzed using Leica LASX software. The purpose of using the software was to 
utilize the classifier to more accurately categorize cells based on morphology. Figure II-6 
shows the cells in each of three categories determined by the classifier. In order to place 
each cell into a category, the classifier had to be “trained” on which cells belong in which 
category. A control image was used to train the classifier containing several cells in each 
group. It is necessary to give the classifier a range of cells in each group so it can more 
accurately categorize every cell because each one is slightly different. Multiple factors 
are taken into account when determining this categorization including: area, length, 
perimeter, roundness, and shape, as shown in Table 1. How each factor is weighed to 
determine the proper category is proprietary information belonging to Leica 
Microsystems, Inc. Once the classifier was properly trained, the same classifier was used 
for every image to increase consistency in cell classification thus reducing human bias 
between images. 
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Figure II-6. LASX Classifier Image. LASX Classifier Image depicting classification of 
cells based on morphology. The classes are represented as: rounded (pink), spreading 
(green), and flattened (blue). 
 
Table 1. LASX Classification Measurements.  
 
 
Classification of each cell in a given image is determined by analysis of multiple 
measurements, including: surface area, length, perimeter, roundness, and shape. The 
influence of each measurement on classification is proprietary information belonging to 
Leica Microsystems, Inc. 
 
 During the analysis process there was a need to manually remove cell debris, or 
cells touching the edge of the image. It was also necessary to split cells that were 
touching in order for the software to recognize them as individual cells. On occasion the 
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PHANTAST edge detection processing incorporated some of the background into the 
identified cell boundary. This occurred when the initial image lacked sufficient contrast 
and cell borders could not be differentiated from the background at the pixel level. This 
was solved by manual edge detection and further exclusion of background. 
 A comparison of manual counts versus software counts was done to validate the 
use of the Leica LASX software to analyze the attachment and spreading assay images. 
Figure II-7 illustrates the manual classification and the software classification of SPARC+ 
UROtsa parent control cells. With the manual count, observation only allowed for 
classification into two categories: rounded or spreading and flattened. However, the 
software classifier was not able to accurately categorize cells into two categories making 
it necessary to split spreading and flattened into separate categories creating three total 
categories: rounded, spreading, and flattened. The spreading category in the software 
analysis is an in-between that categorizes the cells that have started spreading but have 
not fully flattened out. Therefore, the black bar, representing spreading and flattened 
cells, in the manual count is compared to the dark gray (spreading) and black (flattened) 
bar in the software count. These results show nearly identical cell numbers in each 
category between the manual count and the software count, validating that the Leica 
LASX software can accurately classify cells based on morphology. The classification 
boundary between the spreading and flattened categories may be more ambiguous than 
the boundary between rounded and flattened. Some cells classified as spreading may be 
flattened based on observation and vice versa. However, each image was analyzed with 
the same classifier increasing consistency between images and reducing human bias. 
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Figure II-7. Classification Comparison of SPARC+ UROtsa Parent Cells. 
Classification of SPARC+ Control UROtsa parent cells counted in one field at 10x 
magnification comparing a (A) manual cell count and a (B) Leica LASX software cell 
count at 30 minutes, 60 minutes, and 120 minutes. 
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Preliminary Cell Attachment and Spreading of SPARC Expressing and Non-
SPARC Expressing Urothelial Cells on a Collagen I Matrix 
 
 SPARC is known to interact with fibrillary collagens (Bradshaw and Sage, 2001). 
Therefore, it was important to test attachment and spreading of SPARC expressing and 
non-SPARC expressing bladder cells on a collagen I matrix. Figure II-8 illustrates the 
percent of the total cells attached in each of three categories: rounded, spreading, and 
flattened. Less than 30% of the SPARC+ control cells were still rounded at 30 minutes 
and that number dropped to approximately 15% at 60 minutes. Just under 60% of the 
SPARC+ control cells were spreading at 30 minutes and approximately half of the cells 
show a flattened phenotype at 60 minutes. In contrast, The Cd #1 cells showed nearly 
90% of the cells rounded at 30 minutes with only 10% fewer rounded cells at 60 minutes. 
The Cd #1 cells appeared to not reach a flattened phenotype (<1%) within the 
experimental time frame; showing only about 20% of cells starting to spread by 60 
minutes. The Cd #1-SPARC cells showed less rounded cells than Cd #1 but more 
rounded cells than the SPARC+ control at both 30 minutes (60%) and 60 minutes (50%). 
The Cd #1-SPARC cells did show a slightly higher percentage of cells reaching a 
flattened phenotype (6.75%) compared to the Cd #1 cells as well as a higher percentage 
of spreading cells (50-60%). Overall, these results show a delay in cell spreading in the 
Cd #1 cells lacking SPARC expression compared to the SPARC+ control cells and the Cd 
#1-SPARC transfected cells. 
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Figure II-8. Preliminary Cell Spreading Assay Quantitation on a Collagen I Matrix. 
Data represents the percent of total cells counted in five fields at 10x magnification in 
each of three classes: (A) rounded, (B) spreading, or (C) flattened at 30 and 60 minutes, 
analyzed using Leica LASX software. 
 
The relative surface area (px2) of the attached cells in Figure II-9 shows a larger 
surface area for the SPARC+ control and the Cd #1-SPARC cells than the Cd #1 non-
SPARC expressing cells further indicating that SPARC+ cells were spreading sooner than 
the SPARC- cells. The SPARC+ control cells show an increase in surface area from 
approximately 430px2 at 30 minutes to just under 600px2 at 60 minutes indicating a more 
flattened phenotype. Although the increase in surface area with increased time in the Cd 
#1-SPARC cells is not as obvious, the overall surface area (approximately 325px2) at 
both time points is larger than the Cd #1 cells (approximately 250px2). These results 
support the classification of the cells representing the morphology of the majority of the 
cell population at 30 minutes and 60 minutes.  
 
Figure II-9. Preliminary Relative Surface Area Comparison of Attached Cells. 
Preliminary cell attachment and spreading assay on a collagen I matrix analyzed using 
Leica LASX software. Each graph depicts the relative surface area of all attached cells in 
5 fields at 10x magnification at (A) 30 minutes, and (B) 60 minutes. 
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The total number of cells attached in figure II-10 potentially illustrates an 
interaction between SPARC and collagen I that is inhibitory to cell attachment. Results 
showed 3 to 3.5 times more non-SPARC expressing Cd #1 cells attached than the 
SPARC+ control cells or the Cd #1-SPARC cells. Although there are less total cells 
attached in the SPARC expressing cell lines these cells appeared to spread sooner than 
the non-SPARC expressing cells. Taken together these results indicate that SPARC plays 
a potential role in both cell attachment and cell spreading. Furthermore, the results were 
conclusive enough to warrant further assessment and experimental optimization to 
elucidate a cell biological role for SPARC in our model system. 
 
Figure II-10. Preliminary Total Cell Attachment on a Collagen I Matrix. Preliminary 
attachment and spreading assay total cell count of SPARC+ Control UROtsa parent, Cd 
#1, and Cd #1-SPARC cells on a collagen I matrix. Graph shows the total number of cells 
counted in 5 fields at 10x magnification at 30 and 60 minute time points. 
 
Cell Attachment and Spreading of SPARC Expressing and Non-SPARC Expressing 
Urothelial Cells on a Collagen I Matrix 
 
 Once experimental conditions were optimized the cell attachment and spreading 
assay was repeated on a collagen matrix using additional time points. As seen in Figure 
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II-11, the cell spreading results from this experiment were similar to those from the 
preliminary experiment. At 30 and 45 minutes post-plating, non-SPARC expressing Cd 
#1 cells show greater than 80% and 50% of the population, respectively, still rounded. In 
contrast, the SPARC+ control cells and Cd #1-SPARC cells show less than 30% of their 
cell populations rounded at the same time points. The SPARC expressing cell lines show 
a more flattened phenotype at 30 and 45 minutes post-plating compared to the non-
SPARC expressing Cd #1 cells. 15-20% of SPARC+ control cells show a flattened 
morphology at 30 minutes with this percentage increasing to more than 40% at 45 
minutes. The Cd #1-SPARC cells show an even greater percentage of flattened cells with 
35-40% of the population flattened at 30 minutes and 45-50% of cells flattened at 45 
minutes. The non-SPARC expressing Cd #1 cells show a delay in reaching a flattened 
phenotype in the first 60 minutes post-plating. At 30 minutes less than 2% of the cells 
have flattened and this percentage only increases to 5% at 45 minutes. Cellular spreading 
at 60 minutes shows the same trend as earlier time points; however, there is no statistical 
difference in the amount of spreading. Overall, similar to the preliminary results, non-
SPARC expressing cells show a delay in cell spreading compared to SPARC expressing 
cells. 
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Figure II-11. Quantitation of Cell Spreading on a Collagen I Matrix. Data shows the 
percent of total cells in each of three classes: (A) rounded, (B) spreading, or (C) flattened. 
Experiment was performed in triplicate with each time point representing the mean 
±SEM of 10 fields analyzed using Leica LASX software. Statistical significance 
determined using a one-way ANOVA with Dunnett’s Multiple Comparison post hoc test. 
**(p≤0.01), ***(p≤0.001). 
 
 The relative surface area results shown in Figure II-12 support the classification 
results shown in the previous figure. All cell lines show an overall increase in relative 
surface area (px2) as time increases. However, the SPARC expressing cells show a larger 
surface area at 30, 45, and 60 minutes post-plating. This difference is significant when 
compared to the Cd #1 cells at 45 minutes. Interestingly, the Cd #1-SPARC cells show a 
significantly larger relative surface area at 30 minutes compared to the Cd #1 cells. The 
SPARC+ control cells do show a larger relative surface area at 30 minutes although the 
difference is not significant. Additionally, Cd #1 cells do not reach a surface area larger 
than 1500px2 in the experimental time frame, when compared to SPARC+ control cells 
and Cd #1-SPARC cells showing surface areas larger than 1500px2 at the final three time 
points. Therefore, Cd #1 cells remain rounded for a longer period of time than SPARC+ 
control cells and Cd #1-SPARC cells which attach and start spreading quickly. 
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Figure II-12. Relative Surface Area Comparison of Attached Cells. Cell attachment 
and spreading assay analyzed using Leica LASX software. Graphs show the relative 
surface area of all cells attached for each cell line at (A) 15 minutes, (B) 30 minutes, (C) 
45 minutes, and (D) 60 minutes. Experiment was performed in triplicate with each graph 
depicting the mean ±SEM. Statistical analysis was determined using Dunnett’s Multiple 
Comparison post hoc test. *(p≤0.05), **(p≤0.01). 
 
 The total number of cells attached, spreading, and flattened in Figure II-13 
illustrates no difference in the number of cells attached at any time points between cell 
lines. Generally, the number of cells attached increases as time increases. This is 
somewhat expected as both SPARC expressing and non-SPARC expressing cell lines 
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form a monolayer at confluency (Rossi et al., 2001, Somji et al., 2010, Slusser et al., 
2016). Unfortunately, this is different than the preliminary results, depicted in Figure II-
10, which showed decreased cell attachment of SPARC expressing cells. Optimization of 
attachment and spreading assay conditions, namely the decreased number of cells plated, 
may have abrogated SPARC’s effect on cell attachment, resulting in a similar number of 
cells attached across all cell lines. 
 
Figure II-13. Total Cell Attachment on a Collagen I Matrix. Attachment and 
spreading assay total cell count of UROtsa parent, Cd #1, and Cd #1-SPARC cells on a 
collagen I matrix. Graph shows the total number of cells counted in 10 fields at 20x 
magnification for each of four 15 minute time points. Each bar represents triplicate wells. 
Statistical significance determined using a one-way ANOVA with Dunnett’s Multiple 
Comparison post hoc test. 
 
Immunofluorescent Microscopy of F-actin during Cell Spreading 
 
 Representative images in figure II-14 show F-actin localization of cell spreading 
at 45 minutes. The SPARC+ control cells show strong stress fiber formation illustrating 
flattened cells with well-organized cytoskeletal structure in long stress fibers. The Cd #1 
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cells, in contrast, show very little stress fiber formation and cell populations are still 
rounded or potentially very early in the spreading process. When comparing these two 
cell populations to the Cd #1-SPARC cells, stress fiber formation is evident mostly at the 
cell periphery, indicating that they fall between the SPARC+ control cells and the Cd #1 
cells. These cells are late in the spreading process or early in the flattening process and 
progressing toward a mature phenotype. These results show that SPARC is important for 
cell spreading and potentially actin organization, ultimately aiding in cell survival. 
 
Figure II-14. F-Actin Localization during Cell Spreading on a Collagen I Matrix. 
Representative immunofluorescent microscopy images of cell spreading. Images show 
actin cytoskeletal organization using Phalloidin antibody with DAPI as a nuclear stain. 
(A and D) SPARC+ control cells, (B and E) Cd #1 cells, (C and F) Cd #1-SPARC cells. 
 
SPARC siRNA Knockdown in Cd #1-SPARC Transfected Cell Line 
 Previous results indicate a potential role for SPARC in urothelial cell spreading. 
Therefore, to further validate this, SPARC was knocked down via siRNA transfection 
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with the ultimate goal to test cell attachment and spreading when SPARC is repressed in 
cells previously forced to express SPARC. Figure II-15 shows SPARC mRNA and 
protein expression following 24 hour transfection with SPARC specific siRNA. mRNA 
results, in Figure II-15A, show a greater than 40% knockdown in SPARC expression 
with the control transfections not showing any significant change in expression. Protein 
expression was then determined to ensure that the knockdown in mRNA also resulted in 
decreased protein expression within the experimental time frame. Western blot analysis, 
in Figure II-15B, shows knockdown of SPARC expression in the siRNA treated cells 
with no change in expression in the control transfections. These results indicated 
successful knockdown of SPARC in Cd #1-SPARC cells, at both the mRNA and protein 
levels, at 24 hours post-transfection. 
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Figure II-15. siRNA Knockdown of SPARC in Cd #1-SPARC Cells. SPARC mRNA 
and protein expression in Cd #1-SPARC cells treated with SPARC siRNA for 24 hours. 
(A) RT-qPCR results normalized to Untreated Control with data represented as mean 
±SEM. Statistical significance determined using a one-way ANOVA with Dunnett’s 
Multiple Comparison post hoc test. *** denotes significance (p≤0.001). (B) Western blot 
analysis showing SPARC and its corresponding β-actin expression. 
 
Cell Attachment and Spreading Following SPARC siRNA Knockdown in Cd #1-
SPARC Cells. 
 
 Cell attachment and spreading was tested following siRNA knockdown of 
SPARC in Cd #1-SPARC cells. Previous results showed delayed cell spreading in non-
SPARC expressing Cd #1 cells compared to SPARC+ control cells and Cd #1-SPARC 
cells. Results in Figure II-16 show that the increased cell spreading of Cd #1-SPARC 
cells, depicted as Cd #1-SPARC (knockdown), is reversed when these cells are 
transfected with SPARC siRNA. After 24hours of transfection with SPARC-specific 
siRNA and 30 minutes post-plating, Cd #1 and Cd #1-SPARC (knockdown) cells show 
60-70% of the cell population rounded compared to the SPARC+ control cells showing 
less than 30% of the cell population rounded. 30% of the SPARC+ control cells have 
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reached a flattened phenotype at 30 minutes compared to the Cd #1 and Cd #1-SPARC 
(knockdown) cells showing less than 5% of cells reaching a flattened phenotype. 
Although the results at 45 minutes and 60 minutes are not significant, the SPARC+ 
control cells show a greater percentage of flattened cells compared to Cd #1 and Cd #1-
SPARC (knockdown) cells. Overall, there is a delay in cell spreading of Cd #1 cells and 
Cd #1-SPARC (knockdown) cells following siRNA knockdown of SPARC. 
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Figure II-16. Quantitation of Cell Spreading Following SPARC siRNA Knockdown. 
Data shows the percent of total cells in each of three classes: (A) rounded, (B) spreading, 
or (C) flattened. Experiment was performed in triplicate with each time point 
representing the mean ±SEM of 10 fields analyzed using Leica LASX software. 
Statistical significance determined using a one-way ANOVA with Dunnett’s Multiple 
Comparison post hoc test. **(p≤0.01). 
 
 As with previous results, relative surface area (px2) shown in Figure II-17 shows a 
general overall increase in surface area as time increases. Cd #1 and Cd #1-SPARC 
(knockdown) cells do not reach a relative surface area larger than 1900px2 by 60 minutes. 
In comparison, SPARC+ control cells reach a relative surface area of 1900px2 at 30 
minutes and ultimately reach a relative surface area of 2250px2 at 60 minutes. 
Interestingly, the difference in relative surface area observed at 30 minutes is significant 
for both Cd #1 and Cd #1-SPARC (knockdown) cells. Additionally, the difference in 
relative surface area remains significant for the Cd #1 cells at 45 minutes; however, the 
difference between the SPARC+ control cells and the Cd #1-SPARC (knockdown) cells, 
although observable, is no longer significant. Overall, these results support the 
classification results, in Figure II-16, that knockdown of SPARC in Cd #1-SPARC 
(knockdown) cells delays cell spreading similar to that of Cd #1 cells. 
 74 
 
 
 
 
Figure II-17. Relative Surface Area Comparison of Attached Cells Following 
SPARC siRNA Knockdown. Cell attachment and spreading assay analyzed using Leica 
LASX software. Graphs show the relative surface area of all cells attached for each cell 
line at (A) 15 minutes, (B) 30 minutes, (C) 45 minutes, and (D) 60 minutes. Experiment 
was performed in triplicate with each graph depicting the mean ±SEM. Statistical 
analysis was determined using Dunnett’s Multiple Comparison post hoc test. *(p≤0.05), 
***(p≤0.001). 
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 The total number of attached cells (Figure II-18) was calculated for this 
experiment and, again, there was no difference in the total number of cells attached 
between cell lines at any time point. As seen in the previous experiment, there is an 
overall increase in the number of cells attached as time increases. Therefore, it does not 
appear that SPARC is significantly influencing urothelial cell attachment to collagen I. 
 
Figure II-18. Total Cell Attachment on a Collagen I Matrix Following SPARC 
siRNA Knockdown. Attachment and spreading assay total cell count of SPARC+ 
Control UROtsa parent cells, Cd #1, and Cd #1-SPARC (knockdown) cells on a collagen 
I matrix. Graph represents the total number of cells counted in 10 fields at 20x 
magnification for each of four 15 minute time points. Experiment was done in triplicate 
with data represented as the mean ±SEM. Statistical significance determined using a one-
way ANOVA with Dunnett’s Multiple Comparison post hoc test. 
 
Discussion 
 Previous lab results have analyzed various cell biological roles for SPARC 
including cell growth, migration, and invasion. Here, a variation of the wound closure 
experiment was used to analyze migration and proliferation of non-SPARC expressing 
and SPARC expressing bladder cells. Interestingly, based on results from this study and 
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previous studies, SPARC does not appear to play a significant role in wound closure in 
our model system. Alternatively, SPARC may play a role in wound closure that can be 
overtaken by a similar protein such as Hevin, from the same family, when SPARC is 
absent; resulting in no obvious difference in wound closure. SPARC and other family 
members have been described to play a role in normal wound closure processes, 
including the inflammatory phase as well as the proliferation and migration phase 
(Kyriakides and Bornstein, 2003). Because these results do not indicate a role for SPARC 
in wound closure in urothelial cells, it is possible there is an alternative role for SPARC 
that is more important to cell survival in this system. 
SPARC’s known interaction with collagen I, the most abundant collagen in the 
extracellular matrix space, and overall unknown functional role in bladder cancer 
prompted assessment of cellular attachment and spreading. Preliminary results showed a 
decrease in SPARC expressing cell attachment indicating a potential role for SPARC. 
SPARC has been shown to bind to collagen in a calcium-dependent manner blocking 
integrin-mediated cell binding to collagen (Bradshaw et al., 2009). Although subsequent 
experiments showed no difference in cell attachment to a collagen I matrix, it is possible 
that reducing the number of cells plated from 50,000 cells/well to 30,000 cells/well was 
sparse enough to abrogate paracrine effects of SPARC on cell attachment. Interestingly, 
results consistently showed a delay in cell spreading in cells lacking SPARC expression. 
Sufficient knockdown of SPARC in the malignant cell line transfected with SPARC was 
necessary to provide further evidence for SPARC’s role in cell spreading. Overall, there 
was no difference in cell attachment; however, the results of cell spreading indicate a 
potential autocrine role for SPARC in our model system. Based on these results, once 
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SPARC expressing cells attach, secreted SPARC may act to increase cell spreading 
allowing this cell to receive survival signals quicker. 
Manual analysis of cell attachment and spreading was a tedious process and 
imparted an aspect of human bias that needed to be addressed. Several studies have 
utilized observation to classify cells based on morphology (Everitt and Sage, 1992, 
Motamed and Sage, 1998, Hudson et al., 2005, Delostrinos et al., 2006). The large 
experimental set up in this study necessitated use of an automated, computer-based 
method to classify cells. Fiji, with the PHANTAST plugin, developed by Jaccard et al. 
(2014), allowed gray-scale phase contrast images to be analyzed and categorized using 
the classifier from the Leica LASX program. Interestingly, several programs have been 
developed to analyze cell attachment and spreading; however, the user-friendly interface 
of the Leica LASX program was important, considering the amount of images needed to 
be classified. Although there was an increase in the “pre-processing” needed to analyze 
the attachment and spreading results, these tools taken together made the end result more 
efficient and more consistent by reducing human bias. To the author’s knowledge, this 
work represents the first time these two software programs have been used in conjunction 
for cell attachment and spreading analysis of phase contrast images. 
The described role for SPARC promoting cell spreading in our model system of 
cadmium induced bladder cancer is contradictory to the literature. SPARC has been 
shown to play tissue-specific roles in cell biological processes, including inducing cell 
rounding in other systems via focal adhesion turnover (Lane and Sage, 1994). Since this 
role for SPARC has not been previously described, the mechanism behind SPARC’s role 
in promoting urothelial cell spreading remains unknown. It is possible that SPARC’s 
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interaction with the cell surface did not interfere with the receptors for attachment, but 
rather promoted activation of those receptors utilized for cell spreading. Interestingly, the 
α2β1 integrin receptor is known to bind to collagen I fibrils and promote cell spreading 
(Jokinen et al., 2004). Therefore, SPARC could be preferentially inhibiting binding of 
alternative integrins to collagen leaving the α2β1 integrin receptor available for enhanced 
binding and subsequent cell spreading. However, currently there are no known epithelial 
cell surface receptors for SPARC so it is also possible that SPARC’s role is indirect and 
its effect is elicited through regulation of growth factors or other cell signaling molecules. 
Analysis of relevant cell signaling pathways could provide further insight into the 
mechanism behind SPARC’s role in promoting cell spreading. These results suggest a 
role for SPARC in promoting cell spreading that may inhibit tumor formation, requiring 
it to be repressed. 
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CHAPTER III 
TRANSCRIPTION FACTOR BINDING AND SPARC REPRESSION IN CD-
TRANSFORMED UROTHELIAL CARCINOMA CELLS 
 
Introduction 
 SPARC, has been shown to be differentially regulated in many types of cancers 
(Nagaraju et al., 2014). This has led to it being described as oncogene-like and tumor 
suppressor-like depending on the cancer (Nagarju et al., 2014). There have been organ-
specific and cancer-specific publications proposing mechanisms for SPARC gene 
regulation, including: promoter hypermethylation, microRNA inhibition, and alternative 
transcription factor binding (Liu et al., 2018, Ahir et al., 2019, Munk et al., 2019). 
However, there is little known about the regulation of SPARC in bladder and bladder 
cancer.  
Previous microarray analysis of the arsenic and cadmium transformed UROtsa 
cells showed SPARC as the gene with the largest change in expression across all of the 
transformed lines (Garrett et al., 2014). SPARC was significantly repressed to below 
detectable limits following arsenic or cadmium exposure (Larson et al., 2010, Garrett et 
al., 2014). These results warranted investigation into the mechanism by which SPARC 
was being repressed. One hypothesis was that this repression was the result of one or 
more epigenetic modifications. Two modifications previously studied were histone 
acetylation and methylation. Experiments were performed to inhibit methylation and 
acetylation in the arsenic and cadmium transformed cells using methyltransferase 
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inhibitor 5-Aza-2’-deoxycytidine (5-AZC) and/or a histone deacetylase inhibitor MS-275 
in an attempt to rescue SPARC expression (Larson et al., 2010). Results from this 
experiment showed that inhibiting DNA methylation, or histone acetylation, did not 
result in an increase in SPARC expression (Larson et al., 2010). Based on these results, it 
was concluded that DNA methylation and/or histone acetylation was most likely not 
responsible for SPARC gene repression in our system. Additionally, several miRNAs 
were investigated for differential expression in the transformed cell lines; however, no 
clear results were found. These results lead the current study to focus on an alternative 
explanation for SPARC gene repression by analyzing transcription factor binding to the 
SPARC promoter. 
The SPARC promoter region has been described and characterized by several 
groups and determined to be highly conserved between human, mouse, and bovine 
species (Hafner et al., 1994, McVey et al., 1988, Young et al., 1989). Vial et al. (2000) 
summarizes important similarities in the SPARC promoter between these species. All 
three contain a GGA-rich motif that is necessary for transcriptional activation. There are 
two described GGA boxes that are separated by a small spacer region that has been 
associated with gene repression (Hafner et al., 1994). Interestingly, Hafner et al. (1994) 
found that the GGA boxes did not contribute to human cell-specific expression of 
SPARC, in contrast to this being described for GGA sequences in the bovine SPARC 
promoter. Additionally, there is no TATA box or CAAT box for RNA polymerase II 
docking and transcription initiation (McVey et al., 1988). The GGA boxes are located 
between 50 and 130bp upstream of the transcriptional start site located within the short 
first exon (McVey et al., 1988, Young et al., 1989). In a TATA-less promoter region, Sp1 
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and/or Sp3 bind and recruit the necessary transcription machinery, including the TATA-
box binding protein (TBP) using tethering co-factors (Vizcaíno et al., 2015). 
Interestingly, Sp1, specifically, has been described as necessary for activation of TATA-
less genes (Vizcaíno et al., 2015). Therefore, with SPARC lacking a TATA box, Sp1 and 
Sp3 present as intriguing transcription factors to focus on with this study. 
Specificity Protein 1 (Sp1) and Sp3 are two transcription factors that have been 
described to bind to the SPARC gene promoter and activate gene expression 
(Chamboredon et al., 2003, Briggs et al., 2002, Xu et al., 2010). They contain three 
highly conserved C-terminal zinc-finger motifs and bind to the same GC-rich consensus 
sequence; however, DNA-binding properties and regulatory functions differ between the 
two (Vizcaíno et al., 2015). Sp1 has been described to have two isoforms, differing only 
slightly in the N-terminal domain. In contrast, Sp3 has been shown to have four isoforms 
due to multiple translational start sites (Li and Davie, 2010). The two long isoforms only 
differ slightly, again, in the N-terminal domain and resemble the structure of Sp1; 
however, the short isoforms are missing one of the activating domains near the N-
terminus of the full-length protein and is thought to be responsible for Sp3 gene 
repression (Li and Davie, 2010). Sp1 and Sp3 transcription factors are ubiquitously 
expressed and can positively or negatively regulate thousands of gene targets, including 
autoregulating itself (Vizcaíno et al., 2015). Interestingly, Sp1 and Sp3 may preferentially 
bind to specific binding sites on the same promoter (Li and Davie, 2010). Which 
transcription factor is bound to which site could potentially influence gene expression via 
recruitment of active or repressive transcription complexes (Li and Davie, 2010). 
Downstream target genes include those for many important cellular processes, cell cycle 
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regulation, development, and hence, those important for the “hallmarks of cancer” (Li 
and Davie, 2010, Vizcaíno et al., 2015). Additionally, these transcription factors have 
been shown to be susceptible to oxidative stress resulting in their repression; as well as, 
post-translational modifications affecting DNA binding, subcellular localization, and 
ability to recruit chromatin remodeling complexes (Jutooru et al., 2010, Larabee et al., 
2005, Vizcaíno et al., 2015).  
SOX5 is an alternative transcription factor implicated in regulating SPARC 
expression (Huang et al., 2008). SOX5 is one of over 20 members belonging to the sex-
determining region on the Y chromosome-related high mobility group box (SOX) 
transcription factor family (Grimm et al., 2019). SOX5 is in group D with SOX6 and 
SOX13 showing a relatively extensive and conserved N-terminal domain as well as a 
coiled-coil domain. The coiled-coil along with a leucine zipper and glutamine-rich 
domain enable formation of dimers that can enhance DNA binding (Grimm et al., 2019). 
This family of proteins is structurally quite diverse; however, they are defined by the 
highly conserved High Mobility Group (HMG) domain containing the DNA binding 
motif (Grimm et al., 2019). Also within this domain are nuclear localization signals and a 
leucine-rich nuclear export signal for efficient transport into and out of the nucleus 
(Grimm et al., 2019). This domain was found to recognize a (A/T)(A/T)CAA(A/T) 
consensus sequence on the DNA; but, SOX transcription factors do not show a high 
binding affinity (Grimm et al., 2019, Harley et al., 1994). However, Wegner (2010) 
addresses the short length of the consensus sequence and extensively reviews proposed 
mechanistic details regarding differences in DNA binding between specific SOX family 
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groups. Ultimately, it was concluded that more than the consensus sequence is needed to 
fully describe SOX transcription factor binding to DNA (Wegner, 2010). 
SOX transcription factors are critical for development and cell fate; hence, their 
expression is tightly regulated (Grimm et al., 2019, Lefebvre et al., 2007). They show 
tissue and time-specific expression and can be regulated by post-translational 
modifications as well as recruitment of necessary protein partners (Grimm et al., 2019). 
Tightly regulated proteins can be ideal targets for cancer initiation and progression, 
especially those important for development and cellular reprogramming. Two recent 
studies linked SOX5 to epithelial to mesenchymal transition (EMT) via regulation of 
Twist1 in breast cancer and hepatocellular carcinoma progression (Pei et al., 2014, Wang 
et al., 2015). Interestingly, one study linked SOX5 to nasopharyngeal carcinoma 
progression via downregulation of SPARC (Huang et al., 2008). Additionally, Huang et 
al. (2008) found no change in SPARC expression with treatment of 5-AZC; similar to 
previous studies performed by Larson et al. (2010) in our model system of bladder 
urothelial carcinoma. Analysis of the SPARC sequence from UCSC genome browser, 
identified a putative SOX5 consensus sequence within the SPARC promoter 
approximately 650bp upstream of the transcriptional start site. SOX5 has been implicated 
in a few cancer types with both tumor suppressor and oncogene characteristics; however, 
not much is known about SOX members, SOX5 specifically, in bladder cancer. 
Cadmium has been described to indirectly increase ROS production, ultimately 
increasing oxidative stress (Rani et al., 2014). Cadmium has also been shown to replace 
zinc in zinc-finger transcription factors (Larabee et al., 2004); making Sp1 and Sp3 
transcription factors viable targets to study their binding to the SPARC promoter and 
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potential regulation of gene expression in our model system. However, the link between 
cadmium and SOX5 is not as clear as that with Sp1 and Sp3. Although there is currently 
no literature linking cadmium to SOX5, cadmium may be indirectly promoting its 
binding to the SPARC promoter. Lefebvre et al., (1998) showed that SOX5 homo- or 
heterodimerization with SOX6, through conserved coiled coil motifs, enhanced 
transcription factor binding of two or more neighboring recognition sites. Interestingly, 
there are three putative SOX5 recognition sites in the SPARC promoter (Kent et al., 
2002). This, in conjunction with, Huang et al. (2010) reporting SOX5 repression of 
SPARC, make SOX5 a reasonable transcription factor to study in our model system. 
Preliminary studies performed by Vijayalekshmi Nair in our laboratory 
(unpublished data) assessed Sp1 and Sp3 expression in our model system along with the 
effect of acute cadmium exposure on Sp1 and Sp3 expression. Expression results showed 
a slight decrease in mRNA expression in the cadmium-transformed cell lines compared to 
the non-transformed UROtsa parent cells. However, protein expression was variable 
among the cadmium-transformed cell lines showing increased expression, decreased 
expression, and no change in expression. Next, 24h exposure to 0.5, 1, 2, or 4μM 
cadmium to UROtsa parent cells resulted in a dose-dependent decrease in Sp1, Sp3, and 
SPARC protein expression in this cell line. Therefore, cadmium may be influencing 
expression of transcription factors necessary for SPARC expression in the control, 
SPARC-expressing parental cell line. These preliminary results, in conjunction with the 
strong permanent repression of SPARC led to our hypothesis that cadmium may be 
significantly decreasing SPARC expression by silencing the promoter early in the 
malignant transformation process. Alternative transcription factor binding may be 
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contributing to the mechanism used by cadmium to silence the promoter in our in vitro 
model system of cadmium-induced bladder urothelial carcinoma. 
Materials and Methods 
Cell Culture 
 SPARC+ UROtsa parent and Cd #1 cells were maintained in 25cm2 tissue culture 
flasks and cultured as previously described in Chapter II Materials and Methods section. 
Cells were expanded into 75cm2 tissue culture flasks when experimental protocols 
dictated. Once expanded, cells were fed fresh growth media every 3 days and cultured as 
previously described. 
RNA and Protein Isolation from SPARC+ UROtsa Parent and Cd #1 Cell Line 
Total RNA and protein were isolated from cells as previously described in 
Chapter II Materials and Methods section, using TRI REAGENTTM (MRC), and PBS 
lysis buffer with protease inhibitors, respectively. RNA concentration was determined 
using the Nanodrop One (Thermo Scientific) and a portion of each sample was diluted to 
20ng/µl concentration for subsequent RT-qPCR analysis. Protein concentration was 
determined via BCA colorimetric assay, as previously described, for subsequent use in 
Western Blot analysis. 
RT-qPCR Analysis of Sp1, Sp3 and SOX5 Transcription Factors in SPARC+ 
UROtsa Parent and Cd #1 Cell Line 
 
 Sp1, Sp3, and SOX5 mRNA expression in UROtsa Parent and Cd #1 cells was 
determined using real-time reverse transcription polymerase chain reaction (RT-qPCR). 
cDNA synthesis was performed as previously described in Chapter II Materials and 
Methods section. 
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 2µL of cDNA was amplified using 20µM Sp1, Sp3, or SOX5 specific primers 
(Qiagen #QT01870449, #QT00094892, and #QT00084784 respectively) and recorded 
using SYBR green fluorescence in a total reaction volume of 20µL. Samples were run on 
a CFX960 Thermocycler (Bio Rad) using the following cycling parameters for Sp1 and 
Sp3: 5 min. at 95°C, denaturation – 15sec. at 95°C, annealing – 45sec. at 62°C, repeat 
denaturation and annealing steps x39, and collection of the melt curve. SOX5 cycling 
parameters were similar but used a slightly lower annealing temperature at 60°C. Sp1 and 
Sp3 expression was determined using a relative standard curve generated from 1:2 
dilutions of the SPARC+ UROtsa Parent cells. SOX5 expression was determined using a 
relative standard curve generated from 1:2 dilutions of Cd #1 cells. Sp1, Sp3, and SOX5 
mRNA expression was normalized to β-actin amplified using an Invitrogen primer set 
with the following sequences, sense: CGACAACGGCTCCGGCATGT, anti-sense: 
TGCCGTGCTCGATGGGGTACT, under the same cycling parameters as Sp1 and Sp3. 
β-actin expression was determined using a relative standard curve generated from 1:2 
dilutions of UROtsa Parent cells. Expression data was graphed and statistical analysis 
performed using Graphpad PRISM v5.01 (Graphpad Software). 
Western Blot Analysis of Sp1, Sp3 and SOX5 Transcription Factors in SPARC+ 
UROtsa Parent and Cd #1 Cell Lines 
 
 Sp1, Sp3, and SOX5 protein expression in UROtsa Parent and Cd #1 cells was 
determined using Western Blot analysis as previously described in Chapter II Materials 
and Methods section. Membranes were incubated with rabbit anti-human Sp1 antibody 
(Cell Signaling #9389) using a 1:1,000 dilution, mouse anti-human Sp3 antibody (Santa 
Cruz Biotechnology, Inc. #sc-28305X) [Dallas, TX] at 2.0µg/mL using a 1:500 dilution, 
or rabbit anti-human SOX5 antibody (Abcam #ab94396) at 1.0mg/mL concentration 
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using a 1:1,000 dilution in 5% powdered milk in TBS-T overnight at 4°C. Membranes 
were washed three times with TBS-T and Sp1 and SOX5 membranes were incubated 
with anti-rabbit IgG HRP-linked antibody (Cell Signaling #7074) at 1:3,000 and anti-
biotin HRP-linked antibody (Cell Signaling #7075) at 1:1,500 in 1% powdered milk in 
TBS-T for 1.25h at room temperature. SOX5 membrane was incubated with anti-mouse 
IgG HRP-linked antibody (Cell Signaling #7076) at 1:3,000 and anti-biotin HRP-linked 
antibody (Cell Signaling #7075) at 1:1,500 in 1% powdered milk in TBS-T for 1.25h at 
room temperature. Membranes were washed and protein visualized as previously 
described in Chapter II Materials and Methods section. The membranes used for Sp1, 
Sp3, and SOX5 protein expression were then stripped and re-probed for β-actin as 
previously described in Chapter II Materials and Methods section. 
PCR Primer Design Using NCBI Genome Browser and Oligo7 for Transcription 
Factor Binding to SPARC Promoter 
 
 The SPARC gene sequence plus 1,000 base pairs upstream was extracted from the 
NCBI UCSC Genome Browser (Kent et al., 2002) into a word document. A literature 
search revealed putative binding sites within the SPARC promoter for Sp1, Sp3, and 
SOX5 transcription factors (Chamboredon et al., 2003, Huang et al., 2008, Xu et al., 
2010). The SPARC sequence extracted from UCSC Genome Browser was searched for 
these binding sites to validate using Oligo7 to design primers for Chromatin 
Immunoprecipitation experiments. 
 The sequence upstream of the SPARC gene containing the putative transcription 
factor binding sites was uploaded into Oligo7. Once there, primers were designed to 
amplify those specific regions using PCR. Briefly, 19-25 base pair segments of the 
sequence upstream and downstream of the putative binding sites were analyzed for 
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potential primers. Once segments were selected, several measurements were determined 
to estimate the success of the primer. The measurements included: melting temperature, 
product size, CG content, and priming efficiency. Based on these measurements, ten 
primer pairs were designed for the putative Sp1 and Sp3 transcription factor binding sites 
and ten primer pairs were designed for the putative SOX5 transcription factor binding site 
within the SPARC promoter. Primers were obtained from Invitrogen with sequences 
outlined below in Table 2. 
Table 2. Sp1/Sp3 and SOX5 Primer Sequences. 
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Genomic DNA Isolation from SPARC+ UROtsa Parent Cell Line 
 Genomic DNA was isolated from the UROtsa Parent cell line to verify PCR 
product amplification using the primers designed for the Chromatin ImmunoPrecipitation 
experiments. DNA was isolated and purified according to the manufacturer’s protocol 
using the DNeasy Blood and Tissue Kit (Qiagen #69504). Briefly, a harvested UROtsa 
Parent cell pellet was resuspended in PBS and Proteinase K and buffer were added. The 
sample was vortexed and incubated at 56°C for 10 minutes. Then ethanol was added and 
the solution was pipeted into a DNeasy mini spin column to precipitate out the DNA. The 
column/DNA was then washed and centrifuged at ≥8,000 rpm. This was followed by a 
second wash and centrifuge at ≥14,000 rpm to dry the membrane. The column was then 
removed and placed in a clean RNase/DNase free tube and buffer was added to the 
membrane. This was then centrifuged at ≥8,000 rpm to elute the DNA. The DNA was 
then quantified using the Nanodrop One (Thermo Scientific). Once the concentration was 
determined the sample was utilized for conventional PCR analysis.  
Conventional PCR and Gel Electrophoresis of Genomic DNA from SPARC+ 
UROtsa Parent Cell Line 
 
 Conventional PCR was run to analyze the success of the primers designed for 
Sp1, Sp3, and SOX5 transcription factor putative binding sites within the SPARC 
promoter. Briefly, a 45µL mastermix was made for each primer set using: 4.5μL/reaction 
PCR Buffer II (10% of total reaction volume), 3.6µL/reaction Magnesium Chloride (8% 
of total reaction volume), 0.9µL/reaction upper primer (2% of total reaction volume), 
0.9µL/reaction lower primer (2% of total reaction volume), 0.45µL/reaction TAQ 
Polymerase (1% of total reaction volume), 18.45µL/reaction PCR H20 (41% of total 
reaction volume), 7.2µL/reaction dNTP mixture (16% of total reaction volume), and 
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9µL/reaction genomic DNA (20% of total reaction volume). The mastermix constituents 
were part of the GeneAmp PCR Reagent Kit with AmpliTaq® DNA Polymerase (Applied 
Biosystems #N801-0055) [Foster City, CA] The samples were then run on a GeneAmp 
PCR System 9700 (Applied Biosystems) using the following cycling parameters: 5 min. 
at 94°C; denaturation – 30sec. at 94°C; annealing – 30sec. at 55°C; extension – 30sec. at 
72°C; repeat denaturation, annealing, and extension steps x39, followed by a final 
extension at 72°C for 7m, and a hold at 4°C until samples were properly stored. The 
cycling parameters for the SOX5 primers were the same except an annealing temperature 
of 52°C was used. 10µL of sample was removed from each tube and added to a fresh 
0.5µL cDNA microfuge tube every 5 cycles starting at 25 cycles to optimize the amount 
of cycles needed to amplify product. 
 Once products were amplified, gel electrophoresis was used to visualize the 
products. 500mL of 1xTAE was made from a 50x TAE stock solution. 2% small or 
medium agarose gels were made by adding 0.8g agarose (Fisher Scientific) to 40mL 
1xTAE or 1.3g agarose to 65mL 1xTAE, respectively, in an Erlenmeyer flask. This was 
then covered using a paper towel and microwaved until solution was clear. Once clear, 
the solution was cooled slightly until able to be handled. Then, 1µL or 1.62µL, based on 
the gel size, of 10µg/µL ethidium bromide (EtBr) was added to the agarose solution and it 
was poured into a taped gel cassette. While the gel was solidifying the samples were 
prepared to be loaded. 9µL sample was added to 2.25µL loading dye and mixed.  
Once the gel was solidified the tape was removed and the comb was removed 
revealing the wells. The gel was placed into the electrophoresis chamber and covered 
with 1xTAE buffer. 5µL of the high/lo ladder (Bionexus #BN2050) [Oakland, CA] was 
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loaded into the first and last well and 10µL of each sample were loaded into respective 
wells between the ladder. The cover was placed on the electrophoresis unit and the 
electrodes were connected to the power source. The DNA in the wells that had been 
amplified was separated on the gel from anode (negative) to cathode (positive) for 1-1.5h 
at 100-110 volts. 
Once the gel finished, it was removed from the electrophoresis chamber and 
stained with an EtBr solution (80µL H2O:2µL EtBr for small gel and 160µL H2O:4µL 
EtBr for a medium gel) on the orbital shaker at room temperature for 30 minutes. The gel 
was then quick washed three times with H2O followed by three 5-10 minute washes with 
H2O. The gel was then taken and imaged on the ChemiDoc MP Imaging System (Bio 
Rad).  
Chromatin ImmunoPrecipitation Assay for Sp1, Sp3, and SOX5 Transcription 
Factors In SPARC+ UROtsa Parent and Cd #1 Cell Lines 
 
 Chromatin ImmunoPrecipitation was performed using the ChIP-IT Express 
Enzymatic Magnetic Chromatin Immunoprecipitation Kit and Enzymatic Shearing Kit 
(Active Motif #53009 and #53035, respectively) [Carlsbad, CA] and as described in 
Somji et al. (2011). UROtsa Parent and Cd #1 cells were expanded and grown in 75cm2 
tissue culture flasks. Once cells were a confluent monolayer they were fixed using 1% 
formaldehyde (Sigma #F8775) for 10 minutes. The cells were washed with 1xPBS and 
treated with glycine stop solution to stop the fixation. The cells were then washed again 
and the monolayer was scraped off the flask using PBS containing 2mM PMSF. The 
cell/scraping solution was transferred into a 15mL connicle tube and centrifuged at 
2,500rpm for 10 minutes at 4°C. The supernatant was removed and the cell pellet was 
stored at -80°C. 
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 The thawing cell pellet was resuspended in lysis buffer containing PMSF and 
Protease Inhibitor Cocktail (PIC) and incubated on ice for 30 minutes. Then, the cell/lysis 
buffer solution was transferred to the dounce homogenizer (Active Motif #40401) and 
homogenized on ice for 10 strokes to aid in nuclei release from cells. Homogenate was 
transferred to a RNase/DNase free tube and centrifuged at 5,000rpm for 10 minutes at 
4°C to pellet the nuclei. The supernatant was removed and the pellet was resuspended in 
digestion buffer supplemented with PMSF and PIC and incubated for 5 minutes at 37°C. 
Enzymatic shearing cocktail was added to warmed nuclei and incubated for 5 minutes for 
UROtsa Parent nuclei and 7.5 minutes for Cd #1 nuclei. This difference in incubation 
times is due to the compactness of the epithelial monolayer formed by the malignant Cd 
#1 cells and has been previously optimized (Somji et al., 2011). The enzymatic shearing 
was stopped by adding ice-cold EDTA and tubes were chilled on ice for 10 minutes. The 
sheared chromatin was then centrifuged at 4°C for 10 minutes at maximum speed. The 
sheared chromatin supernatant was then transferred to RNase/DNase free tubes. 
 An aliquot of UROtsa Parent and Cd #1 sheared chromatin was then cleaned to 
assess the shearing efficiency and obtain a DNA concentration. 5M NaCl was added to 
each sample followed by a 4h incubation at 65°C to reverse the protein-DNA cross-
linking. RNase A was then added and samples were incubated at 37°C for 15 minutes to 
degrade RNA. Protein was degraded by adding Proteinase K and incubating samples at 
42°C for 1.5h. UltrapureTM Phenol:Chloroform:Isoamyl Alcohol (Invitrogen #15593-031) 
was added and samples were vortexed. They were then centrifuged for 5 minutes at 
maximum speed and the aqueous phase transferred to a fresh RNase/DNase microfuge 
tube. Finally, 3M sodium acetate pH 5.5 (Ambion®, Waltham, MA) and 100% EtOH 
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(Sigma-Aldrich) were added and the samples were vortexed and place in the -20°C 
freezer overnight. 
 Samples were then centrifuged at 4°C for 10 minutes at maximum speed and the 
supernatant discarded. The DNA pellet was washed with ice-cold 70% EtOH and 
centrifuged at 4°C for 5 minutes at maximum speed. The supernatant was discarded and 
the pellet was air dried and resuspended in 1xTE. DNA concentration was determined 
using the NanoDrop One (Thermo Scientific). Once the concentration was determined, 
samples were run on a 1% agarose gel, prepared as previously described, loading 5μL 
and 10μL of each sample and visualized on the ChemiDoc MP Imaging System (Bio 
Rad) showing 200bp-1500bp fragments of chromatin. The concentration determined here 
was used to add equal amounts of chromatin to each immunoprecipitation reaction. 
 Once the shearing efficiency and DNA concentration were determined, 
immunoprecipitation was performed. 10μL of input DNA from each sample was set 
aside, not immunoprecipitated, and stored. ChIP reactions were set up for UROtsa Parent 
and Cd #1 cells using 4 different antibodies: Sp1, Sp3, SOX5, and Negative IgG control 
resulting in eight total reactions. 50μg/μL Bovine Serum Albumin (BSA) was added to 
each reaction to coat the magnetic beads and reduce any non-specific binding. 7μg of 
sheared chromatin was incubated with: BSA, Protein-G magnetic beads, buffer, protease 
inhibitor cocktail (PIC), H2O, and 3μg of Sp1, Sp3, SOX5, or Negative IgG control 
antibody. Samples were incubated on an end-to-end rotator for 4h at 4°C. The samples 
were briefly spun and then placed on a magnetic stand to pellet the beads. The 
supernatant was discarded and the beads were washed three times with ChIP Buffer 1 and 
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2. Each time they were washed, the samples were placed back in the magnetic stand to 
pellet the beads and discard the supernatant. 
 The washed beads were then resuspended in elution buffer and incubated on an 
end-to-end rotator for 15 minutes at room temperature. Samples were briefly spun and 
reverse cross-linking buffer was added. The samples were then, again, placed in the 
magnetic stand and the beads were pelleted. The supernatant containing the chromatin 
was then transferred to a fresh RNase/DNase free tube. The input DNA was then 
processed with the ChIP samples. 5M NaCl and buffer were added to the input DNA 
bringing the volume to equal that of the ChIP samples. All samples, input and ChIP, were 
then incubated at 95°C for 15 minutes in the GeneAmp PCR System 9700 (Applied 
Biosystems). Samples were brought back to room temperature and Proteinase K was 
added to degrade any remaining protein. The samples were then incubated at 37°C for 1h. 
Again, samples were returned to room temperature and Proteinase K Stop Solution was 
added. All samples could then be used for conventional PCR and gel electrophoresis 
analysis; or, samples could be further purified for use in RT-qPCR analysis. 
Conventional PCR and Gel Electrophoresis of Sp1, Sp3 and SOX5 ChIP DNA in 
SPARC+ UROtsa Parent and Cd #1 Cell Lines 
 
 Conventional PCR was run to analyze the amplification of DNA associated with 
Sp1, Sp3, and SOX5 transcription factor putative binding sites within the SPARC 
promoter. Briefly, a 20µL/reaction mastermix was made for each primer set as described 
previously, comprised of: PCR Buffer II (10% of total reaction volume), Magnesium 
Chloride (8% of total reaction volume), upper primer (2% of total reaction volume), 
lower primer (2% of total reaction volume), TAQ Polymerase (1% of total reaction 
volume), PCR H20 (41% of total reaction volume), dNTP mixture (16% of total reaction 
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volume), and ChIP DNA (20% of total reaction volume). The ChIP samples were then 
run on a GeneAmp PCR System 9700 (Applied Biosystems) using Sp1/Sp3-10 or SOX5-
5 primer sets (Invitrogen) with sequences outlined in Table 2. This was performed using 
the cycling parameters described previously. 
 Once products were amplified, gel electrophoresis was used to visualize the 
products as previously described in this section. Integrated Optical Densitometry (I.O.D.) 
analysis was performed using ImageLab version 4.1 (Bio Rad). Data was graphed and 
statistical analysis performed using Graphpad PRISM v5.01 (GraphPad Software). 
Sp1, Sp3, and SOX5 siRNA Transfection of SPARC+ UROtsa Parent and Cd #1 Cell 
Lines 
 
 UROtsa Parent and Cd #1 cells were plated and grown to confluency in 12 well 
tissue culture plates. Two wells of each plate contained coverslips for confocal 
visualization of fluorescently labeled positive control siRNA. These wells were seeded 
with more cells than the other wells of the plate due to slightly delayed growth on glass 
coverslips compared to tissue culture plastic. Once confluent, duplicate wells were 
treated with one of five siRNAs: siGLO Lamin A/C control (Dharmacon #D-001620-02-
05) a fluorescently labeled positive control, Non-targeting Scrambled (Dharmacon #D-
001810-01-05), Human Sp1 (Dharmacon #J-026959-05-0002), Human Sp3 (Dharmacon 
#J-023096-07-0002), or Human SOX5 (Dharmacon #J-008203-05-0002), for 24h or 48h.  
siRNAs were added to specified wells as described previously in Chapter II 
Materials and Methods section. The plate was gently swirled to mix and placed in the 
37°C tissue culture incubator for 24h or 48h. The siGLO Lamin A/C and Non-targeting 
Scrambled siRNA were used as controls along with: siQuest only, Sp1 siRNA only, and 
untreated wells. 
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SiGLO Lamin A/C treated coverslips were then washed twice with DMEM-F12-
no phenol red (Gibco) and incubated in 3.7% methanol-free formaldehyde (Polysciences, 
Inc., #18814-10) for 10 minutes at room temperature. Coverslips were washed twice with 
PBS- and once with PBS+ containing calcium and magnesium salts. Free aldehyde groups 
were quenched using 0.1M NH4Cl (Sigma) in PBS for 15 minutes at room temperature 
and again washed. Coverslips were then mounted on microscope slides using ProLong 
DIAMOND DAPI medium (Life Technologies, #P36971) for nuclear staining. 
Transfection efficiency was visualized and shown to be successful under the transfection 
parameters used (data not shown). 
RNA Isolation of Sp1, Sp3, and SOX5 siRNA Transfected SPARC+ UROtsa Parent 
and Cd #1 Cell Lines 
 
Total RNA was isolated from siRNA treated cells using TRI REAGENTTM 
(MRC) as previously described in Chapter II Materials and Methods section. RNA 
concentration was determined on the Nanodrop One (Thermo Scientific) and a portion of 
each sample was diluted to 20ng/µl concentration for subsequent RT-qPCR analysis. 
RT-qPCR Analysis of Sp1, Sp3, and SOX5 Transcription Factors in siRNA Treated 
SPARC+ UROtsa Parent and Cd #1 Cell Lines 
 
 Sp1, Sp3, and SOX5 mRNA expression in siRNA treated UROtsa Parent and Cd 
#1 cells was determined using real-time reverse transcription polymerase chain reaction 
(RT-qPCR) as previously described in this section. Expression data was graphed and 
statistical analysis performed using Graphpad PRISM v5.01 (GraphPad Software). 
RT-qPCR Analysis of SPARC mRNA Expression in siRNA Treated SPARC+ 
UROtsa Parent and Cd #1 Cell Lines 
 
 SPARC mRNA expression in siRNA treated cells was determined using real-time 
reverse transcription polymerase chain reaction (RT-qPCR) as previously described in 
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Chapter II Materials and Methods section, using 20µM human SPARC specific primers 
(Qiagen #QT00018620). Expression data was graphed and statistical analysis performed 
using Graphpad PRISM v5.01 (GraphPad Software). 
Statistics 
 All data was analyzed using Graphpad PRISM v5.01 software (GraphPad 
Software). ChIP statistical analysis was performed using a 1-way ANOVA and 
Bonferroni’s Multiple Comparison post hoc testing. Statistical analysis for mRNA 
expression was performed using a 1-way ANOVA and Dunnett’s Multiple Comparison 
post hoc testing. Statistical significance determined for all results using p<0.05. 
Results 
Sp1 mRNA and Protein Expression in SPARC+ UROtsa Parent and Cd #1 Cell 
Lines 
 
 UROtsa parent and Cd #1 cells were analyzed for Sp1 expression. This is a 
transcription factor that has been implicated in binding to the SPARC promoter and has 
shown susceptibility to cadmium exposure (Chamboredon et al., 2003, Larabee et al., 
2004). Cadmium has been shown to use mimicry and take the place of essential metals 
such as zinc (Zalups et al., 2003). In this case, it is plausible that cadmium is replacing 
zinc in the zinc-finger transcription factor and changing its shape; ultimately, rendering it 
inactive and unable to bind to the promoter region to activate gene expression. Although 
cadmium may be replacing zinc, Figure III-1 shows mRNA (A) and protein (B) 
expression of Sp1 is not significantly different between the Cd #1 cells and the SPARC+ 
UROtsa parent cells. Therefore, it does not appear that cadmium is repressing Sp1 
expression following long-term exposure and malignant transformation. Protein 
 98 
 
expression of Sp1 appears to be slightly higher in the Cd #1 cells compared to the 
SPARC+ UROtsa parent cells, which is consistent with previous preliminary studies. 
 
Figure III-1. Sp1 mRNA and Protein Expression in SPARC+ UROtsa Cells and 
Non-SPARC Expressing Cd #1 Cells. (A) Relative mRNA expression was determined 
using RT-qPCR, with a human Sp1 specific primer, and normalized to β-actin. 
Experiment was run in triplicate with statistical analysis determined using an unpaired 
student’s t-test. (B) Western blot analysis showing total cellular Sp1 protein expression 
with the corresponding β-actin control. 
 
Sp3 mRNA and Protein Expression in SPARC+ UROtsa Parent and Cd #1 Cell 
Lines 
 
 UROtsa parent and Cd #1 cells were analyzed for Sp3 expression. Sp3 
transcription factor is in the same family as Sp1, and therefore has a conserved zinc-
finger motif subject to cadmium replacement. Figure III-2 shows no statistical difference 
in Sp3 mRNA (A) and protein (B) expression between SPARC+ UROtsa parent cells and 
Cd #1 cells. Again, it appears there is a slight increase in protein expression, which is 
consistent with previous preliminary results. Cadmium exposure does not seem to 
significantly alter expression of Sp3 zinc-finger transcription factor.  
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Figure III-2. Sp3 mRNA and Protein Expression in SPARC+ UROtsa Cells and 
Non-SPARC Expressing Cd #1 Cells. (A) Relative mRNA expression was determined 
using RT-qPCR, with a human Sp1 specific primer, and normalized to β-actin. 
Experiment was run in triplicate with statistical analysis determined using an unpaired 
student’s t-test. (B) Western blot analysis showing total cellular Sp3 protein expression 
with the corresponding β-actin control. 
 
SOX5 mRNA and Protein Expression in SPARC+ UROtsa Parent and Cd #1 Cell 
Lines 
 
 UROtsa parent and Cd #1 cells were also analyzed for SOX5 transcription factor. 
This is an alternative transcription factor that has been implicated in binding to the 
SPARC promoter contributing to its repression in nasopharyngeal cancer (Huang et al., 
2008). Although not significant, mRNA (A) and protein (B) expression analysis show an 
increase in SOX5 expression in the Cd #1 cells compared to the SPARC+ UROtsa parent 
cells. The western blot analysis does not appear to show a band for the UROtsa parent 
cells and only a faint band for the Cd #1 cells. The mRNA expression levels, although 
present, were fairly low for both UROtsa parent and Cd #1 cells. 
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Figure III-3. SOX5 mRNA and Protein Expression in SPARC+ UROtsa Cells and 
Non-SPARC Expressing Cd #1 Cells. (A) Relative mRNA expression was determined 
using RT-qPCR and normalized to β-actin. Experiment was run in triplicate with 
statistical analysis determined using an unpaired student’s t-test. (B) Western blot 
analysis showing total cellular SOX5 protein expression with the corresponding β-actin 
control. 
 
ChIP Analysis of Sp1 and/or Sp3 Transcription Factor Binding to the SPARC Gene 
Promoter in UROtsa Parent and Cd #1 Cell Lines 
 
 Once it was determined that both Sp1 and Sp3 were expressed in the SPARC+ 
UROtsa parent control cells and the Cd #1 cells and that there was not significant 
difference in expression; the functional role for SPARC was investigated. DNA binding 
is a primary role for transcription factors. If cadmium is mimicking zinc and changing the 
shape of Sp1 and/or Sp3 it is possible this change is rendering the protein inactive. 
Therefore, there will be no DNA binding or abnormal DNA binding resulting in gene 
repression. ChIP results were normalized to sheared, non-precipitated input DNA and 
presented as percent input. Conventional PCR was run utilizing primer sets specifically 
designed for the putative binding sites within the SPARC promoter. Once designed, 
primers were tested on genomic DNA isolated from UROtsa parent cells (data not 
shown) and chosen based on specificity. Figure III-4 illustrate that Sp1 and Sp3 appear to 
be binding to the SPARC promoter region in the SPARC+ UROtsa parent cells. Results 
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also show little, if any, binding of Sp1 and Sp3 to the SPARC promoter in the Cd #1 
cells. Sp3 binding does not appear to be significantly higher than the input in the UROtsa 
parent; however, it is significantly higher than Sp3 binding in the Cd #1 cells. These 
results indicate that Sp1 and/or Sp3 are necessary transcription factors for SPARC 
expression. Without Sp1 and/or Sp3 binding to the SPARC promoter, gene transcription 
will not occur resulting in little, if any, SPARC expression in cadmium-transformed 
UROtsa cells. It is possible the long-term exposure to cadmium resulted in a permanent 
change in transcription factor binding contributing to the continued repression of SPARC. 
 
 
Figure III-4. Chromatin ImmunoPrecipitation Analysis of Sp1/Sp3 Binding at the 
SPARC Promoter. Sp1 and Sp3 transcription factor binding represented as percent 
input. Negative control immunoprecipitated with non-specific negative IgG antibody. 
Statistical analysis determined using a One-Way ANOVA with Bonferroni post hoc test. 
***(p≤0.001). 
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ChIP Analysis of SOX5 Transcription Factor Binding to the SPARC Gene 
Promoter in UROtsa Parent and Cd #1 Cell Lines 
 
 It was determined that SOX5 was expressed in both UROtsa parent and Cd #1 
cells and was slightly higher in the Cd #1 cells. These results supported our hypothesis of 
alternative transcription factor binding to the SPARC promoter resulting in its repression 
in cadmium-transformed cells. Therefore, it was plausible to investigate SOX5 binding to 
the SPARC promoter, here. As described earlier, conventional PCR was run utilizing 
validated primer sets, specifically designed for the putative binding site within the 
SPARC promoter. Results in Figure III-5, are presented as percent input and indicate 
significant enrichment of SOX5 at the SPARC promoter region in Cd #1 cells compared 
to SPARC+ UROtsa parent cells which show limited binding of SOX5. Earlier results 
indicated that both UROtsa parent and Cd #1 cells express SOX5; however, these results 
indicate that SOX5 is preferentially binding to the SPARC promoter in the Cd #1 cells. 
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Figure III-5. Chromatin ImmunoPrecipitation Analysis of SOX5 Binding at the 
SPARC Promoter. SOX5 transcription factor binding represented as percent input. 
Negative control immunoprecipitated with non-specific negative IgG antibody. Statistical 
analysis determined using a One-Way ANOVA with Bonferroni post hoc test. 
***(p≤0.001). 
 
Sp1, Sp3, and SOX5 mRNA Expression in siRNA Treated SPARC+ UROtsa Parent 
and Cd #1 Cell Lines 
 
 The next experiment was to knockdown expression of these three transcription 
factors and determine mRNA expression levels of SPARC. This was done using siRNA 
transfection for 24 and 48 hours in SPARC+ UROtsa parent cells and Cd #1 cells. The 
results from this experiment were somewhat ambiguous and difficult to interpret. Overall, 
there appears to be successful knockdown of the three transcription factors in both 
UROtsa parent cells and Cd #1 cells with the exception of Sp3 in the Cd #1 cells at 48 
hours. Figure III-6 illustrates similar Sp1 knockdown of < 0.6 that of the untreated 
control, between UROtsa parent (A and B) and Cd #1 (C and D) cells at both time points. 
Sp1 showed further knockdown in the both cell lines from 24 hours to 48 hours; however, 
the continued knockdown in UROtsa parent was slightly more than in Cd #1 cells. Sp3 
did not show as significant of knockdown in the Cd #1 cells (C and D) compared to the 
UROtsa parent cells (A and B) at either time point in Figure III-7. In fact, at 48 hours it 
appears there is little, if any, knockdown of Sp3 in the Cd #1 cells compared to > 0.8 fold 
knockdown in the UROtsa parent cells. This transcription factor may be necessary for 
specific gene expression and therefore is most likely resistant to knockdown to prevent 
cell death. SOX5, as with Sp1, showed similar knockdown at 24 hours in both UROtsa 
parent (A) and Cd #1 (C) cells, as seen in Figure III-8. There was also significant 
knockdown of SOX5 in the Cd #1 cells at 48 hours (Figure III-8, D). However, SOX5 
expression in the UROtsa parent cells at 48h (Figure III-8, B) is variable potentially due 
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to the low expression levels prior to knockdown. It also appears there is alteration of Sp1 
and SOX5 transcription factor expression in various controls. However, Sp3 did not show 
any change in expression in the control samples. This could be indicative of stress from 
the transfection and further suggest that Sp1 and SOX5 expression and subsequent 
function may be particularly susceptible to stress. 
 
 
Figure III-6. Sp1 mRNA Expression in SPARC+ UROtsa Cells and Non-SPARC 
Expressing Cd #1 Cells Following siRNA Knockdown of Sp1. (A) 24 hour and (B) 48 
hour siRNA treatment in UROtsa parent cells. (C) 24 hour and (D) 48 hour siRNA 
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treatment in Cd #1 cells. Untreated samples used as control as well as scrambled siRNA, 
Sp1 siRNA only, and siQuest transfection reagent only. All data represented as mean ± 
SEM of triplicates normalized to the untreated control. Statistical significance determined 
with one-way ANOVA and Dunnett’s Multiple Comparison post hoc test. *(p≤0.05), 
**(p≤0.01), and ***(p≤0.001). 
 
 
Figure III-7. Sp3 mRNA Expression in SPARC+ UROtsa Cells and Non-SPARC 
Expressing Cd #1 Cells Following siRNA Knockdown of Sp3. (A) 24 hour and (B) 48 
hour siRNA treatment in UROtsa parent cells. (C) 24 hour and (D) 48 hour siRNA 
treatment in Cd #1 cells. Untreated samples used as control as well as scrambled siRNA, 
Sp1 siRNA only, and siQuest transfection reagent only. All data represented as mean ± 
SEM of triplicates normalized to the untreated control. Statistical significance determined 
with one-way ANOVA and Dunnett’s Multiple Comparison post hoc test. *(p≤0.05), and 
***(p≤0.001). 
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Figure III-8. SOX5 mRNA Expression in SPARC+ UROtsa Cells and Non-SPARC 
Expressing Cd #1 Cells Following siRNA Knockdown of SOX5. (A) 24 hour and (B) 
48 hour siRNA treatment in UROtsa parent cells. (C) 24 hour and (D) 48 hour siRNA 
treatment in Cd #1 cells. Untreated samples used as control as well as scrambled siRNA, 
Sp1 siRNA only, and siQuest transfection reagent only. All data represented as mean ± 
SEM of triplicates normalized to the untreated control. Statistical significance determined 
with one-way ANOVA and Dunnett’s Multiple Comparison post hoc test. *(p≤0.05), 
**(p≤0.01), and ***(p≤0.001). 
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SPARC mRNA Expression in siRNA Treated SPARC+ UROtsa Parent and Cd #1 
Cell Lines 
 
 After siRNA knockdown of Sp1, Sp3 or SOX5 transcription factors in SPARC+ 
UROtsa cells and Cd #1 cells, it was necessary to determine if SPARC expression was 
affected. Figure III-9 illustrates SPARC mRNA expression in all siRNA treated samples 
as well as the control samples for both UROtsa parent (A and B) and Cd #1 (C and D) 
cells. Results showed that in the UROtsa parent cells, there is a significant decrease in 
SPARC expression when Sp3 is knocked down for 48 hours. However, this was not the 
case for Sp3 at 24 hours. The knockdown of the other transcription factors, Sp1 and 
SOX5, did not show any significant difference in SPARC expression in the UROtsa 
parent cell line at either time point. It was consistently noted that the untreated control 
and the Sp1 siRNA only samples appeared more confluent at 24 hours and 48 hours than 
the samples treated with the transfection reagent, based on phase-contrast microscopy 
observation (data not shown). The Cd #1 cells already repress SPARC expression below 
detectable limits so the goal with this experiment was to determine if knockdown of 
SOX5, specifically, resulted in an increase in SPARC expression. Results show that there 
is, in fact, a significant increase in SPARC expression at 48 hours with knockdown of 
SOX5 transcription factor. Sp1 and Sp3 knockdown resulted in a slight increase in 
SPARC expression but it was not significant. Concerns with these experiments include 
the Sp1 siRNA only control consistently showing a slight increase in SPARC expression; 
as well as, increased variabilities with detecting SPARC levels in cells that have little to 
no SPARC expression initially. These results do, however, further indicate that alteration 
of transcription factor binding, Sp1/Sp3 to SOX5, could potentially contribute to the 
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permanent repression of SPARC in our model system of cadmium-induced bladder 
urothelial carcinoma. 
 
Figure III-9. SPARC mRNA Expression in SPARC+ UROtsa Cells and Non-SPARC 
Expressing Cd #1 Cells Following siRNA Knockdown of Sp1, Sp3, or SOX5. (A) 24 
hour and (B) 48 hour siRNA treatment in UROtsa parent cells. (C) 24 hour and (D) 48 
hour siRNA treatment in Cd #1 cells. Untreated samples used as control as well as 
scrambled siRNA, Sp1 siRNA only, and siQuest transfection reagent only. All data 
represented as mean ± SEM of triplicates normalized to the untreated control. Statistical 
significance determined with one-way ANOVA and Dunnett’s Multiple Comparison post 
hoc test. *(p≤0.05), **(p≤0.01), and ***(p≤0.001). 
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Discussion 
 The strong repression of SPARC observed in our system warranted investigation 
into the potential mechanism utilized by cadmium to inhibit SPARC expression after 
transformation by long term, low dose cadmium exposure. Previous studies assessed 
aberrant DNA methylation and histone acetylation by treating cells with 5-AZC and MS-
275, respectively; where, results from these studies did not show any change in SPARC 
expression, indicating that these common methods of transcriptional repression were not 
contributing to decreased SPARC levels (Larson et al., 2010). Studies performed in other 
laboratories described hypermethylation as a mechanism for repression of SPARC in 
several cancer types, including: gastric, prostate, ovarian, and T-cell non-hodgkins 
lymphoma; in which, treatment with 5-AZC restored SPARC expression and function 
(Chen et al., 2014, Liu, et al., 2018, Socha, et al., 2009, Yan et al., 2018). However, this 
did not appear to be the case with our cadmium-induced bladder urothelial carcinoma 
system and required further investigation into gene repression via alternative 
mechanisms, primarily related to transcription factor binding to the SPARC promoter. 
 Mechanisms proposed for SPARC regulation focused on transcription factor 
binding to the promoter. Studies performed by Huang et al. (2008) investigated SPARC 
regulation in nasopharyngeal carcinoma. Interestingly, they also could not restore 
SPARC expression and function by treating with 5-AZC; however, short-hairpin RNA 
(shRNA) knockdown of SOX5 transcription factor resulted in restoration of tumor-
suppressor actions attributed to SPARC (Huang et al., 2008). In addition, two other 
transcription factors, Sp1 and/or Sp3, have been shown to bind to the SPARC promoter 
and elicit gene activation (Chamboredon et al., 2003). Additionally, cadmium cannot 
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directly bind to DNA; however, it has been shown to replace zinc in zinc-finger 
transcription factors, such as Sp1 and Sp3, thereby rendering them inactive (Kothinti et 
al., 2010a, 2010b). 
 Results from this study show that following malignant transformation with 
cadmium, Sp1 and Sp3 are expressed at a level similar to that of the non-transformed 
UROtsa parent cells; indicating, cadmium does not appear to be drastically altering Sp1 
and Sp3 expression. Interestingly, SOX5 appears to be slightly up-regulated in Cd #1 
cells compared to the non-transformed UROtsa parent cells, although both cell lines 
expressed SOX5 at low levels. The verification of similar transcription factor expression 
in both cell lines indicates cadmium transformation may be hindering proper functioning 
of the transcription factors and hence affecting transcription of downstream target genes 
during the malignant transformation process. 
Although cadmium cannot directly bind to DNA, it can elicit DNA damage 
through a variety of mechanisms, including ROS production (Rani et al., 2014). It has 
been shown that prolonged DNA damage can result in carcinogenesis and a state of redox 
imbalance (Dayem et al., 2010, Ogasawara and Zhang, 2009). Therefore, it is possible 
that long-term cadmium exposure is causing indirect, prolonged DNA damage resulting 
in aberrant transcription of SPARC. Alternatively, cadmium can directly affect gene 
transcription by replacing zinc in zinc-finger transcription factors changing their shape. 
This can affect steric hindrance of DNA binding sites within transcription factors and 
lead to a reduction in DNA binding and ultimately, gene repression (Kothinti et al., 
2010a, 2010b). Results from this study indicated decreased binding of Sp1 and Sp3 to the 
SPARC promoter in Cd #1 cells. Cadmium may not be significantly affecting expression 
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of Sp1 and Sp3 in our model system; however, it could be replacing zinc and negatively 
affecting its functionality. 
Therefore, it is possible that Sp1 binding is inhibited by cadmium incorporation 
into the zinc-finger DNA-binding domain resulting in a lack of chromatin remodeling 
complex recruitment and ultimately transcriptional repression. This leaves open the 
opportunity for potential alternative transcription factor binding to accessible chromatin, 
further impacting gene transcription. Interestingly, results indicated increased binding of 
SOX5 to the SPARC promoter in Cd #1 transformed cells. Cadmium’s association with 
SOX5 transcription factor is not as strong as that with Sp1/Sp3. In fact, currently, there is 
no literature to suggest that cadmium has a direct interaction with SOX5. It is not a zinc-
finger transcription factor so cadmium’s impact on SOX5 DNA-binding is likely indirect; 
such as, changes in chromatin accessibility. Nonetheless, there was a slight increase in 
expression of SOX5 in Cd #1 cells along with an increase in SOX5 binding to the 
SPARC promoter; potentially indicating an additional role for cadmium-induced changes 
in gene expression through permanent altered redox homeostasis associated with long-
term stress.  
Transcriptional regulation is a complex process, and understandably so. To better 
understand Sp1, Sp3, and SOX5 impact on SPARC gene expression, siRNA knockdown 
experiments were performed. All three transcription factors were knocked down by 35% 
or more by 24 hours. However, results on the impact of SPARC expression were 
ambiguous and somewhat difficult to interpret. Although there was successful 
knockdown of the transcription factors, there was also varied changes in transcription 
factor expression in the control samples. This was also apparent with β-actin expression 
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in the siRNA transfected cells, as well as the control samples exposed to the transfection 
reagent alone and occasionally siRNA alone as well (data not shown). These results 
indicate potential susceptibility to stress from the siRNA transfection reagents. Although 
ambiguity is somewhat present, SPARC expression did show a significant decrease in the 
SPARC+ UROtsa parent cells following 48 hour Sp3 siRNA exposure. This indicates that 
Sp3 is a potential necessary transcription factor for SPARC expression in our system. 
This is in accord with some studies suggesting Sp3 importance for induced gene 
activation (Li and Davie, 2010). Results also showed a significant increase in SPARC 
expression in Cd #1 cells following 48 hour SOX5 siRNA exposure, suggesting that 
SOX5 is potentially acting as a repressive transcription factor for SPARC, as well. 
Overall, it appears that alternative transcription factor binding to the SPARC promoter is 
contributing to its repression in our in vitro model system of cadmium-induced bladder 
transitional cell carcinoma. The permanence of this change may be due to advantageous 
changes in gene expression, further implicating SPARC as a tumor suppressor-like 
protein in this system.
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CHAPTER IV 
SPARC AND TUMOR INITIATION IN SERIALLY TRANSPLANTED 
BLADDER UROTHELIAL TUMORS 
 
Introduction 
 SPARC has been shown to play a variety of roles in cancer; however, its 
expression and whether changes in expression promote or inhibit tumor initiation and 
progression is tissue- and cancer-dependent. Unfortunately, mechanistic roles are not well 
understood, and are complicated by the complex, tissue-specific roles for SPARC. 
Studies have shown that epithelial cancers show a reduction in SPARC expression, while 
other cancer types have increased SPARC expression; yet, others show a mix of SPARC 
expression, with an increase in expression associated with tumor aggressiveness 
(Brekken and Bradshaw, 2010, Said and Theodorescu, 2013, Podhajcer et al., 2008). 
Interestingly, stromal SPARC expression is similarly variable between cancers (Vaz et 
al., 2015). Therefore, important consideration must be given to the complex interaction 
between the tumor and host microenvironment.  
Utilization of a SPARC-null mouse model has been instrumental in attempting to 
decipher the impact of stromal SPARC on tumor progression; but, it has also led to 
conflicting results. SPARC-null mice display abnormalities in stroma composition and 
strength; therefore, it is thought that stromal SPARC exerts some of its effects through 
extracellular matrix modulation to promote tumor growth (Bradshaw et al., 2003, 
Brekken and Bradshaw, 2010). Brekken et al. (2003) found that Lewis Lung Carcinoma 
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cells subcutaneously injected into SPARC- null mice produced larger tumors than those 
injected into the SPARC-expressing control mice. However, another study showed that 
mouse-derived breast cancer cells had impeded tumor growth in SPARC-null mice, 
resulting in smaller tumors compared to the SPARC-expressing control (Sangaletti et al., 
2003). They concluded that host leukocytes, lacking SPARC expression, did not 
adequately contribute to the stromal organization and support for proper tumor growth. 
These controversial studies indicate that not only is stromal SPARC expression 
important, but also the source of the tumor tissue is important to consider SPARC’s role 
in the dynamic tumor progression process. 
 Overexpression of SPARC has been shown in several cancers, including, 
melanoma and gliomas. It appears that overexpression of SPARC in these cancers is 
associated with increased invasion. Interestingly, Ledda et al. (1997) found that decreased 
SPARC within melanoma tumor cells resulted in decreased tumorigenic growth. A 
separate study found that tumorigenesis and invasiveness in nude mice is dependent upon 
tumor cell SPARC expression and matrix metalloproteinase activity rather than stromal 
SPARC expression; further supporting a tumor promoting role for SPARC in melanoma 
cells (Prada et al., 2007). Gliomas have conflicting reports, with some studies showing 
increased SPARC expression promoting tumor progression and being associated with 
more invasive tumors; however, another report found that increased expression of both 
SPARC and doublecortin in glioma cell lines resulted in: abrogated SPARC-mediated 
cell invasion, increased apoptosis induced by irradiation, along with cell cycle turnover 
interference (Schultz et al., 2002, Shi et al., 2007, Xu et al., 2013). A different study by 
Capper et al. (2010) described high expression of SPARC in astrocytomas that decreased 
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with tumor progression; concluding, that the observed decrease in cell proliferation was 
associated with increased SPARC expression. 
 There are also several cancers that show repression of SPARC within tumor cells, 
including pancreatic cancer and ovarian cancer. In these cancers it appears SPARC is 
inhibitory to tumor formation and progression. Studies of SPARC repression in these 
systems has revealed hypermethylation of the promoter region that was responsible for 
decreased SPARC expression; that was subsequently reversed following treatment with 
5-Aza-2’deoxycytidine (Gao et al., 2010, Sato et al., 2003, Socha et al., 2009). It has been 
shown that the majority of pancreatic cell lines repress SPARC; however, there are some 
pancreatic cell lines that show an overexpression of SPARC. Furthermore, there is 
variability in SPARC expression within some forms of human pancreatic tumors (Sato et 
al., 2003, Prenzel et al., 2006). Interestingly, the stromal fibroblasts that surround the 
tumor often show strong expression of SPARC (Vaz et al., 2015). One study found that 
SPARC expressed by the pancreatic stellate cells increased invasion of pancreatic cancer 
cells via a paracrine action (Mantoni et al., 2008). It was also found that increased 
SPARC expression in surrounding fibroblast cells correlated with poor patient survival 
(Infante et al., 2007). Additionally, it has been consistently found that orthotopic 
pancreatic tumors in SPARC-null mice result in increased metastasis compared to 
SPARC-expressing controls (Arnold et al., 2008, Puolakkainen et al., 2004). This study 
found that the observed increase in metastasis was probably occurring via MMP-9 effects 
on extracellular matrix deposition.  
Ovarian cancer also shows repression of SPARC within cancer cells; which, 
inversely correlates with the degree of malignancy (Mok et al., 1996). Similar to 
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pancreatic cancer, SPARC expression is high in the supporting stromal cells of advanced 
stage ovarian cancer (Said et al., 2007). Interestingly, it appears that stromal SPARC 
attempts to neutralize the microenvironment by decreasing inflammation and subsequent 
tumor growth (Said et al., 2007). Furthermore, SPARC-null mice showed increased 
peritoneal metastasis along with increased macrophage recruitment and subsequent 
decreased activity of ascitic fluid (Said et al., 2007). Additionally, it was shown that 
increased SPARC expression within the ovarian cancer cells resulted in disrupted tumor-
stromal interplay, decreased macrophage recruitment and increased expression of 
inflammatory markers (Said et al., 2008). Interestingly, both pancreatic and ovarian 
cancers show poorer patient survival with increased stromal SPARC expression (Vaz et 
al., 2015). Therefore, it appears that SPARC within the tumor cells is acting in a tumor 
suppressor-like role, while stromal SPARC appears to act in promoting tumor 
progression. 
 Bladder cancer is another cancer type that shows an overall repression of SPARC 
within bladder cancer cells (Larson et al., 2010). Studies have determined an inverse 
correlation between SPARC expression and patient prognosis (Said, 2016, Yamanaka et 
al., 2001). It was also determined that decreased SPARC within bladder cancer cells 
resulted in increased cell proliferation (Said, 2016). This was likely due to cell cycle 
dysregulation at the G1/S checkpoint via increased cyclins A1, D1, and E2 with a 
concomitant decrease in expression of cell cycle inhibitors such as p21 and p27 (Shariat 
et al., 2006, Galmozzi et al., 2006). Said et al. (2013) used a carcinogen-induced bladder 
cancer model and found that SPARC expression within cancer lesions decreased ROS 
generation, along with DNA, protein, and lipid oxidative damage; which, was opposite in 
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lesions from SPARC-null mice. They also found that decreased SPARC in cancer cells 
resulted in strong invasion, increased metastasis, as well as early-onset metastasis. 
Interestingly, Yamanaka et al. (2001) determined that increased SPARC correlated with 
increased MMP-2 expression. However, this group did not appear to distinguish between 
tumor cell-derived SPARC and stromal SPARC expression. Although it appears that 
SPARC is a tumor suppressor-like molecule in bladder cancer cells, the supporting 
stromal tissue shows a high degree of SPARC expression that needs to be considered 
(Said et al., 2013). Overall, there is limited research addressing SPARC and bladder 
cancer. Therefore, further research into SPARC expression, its origin of expression, and 
its function in bladder cancer is critical information that could lead to potential future 
therapeutics. 
 Previous studies in this lab investigated SPARC expression in heterotransplant 
tumors generated from heavy metal Cd2+-transformed UROtsa bladder cells along with 
human transitional cell carcinoma tumors. Larson et al. (2010) found that SPARC 
expression was significantly repressed within heterotransplant tumors and low-grade 
human transitional cell carcinoma tumors. However, human high grade invasive 
carcinoma tumor samples showed strong staining for SPARC protein expression in the 
supporting stroma (Larson et al., 2010). The significant repression of SPARC in both the 
cell lines and heterotransplant tumors prompted investigation into SPARC 
overexpression via stable transfection in Cd2+-transformed malignant cell lines. 
Interestingly, immunohistochemical results showed significant repression of SPARC 
within heterotransplant tumor cells, despite the strongly forced expression in the injected 
cells; with, Cd #1-SPARC transfected heterotransplant tumors showing very low levels of 
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focal SPARC expression in approximately 10% of the total tumor mass (Slusser et al., 
2016). Further experimentation led to the isolation of the proposed cancer-initiating cell 
population (Urospheres) and subsequent heterotransplant tumor formation. These tumors 
resulted in 5-20% focal expression of SPARC within tumor cells generated from the 
SPARC-transfected Urosphere population (Slusser et al., 2016). Additionally, 
heterotransplant tumors generated from one of the two non-SPARC transfected cadmium 
cell lines showed 10-20% focal expression of SPARC within tumor cells (Slusser et al., 
2016). These results led to our hypothesis that SPARC is inhibitory to bladder tumor 
initiation and progression. Therefore, this study will examine SPARC expression in 
serially transplanted bladder heterotransplant tumors. 
Materials and Methods 
Cell Culture 
 Cells were maintained as previously described in Chapter II Materials and 
Methods. The isolation and growth of the proposed cancer initiating cell subpopulation 
(Urospheres) was performed as described in Slusser et al. (2016). Briefly, cells were 
expanded to 75cm2 tissue culture flasks and grown until confluent. Cells were passaged 
and seeded at a 1x106 cell density in 75cm2 Ultra-low attachment flasks (Corning, Inc., 
Corning, NY). Cells were grown in serum-free media containing a 1:1 mixture of DMEM 
(Sigma-Aldrich) and Ham’s F-12 (Sigma-Aldrich) growth medium. The media was 
supplemented with: 5ng/mL selenium, 5μg/mL insulin, 5μg/mL transferrin, 36ng/mL 
hydrocortisone, 4pg/mL triiodothyronine, and 10ng/mL epidermal growth factor. Spheres 
were grown for approximately 7 days and then harvested via centrifugation for 
transplantation into nude athymic mice or for RNA or protein isolation. 
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RNA and Protein Isolation From SPARC+ UROtsa Parent, Cd #1, and Cd #1-
SPARC Cell Lines 
 
 Total RNA and protein were isolated as previously described in Chapter II 
Materials and Methods section. Concentrations were determined using a Nanodrop One 
(Thermo Fisher Scientific). Samples were then utilized for subsequent RT-qPCR and 
Western Blot analysis.  
RT-qPCR Analysis of SPARC mRNA Expression in SPARC+ UROtsa Parent, Cd 
#1, and Cd #1-SPARC Cell Lines 
 
 SPARC mRNA expression from UROtsa Parent, Cd #1, and Cd #1-SPARC cells 
was determined using RT-qPCR as previously described in Chapter II Materials and 
Methods section. SPARC mRNA expression was verified using 20µM SPARC specific 
primers (Qiagen #QT00018620) prior to progressing into in vivo serial heterotransplant 
experiments. Data was graphed and statistical analysis performed using GraphPad 
PRISM v5.01 (GraphPad Software). 
Secreted SPARC Protein Purification from Media of SPARC+ UROtsa Parent, Cd 
#1, and Cd #1-SPARC Cell Lines 
 
 Secreted SPARC protein was purified from the media of cells grown in culture, 
with reference to Sage (2003) and using a protocol refined by Slusser et al. (2016). 
Briefly, UROtsa parent, Cd #1, and Cd #1-SPARC cells were grown to confluency in 
serum-containing media in 75cm2 tissue culture flasks. Once confluent, media was 
replaced with serum-free medium and cells were placed in a 37°C, 5% CO2 tissue culture 
incubator for 24 or 48 hours. Media was collected and centrifuged at 2000 rpm for 5 
minutes at 4°C. During this time, cells were harvested for subsequent RNA and protein 
isolation. The media was then filtered through a 0.2μm syringe filter into a fresh, cooled 
50mL tube and placed on ice. Tubes were placed on an end-over-end rotator and 50% 
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w/v solid ultrapure ammonium sulfate (Sigma #A2939-500G) was added to each sample 
over several hours [5g [NH4]SO4/10mL media] to efficiently precipitate protein while 
maintaining a neutral pH, then incubated on an end-to-end rotator in the 4°C fridge 
overnight. Media was then transferred to high velocity centrifuge tubes and centrifuged 
using a Sorval centrifuge with the SS-34 rotor at 40,000xg for 30 minutes at 4°C. 
Samples were placed on ice and supernatant removed. The pellet was resuspended in PBS 
lysis buffer with protease inhibitors for subsequent Western Blot analysis. Because 
SPARC protein was precipitated from the media, no sonication to shear DNA was 
necessary prior to determining protein concentration via BCA assay. 
 Western Blot analysis was performed similarly to that described in Chapter II 
Materials and Methods section using mouse anti-Osteonectin primary antibody 
(NovocastraTM, Cat # NCL-O-NECTIN) followed by anti-mouse IgG, HRP-linked 
antibody (Cell-Signaling Technology, #7076S) at 1:3,000 and anti-biotin, HRP-linked 
antibody (Cell-Signaling Technology, #7075S) at 1:1,500. The blot for this experiment 
could not be stripped and re-probed for β-actin because the protein was not from the 
cellular fraction but rather the media supernatant; therefore, β-actin was not present. 
Visualization of SPARC Expression in SPARC+ UROtsa Parent, Cd #1, and Cd #1-
SPARC Cell Lines via Immunofluorescent Microscopy 
 
 Cells were grown to confluency on glass coverslips in 24 well tissue culture plates 
(Corning, Inc.). Cells were washed twice with DMEM-F12-no phenol red (Gibco 
#11039-021) and fixed using 3.7% Formaldehyde (Polysciences, Inc. #18814-10) for 10 
minutes at room temperature. Free aldehyde groups were quenched using 0.1M NH4Cl 
(Sigma-Aldrich) for 15 minutes at room temperature and cells were permeabilized using 
0.1% Igepal (Sigma-Aldrich) for 10 minutes at room temperature. Coverslips were 
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incubated with a 1:20 dilution of mouse monoclonal anti-Osteonectin antibody 
(NovocastraTM, Cat # NCL-O-NECTIN) [Leica Biosystems Inc.] for 45 minutes at 37°C. 
Coverslips were washed and incubated with AlexaFluor594 goat-anti-mouse secondary 
antibody (2mg/ml) [Life Technologies #A11005] for 45 minutes at 37°C. Coverslips 
were, again, washed and mounted using ProLong Diamond Antifade mounting medium 
with DAPI (Life Technologies #P36971) for nuclear counterstaining. Cellular SPARC 
expression was visualized using the Leica Laser Scanning SPE Confocal microscope at 
63x magnification. Secondary antibody only samples were used as a control. 
Serial Heterotransplant Tumors in Nude Mice 
 
 Three mice for each of 4 groups: (1) Cd #1 cells and (2) Cd #1 Urospheres, and 
(3) Cd #1-SPARC cells and (4) Cd #1-SPARC Urospheres were used for tumor 
formation studies. Tumor transplantation was performed as described in Sens et al. 
(2004). Briefly, approximately 1x106 cells, suspended in PBS, were subcutaneously 
injected into the dorsal thoracic midline of nude athymic mice. Tumor formation, growth, 
and overall mouse health were assessed weekly. Mice were cared for through tumor 
formation and growth, unless conditions dictated euthanasia, under an Institutional 
Animal Care and Use Committee (IACUC) approved protocol as well as in accordance 
with the National Research Council’s Guide for the Care and Use of Laboratory Animals. 
Once tumors were large enough, approximately 1cm or larger, the mice were sacrificed 
and the tumor was harvested. Approximately 1/3 of the tumor was utilized for 
Hematoxylin and Eosin staining (H&E) along with immunohistochemical analysis of 
SPARC expression. Another 1/3 of the tumor was snap frozen for RNA isolation. Finally, 
1/3 of the tumor was used for serial transplantation into a subsequent mouse. The tumor 
 122 
 
tissue used for serial transplantation was mechanically homogenized using scalpel blades 
in a sterile petri dish. The tumor was resuspended in approximately 500µL of PBS and 
homogenized until able to pass through a 20 gauge needle. 200µL tumor suspension was 
then subcutaneously injected into a subsequent mouse. The serial transplantation process 
was repeated a second time for a total of three rounds of tumor inoculation and formation 
events.  
Immunohistochemical Localization of SPARC Protein Expression in Serial 
Heterotransplant Tumors 
 
 Immunohistochemical analysis was performed on serial heterotransplant samples 
to assess SPARC expression. Additionally, human high grade invasive bladder carcinoma 
was used as a control. Briefly, tumor tissue was formalin fixed and paraffin embedded. 
Then, tissue blocks were serially sectioned at 4-5µm, and placed on microscope slides. 
Slides were then stained using the Leica Bond Max Automated Stainer (Leica 
Microsystems, Inc.) with the Bond Polymer Refine Detection kit (Leica Biosystems 
#DS9800). Generally, slides were heated at 60°C for 15-20 minutes, dewaxed using 
xylene, rehydrated using decreasing concentrations of alcohol and then subjected to 
antigen retrieval. Slides were washed with wash buffer and incubated with a peroxidase 
block. Slides were then stained using a 1:20 dilution of mouse monoclonal anti-
Osteonectin primary antibody (NovocastraTM, Cat # NCL-O-NECTIN) [Leica 
Biosystems, Inc.] for 30 minutes. Again, slides were washed with wash buffer and 
staining was detected using a horseradish peroxidase DAB solution. Slides were then 
counterstained with H&E and visualized and imaged using light microscopy. 
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Immunohistochemical Localization of α-Smooth Muscle Actin Protein Expression in 
Serial Heterotransplant Tumors 
 
 Immunohistochemical analysis was performed on serial heterotransplant samples, 
with the addition of human high grade invasive bladder carcinoma as a control, to assess 
α-smooth muscle actin expression; identifying an activated stroma. Briefly, tumor tissue 
was formalin fixed and paraffin embedded. Then, tissue blocks were serially sectioned at 
4-5µm, and placed on microscope slides. Slides were heated at 60°C for 15-20 minutes, 
dewaxed using xylene, rehydrated using decreasing concentrations of alcohol, and then 
subjected to antigen retrieval using 1x DakoCytomation Target Retrieval Solution Citrate 
buffer (Dako #S2369). Slides were incubated with 1x Tris Buffered Saline with Tween 
20 (TBS-T) [Dako #S3306], washed with wash buffer (Dako #S3006), and incubated 
with peroxidase block (Dako, #K4011). Slides were then stained with rabbit polyclonal 
anti-α-smooth muscle actin antibody (0.2mg/ml) [Abcam #ab5694] for 30 minutes. Slides 
were washed with wash buffer, and stained using Labelled Polymer-HRP Anti-Rabbit 
(Dako #K4011) for 30 minutes. Slides were washed and staining was detected using a 
DAB Substrate Chromogen System (Dako #K3466). Slides were then counterstained 
with H&E and visualized using light microscopy. 
RNA Isolation from Serial Heterotransplant Tumors 
 
 RNA was isolated from serial heterotransplant tumor tissue using the TissueLyser 
LT (Qiagen). Tumor tissue was weighed and cut into three 30mg portions of tissue. Each 
portion was placed in a pre-cooled 2mL bullet tube containing one 5mm diameter 
stainless steel bead (Qiagen #69989). 500µL TRI Reagent (MRC) was added to each 
sample and homogenized using: 45Hz for 3 minutes, 35Hz for 2 minutes, and 35Hz for 2 
minutes as recommended in the manufacturer’s protocol. Homogenized tissue was then 
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transferred to a fresh microfuge tube containing 500µL TRI Reagent and RNA isolation 
continued as described previously in Chapter II Materials and Methods section. RNA 
pellet was resuspended in 100µL nuclease free water (MO BIO Laboratories, Inc.) due to 
pellet size. RNA concentration was determined, using the NanoDrop One (Thermo 
Scientific), for all three portions of tumor tissue separately; then, a fraction of each 
portion was combined, and the concentration determined, to get an even distribution of 
each tumor to sample for PCR analysis. 
RT-qPCR Analysis of hSPARC and mSPARC mRNA Expression in Serial 
Heterotransplant Tumors 
 
 Human SPARC and mouse SPARC mRNA expression from serial 
heterotransplant tumor samples were determined using real-time reverse transcription 
polymerase chain reaction (RT-qPCR), as previously described in Chapter II Materials 
and Methods section. cDNA was amplified using 20µM human SPARC specific primers 
(Qiagen #QT00018620) or 20µM mouse SPARC specific primers (Qiagen 
#QT00161721) and recorded using SYBR green fluorescence. Human SPARC 
expression was determined relative to the UROtsa parent cell line control and mouse 
SPARC was determined relative to mouse brain control. Expression data was graphed 
and statistical analysis performed using Graphpad PRISM v5.01 (GraphPad Software). 
Recombinant hSPARC or mSPARC Treatment of Cd #1-SPARC Cell Line 
 
 Cd #1-SPARC cell line was exposed to recombinant human SPARC (rhSPARC) 
[R&D Systems #941-SP-050] or recombinant mouse SPARC (rmSPARC) [R&D 
Systems #942-SP-050] to determine an effect on endogenous SPARC expression. Cells 
were plated in a 12-well tissue culture plate (Corning, Inc.) and grown to confluency. 
Preliminary experiments tested dose efficacy using: 2.0µg, 0.2µg, 0.02µg, or 0.002µg 
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rhSPARC added to respective wells with an untreated well as a control. Cells were 
incubated in a tissue culture incubator at 37°C, 5% CO2 for 24 hours then harvested for 
RNA isolation and PCR analysis to determine endogenous SPARC expression. In a 
subsequent time-course study, Cd #1-SPARC cells were exposed to 2.0µg rhSPARC for 
12h, 24h, 36h, 48h, and 72h using 0h as a control. Each time point also had an untreated 
well to control for changes in confluency over time. 
 Once the correct dosing and optimal time line were determined, Cd #1-SPARC 
cells were exposed to rhSPARC or rmSPARC. Cells were again plated in a 12-well tissue 
culture plate and grown to confluency. 2.0µg, 0.2µg, 0.02µg, or 0.002µg rhSPARC was 
added to respective wells with an untreated well as a control. Additionally, 20.0µg 2.0µg, 
0.2µg, 0.02µg, or 0.002µg rmSPARC was added to respective wells with an untreated 
well as a control. An additional higher dose was added for rmSPARC exposure to 
account for crossing species. Cells were incubated with rhSPARC or rmSPARC for 36 
hours, based on the previous time-course study, at 37°C, 5% CO2 in a tissue culture 
incubator. Cells were then harvested for RNA isolation and RT-qPCR analysis. 
RNA Isolation of Cd #1-SPARC Cell Line Following Recombinant SPARC 
Treatment 
 
 Total RNA was isolated from human or mouse recombinant SPARC treated cells 
using TRI REAGENTTM (MRC) as described in Chapter II Materials and Methods 
section. RNA concentration was determined on the Nanodrop One (Thermo Scientific) 
and a portion of each sample was diluted to 20ng/µl concentration. Samples were then 
utilized for subsequent RT-qPCR analysis to assess SPARC mRNA expression. 
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RT-qPCR Analysis of SPARC Expression in Cd #1-SPARC Cell Line Following 
Recombinant SPARC Treatment 
 
 SPARC mRNA expression in human or mouse recombinant SPARC treated cells 
was determined using RT-qPCR as previously described in this section using 20µM 
SPARC specific primers (Qiagen #QT00018620). β-actin was amplified using an 
Invitrogen primer set with the following sequences, sense: 
CGACAACGGCTCCGGCATGT, anti-sense: TGCCGTGCTCGATGGGGTACT, under 
the same cycling parameters. β-actin expression was determined relative to the untreated 
control using a standard curve generated from β-actin standards. Expression data was 
graphed and statistical analysis performed using Graphpad PRISM v5.01 (GraphPad 
Software). 
Statistics 
 
 All data was analyzed using GraphPad PRISM v5.01 software (GraphPad 
Software). Statistical analysis for mRNA expression was performed using a 1-way 
ANOVA and Dunnett’s Multiple Comparison post hoc test. Statistical significance 
determined for all results using p<0.05 significance level. 
Results 
 
SPARC mRNA and Secreted Protein Expression in SPARC+ UROtsa Parent, Cd #1, 
and Cd #1-SPARC Cell Lines 
 
 SPARC mRNA and protein expression were verified prior to in vivo studies to 
ensure SPARC was still being stably expressed in the Cd #1-SPARC transfected cell line. 
RT-qPCR analysis in Figure IV-1 (A), revealed significantly higher expression of 
SPARC in the Cd #1-SPARC cell line compared to the non-transfected Cd #1 cell line. 
There did not appear to be a significant difference in SPARC expression between the 
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positive control UROtsa parent cell line and the Cd #1-SPARC cell line. This was 
slightly different from previous results in Slusser et al. (2016) which indicated a 
significant increase in expression following stable SPARC transfection. However, these 
results showed that the Cd #1-SPARC cell line is still expressing SPARC mRNA at 
relatively high levels. 
 To verify this further, protein expression was analyzed using Western Blot 
analysis. Initially, cell lysate was used to examine protein expression; however, results 
did not indicate protein expression that was similar to mRNA expression (data not 
shown). This was strikingly different from results reported in Slusser et al. (2016). 
Through a series of troubleshooting experiments, it was concluded that it was possible the 
Cd #1-SPARC cells were producing SPARC but quickly secreting it; therefore, 
expression was not being captured in the cell lysate fraction. 
 Subsequent Western Blot analysis then verified secreted protein expression using 
SPARC protein precipitated from the tissue culture media. Figure IV-1 (B) indicates 
ample quantities of secreted SPARC expression in both 24h and 48h post confluency 
media from Cd #1-SPARC tissue culture flasks. Additionally, these results show 
substantial secreted SPARC in the UROtsa parent cell line. There also appears to be some 
SPARC expression in the Cd #1 samples when the blot is overexposed. This could be due 
to the Cd #1 cells making and secreting minimal amounts of SPARC protein that are 
undetectable at the mRNA level. It is also possible that the band for Cd #1 is falsely 
intensified due to bleed over from the extreme amount of SPARC from the UROtsa 
parent sample as well as the high amounts of SPARC from the Cd #1-SPARC sample. 
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Overall, these results indicate SPARC is still being stably expressed in the Cd #1-SPARC 
cell line at drastically higher levels than the Cd #1 transformed cell line. 
 
Figure IV-1. SPARC mRNA and Secreted Protein Expression in SPARC+ UROtsa 
Parent, Non-SPARC Expressing Cd #1, and Cd #1-SPARC Transfected Cells. (A) 
Relative SPARC mRNA expression with starting quantity (SQ) determined relative to 
UROtsa parent. Experiment was run in triplicate with statistical analysis determined 
using a one way ANOVA with Dunnett’s Multiple Comparison post hoc test. 
***(p≤0.001). (B) Western blot analysis showing secreted SPARC protein expression in 
tissue culture media collected at 24h and 48h post confluency. 
 
Immunofluorescent Microscopy of SPARC Expression in SPARC+ UROtsa Parent, 
Cd #1, and Cd #1-SPARC Cell Lines 
 
 Immunofluorescent microscopy was utilized to visualize SPARC protein 
expression within UROtsa parent, Cd #1, and Cd #1-SPARC cells. Western blot analysis 
of cell lysate revealed SPARC expression only in the UROtsa parent cell line. However, 
SPARC expression was expected in the Cd #1-SPARC cell line. Figure IV-2 shows 
representative immunofluorescent images of SPARC expression within UROtsa parent 
(A), Cd #1 (B), and Cd #1-SPARC (C) cells. All cell lines were also stained with 
secondary antibody only, as a control (D, E, and F, respectively). UROtsa parent cells 
show SPARC expression within the cytoplasm of the cells. There does not appear to be a 
blur of staining throughout the cytoplasm, but rather, staining puncta; likely visualizing 
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SPARC-containing vesicles. Cd #1 cells do not appear to be expressing SPARC when 
compared to the UROtsa parent cells and the secondary antibody only control. This was 
expected as these cells show very little, if any, mRNA or protein expression with RT-
qPCR or Western Blot analysis, respectively. Immunofluorescent microscopy revealed 
SPARC expression within Cd #1-SPARC cells that was not strongly observed with 
Western Blot analysis of cell lysate. The staining profile was similar to that seen in the 
UROtsa parent cells, showing staining puncta, indicating SPARC-containing vesicles. 
This experiment, in conjunction with Western Blot analysis of secreted SPARC, indicates 
SPARC expression in both UROtsa parent cells and malignant Cd #1-SPARC cells. 
Therefore, the Cd #1 and Cd #1-SPARC cells could be used in the in vivo studies to 
examine SPARC’s role in tumor initiation and progression. 
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Figure IV-2. Visualization of SPARC Expression in UROtsa Parent, Cd #1, and Cd 
#1-SPARC using Confocal Microscopy. Representative images of SPARC expression 
(red) in UROtsa parent (A and D), Cd #1 (B and E), and Cd #1-SPARC (C and F) cell 
lines with a secondary antibody only control for each cell line. Cells were counterstained 
with DAPI (blue) for nuclear staining. Images were taken at 63x with scale bars shown at 
10 µm. 
 
Immunohistochemical Localization of SPARC Protein Expression in Serial 
Heterotransplants 
 
 SPARC expression in serial heterotransplant tumor tissue was determined using 
immunohistochemistry. This experiment consisted of serial inoculations of mechanically 
dissociated tumor tissue to determine SPARC’s role in tumor initiation and progression. 
Three mice were inoculated from each of the 4 groups: Cd #1 cell line, Cd #1 Urosphere, 
Cd #1-SPARC cell line, and Cd #1-SPARC Urosphere. At least one mouse from each 
group, at each tumor inoculation, had tumor formation and subsequent injection into 
another mouse. Therefore, serial transplantation could be assessed in regards to SPARC 
expression. Figure IV-3 illustrates representative immunohistochemical images from 
each group and each tumor formation event, in addition to human high grade invasive 
bladder carcinoma tumor tissue used as a control. This data is further summarized in 
Table 3. 
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Figure IV-3. Immunohistochemistry Images of SPARC Expression in Serial Bladder 
Heterotransplant Tumors. Representative images of Initial, Transplant 1, and 
Transplant 2 serial bladder heterotransplants generated from Cd #1 cell line, Cd #1 
Urosphere, Cd #1-SPARC cell line, and Cd #1-SPARC Urosphere populations. Human 
high grade invasive bladder carcinoma used as a control. All images taken at 200x. 
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Table 3. Summary of Immunohistochemistry Staining for SPARC Expression in 
Serial Bladder Heterotransplant Tumors. 
 
 
 
Table summarizing immunohistochemistry staining of serial heterotransplant tumors 
generated from: Cd #1 cell line, Cd #1 Urosphere, Cd #1-SPARC cell line, and Cd #1-
SPARC Urosphere populations. Tumor # shows three tumors for each group: Initial, 
Transplant 1, and Transplant 2. For both tumor and stroma, staining intensity (Int) is 
determined on a scale of 0-3+ and % indicates the percent of tumor or stroma showing 
SPARC staining. Int and % interpreted by pathologist. SC: subcutaneous, Inv Ca.: 
invasive carcinoma. 
 
Results indicate an increase in intensity as well as percentage of tissue stained for 
SPARC expression in the supporting stromal tissue, from the initial tumor to the final 
transplant 2 tumor in 3 of the 4 groups. Cd #1 cell line initial tumor showed low to 
moderate SPARC staining in approximately 20% of the supporting stromal tissue which 
did not increase in the second transplant 1 tumor. However, there was a marked increase 
in stromal SPARC expression in the final Cd #1 transplant 2 tumor; showing moderate to 
strong staining in approximately 70% of the tumor. The tumors derived from the Cd #1 
Urosphere population showed similar results; however, there was a substantial increase in 
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staining intensity and percentage of stroma stained from the initial tumor (low to 
moderate in 10% of tumor) to the second transplant 1 tumor (moderate to strong in 40% 
of tumor). This group also continued another substantial increase in stromal SPARC 
expression in the transplant 2 tumor; showing moderate to strong staining in 
approximately 80% of the tumor.  
Cd #1-SPARC initial tumor showed moderate stromal SPARC staining in a low 
percentage of the tumor which did not increase in the second transplant 1 tumor. 
However, similar to the Cd #1 cell line tumor, there was a substantial increase in stromal 
SPARC expression in the Cd #1-SPARC cell line transplant 2 tumor; showing moderate 
to strong staining in 60% of the tumor. The Cd #1-SPARC Urosphere tumors did not 
show the same increase in stromal SPARC expression as the other three groups. There 
was an increase in stromal SPARC expression from the initial tumor (low to moderate 
staining in 5% of tumor) to the transplant 1 tumor (moderate to strong staining in 30% of 
tumor). However, this increase was not maintained to the final transplant 2 tumor, which 
showed staining intensity less than that of the initial tumor in only approximately 5% of 
the tumor. Interestingly, the human high grade invasive bladder carcinoma tumor also 
showed strong stromal SPARC expression in 80% of the tumor. Additionally, all tumor 
samples showed strong α-smooth muscle actin (α-SMA) staining in the supporting stroma 
(data not shown) indicating the presence of cancer-associated fibroblasts (CAFs). 
 Results also showed that SPARC expression did not increase nor was it 
maintained in the tumor cells from the initial tumor to the final transplant 2 tumor. Figure 
IV-4 illustrates immunohistochemistry images of the three tumor samples showing 
SPARC expression within the tumor cells. Cd #1 cell line tumors as well as Cd #1-
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SPARC Urosphere tumors did not show any SPARC expression in the tumor cells of any 
of the three tumors. Interestingly, the Cd #1 Urosphere transplant 2 tumor showed 
moderate to strong SPARC staining in approximately 40% of the cancer cells comprising 
the tumor. However, neither the initial tumor nor the transplant 1 tumor displayed any 
SPARC expression within the tumor cells. Additionally, the Cd #1-SPARC cell line 
initial and transplant 2 tumors showed low to moderate SPARC staining in approximately 
10% of the cancer cells comprising the tumor. However, it appeared the overall intensity 
of the tumor cell staining decreased from the initial tumor to the transplant 2 tumor; and, 
the transplant 1 tumor did not show any SPARC staining in the tumor cells. Therefore, 
again, it does not appear that SPARC is maintained within the tumor cells.  
 
Figure IV-4. Immunohistochemistry Images of SPARC Expression within Tumor 
cells of Serial Bladder Heterotransplant Tumors. Images of three serial 
heterotransplant tumors: Cd #1 Urosphere transplant 2 tumor, in addition to Cd #1-
SPARC cell line transplant 1 and transplant 2 tumors, expressing SPARC in the tumor 
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cells. Human high grade invasive bladder carcinoma used as a control (shown in Figure 
IV-3). All images taken at 200x. 
 
 Overall, these results suggest that SPARC expression is not maintained nor 
increased in serial heterotransplant tumor cells. However, results do indicate an increase 
in stromal SPARC expression in serially transplanted bladder tumors. 
Immunohistochemistry observation suggests an increase in disorganization of tumor 
tissue, potentially indicating tumor progression; however, this was not substantiated in 
the pathology results. Additionally, staining intensity, as well as distribution of staining 
in the serial heterotransplants, was most similar between 3 of 4 final transplant 2 tumors 
and the human high grade invasive bladder carcinoma. Therefore, further studies are 
needed to address the increase in stromal SPARC expression and its impact on tumor 
progression. 
Human SPARC and Mouse SPARC mRNA Expression in Serial Heterotransplants 
 
 The stromal SPARC expression observed in the immunohistochemistry 
experiment prompted further investigation into the origin of the SPARC being expressed. 
SPARC is a secreted matricellular protein that acts in the extracellular space. Therefore, 
it was necessary to determine if the tumor cells were making human SPARC and 
secreting it into the surrounding support tissue; or, if the supporting mouse stromal tissue 
was expressing host SPARC. Results indicate high expression of mouse SPARC with no 
human SPARC detected in the majority of the tumor samples. Figure IV-5 (A) illustrates 
at least a 10-fold reduction in human SPARC expression across all serial heterotransplant 
samples compared to the UROtsa parent cell line control. Interestingly, only the initial, 
transplant 1, and transplant 2 Cd #1-SPARC cell line tumors and the initial Cd #1-
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SPARC Urosphere tumor showed any human SPARC mRNA expression; however, 
expression was not significantly different compared to the mouse brain negative control. 
 In contrast, Figure IV-5 (B) shows a substantial increase in mouse SPARC 
expression in all of the serial heterotransplant samples compared to the mouse brain 
positive control. Additionally, as expected, the human UROtsa cell line did not express 
any mouse SPARC. All samples showed at least a 1.5-fold increase in mouse SPARC 
expression, with the transplant 1 Cd #1-SPARC cell line tumor showing a 5-fold increase 
in expression. The initial and transplant 2 Cd #1-SPARC Urosphere tumors showed the 
lowest mRNA expression of mouse SPARC and also showed two of the lowest intensities 
of stromal staining in the immunohistochemistry results. Additionally, the apparent 
increase in stromal SPARC staining from the initial tumor to transplant 2 tumor, observed 
via immunohistochemistry, was not as evident with mouse SPARC mRNA expression 
analysis. This may be due to the overall high mouse SPARC mRNA expression 
compared to the mouse brain positive control, making changes in already high expression 
not obvious. Although there were slight discrepancies between mRNA expression and 
protein expression, identified via immunohistochemistry, overall, the stromal SPARC 
expression observed in the serial heterotransplant tumors was clearly identified to be of 
mouse and not human origin. These results suggest a complex interplay between tumor 
and stroma. 
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Figure IV-5. Human and Mouse SPARC mRNA Expression in Serial Bladder 
Heterotransplant Tumors. (A) Human and (B) mouse SPARC mRNA expression in 
serial heterotransplant tumor samples. For human SPARC expression, UROtsa parent cell 
line used as a positive control and mouse brain used as a negative control. For mouse 
SPARC expression, mouse brain used as a positive control and UROtsa parent cell line 
used as a negative control. Statistical analysis determined using one-way ANOVA with 
Dunnett’s Multiple Comparison post hoc test, represented as mean ±SEM. *(p≤0.05), 
**(p≤0.01), and ***(p≤0.001). 
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SPARC mRNA Expression in Cd #1-SPARC Cell Line Following Recombinant 
SPARC Treatment 
 
 Experiments to further investigate how exogenous SPARC expression affects 
endogenous SPARC expression led to exposing the Cd #1-SPARC cell line, which was 
utilized to generate heterotransplant tumors, to varying amounts of exogenous, 
recombinant human SPARC or mouse SPARC. Preliminary experiments determined 
effective amounts of exogenous SPARC that resulted in a decrease in endogenous 
SPARC expression (data not shown). A subsequent time course study determined the 
greatest effect at 36h post exposure (data not shown). Therefore, Cd #1-SPARC cells 
were exposed to 0.002µg – 2.0µg rhSPARC in 10-fold increments and 0.002µg – 20.0µg 
rmSPARC in 10-fold increments. The extra dose of rmSPARC was to account for 
crossing species from mouse to human. Results in Figure IV-6 (A) illustrate a significant 
decrease in endogenous SPARC expression with 0.2µg rhSPARC. Interestingly, there 
was a significant increase in endogenous SPARC expression with 0.002µg rhSPARC. 
Overall, there appears to be a significant decrease in expression with an attempt to return 
to baseline expression levels. This is similar to an inverted cytokine-like curve showing 
maximal activation followed by a return to baseline when receptors become saturated. 
 Exposure of Cd #1-SPARC cells to 0.02µg, and 2.0µg recombinant mouse 
SPARC also resulted in a significant decrease in endogenous SPARC expression, as seen 
in Figure IV-6 (B). Interestingly, this source of exogenous source did not show a 
significant increase in SPARC expression with the lowest dose, but rather, endogenous 
SPARC expression showed a slight, non-significant, decrease. Additionally, endogenous 
expression returned to baseline with 0.2µg rmSPARC and even showed a slight, non-
significant, increase above baseline at the highest exposure of 20.0µg. This also shows a 
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general bell-shaped curve, like that observed with receptor activation. Overall, it appears 
that exogenous sources of SPARC can contribute to endogenous repression of SPARC. 
 
Figure IV-6. SPARC mRNA Expression in Cd #1-SPARC Cells Exposed to 
Recombinant hSPARC or Recombinant mSPARC. Human endogenous SPARC 
mRNA expression in Cd #1-SPARC cells after 36h exposure to (A) rhSPARC and (B) 
rmSPARC. Expression normalized to untreated 0.0µg control. Statistical analysis 
determined using one-way ANOVA with Dunnett’s Multiple Comparison post hoc test, 
represented as mean ±SEM. *(p≤0.05), **(p≤0.01), and ***(p≤0.001). 
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Discussion 
 SPARC expression has been studied in various cancer types; showing tissue-
specific expression and function. Complicating these results, some tumor cells do not 
express SPARC; but, the supporting stromal cells express high levels of SPARC. Most 
often, in these instances, high stromal SPARC expression has been associated with a 
poorer patient outcome (Vaz et al., 2015). Additionally, increasing SPARC expression 
within tumor cells of some cancers has been associated with a more advanced stage (Vaz 
et al., 2015). Some mechanistic studies have elucidated proposed pathways involved in 
the roles of SPARC in various cancer types; however, the majority of studies are focused 
on SPARC expression and subsequent functional consequences of alterations in 
expression. SPARC expression in some cancers is better characterized than others. 
Overall, SPARC expression and function in bladder cancer remains to be fully 
characterized. This study aimed to determine SPARC expression in bladder urothelial 
serial heterotransplant tumors. 
 Previous results showed significant down regulation of SPARC in malignantly 
transformed cell lines and heterotransplant tumors (Larson et al., 2010, Slusser et al., 
2016). It was found that heterotransplant tumors downregulated SPARC expression; even 
after stable SPARC transfection in cadmium-transformed cell lines used to generate the 
tumors (Slusser et al., 2016). This was an interesting finding because the SPARC open 
reading frame was transfected into the cells under the control of a strong cytomegalovirus 
(CMV) promoter. Therefore, this observed significant downregulation of SPARC 
expression supports the hypothesis that SPARC is a tumor suppressor-like molecule in 
bladder urothelial carcinoma. Interestingly, the human high grade invasive carcinoma 
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tumor sample also showed repression of SPARC within the tumor cells; further 
supporting a tumor suppressor role for SPARC within tumor cells. Serial transplantation 
of tumor cells was used in this study to determine if SPARC expression could increase 
with successive tumor inoculations; or, if tumor initiation potential decreased with 
increasing SPARC expression within tumor cells. Immunohistochemical analysis 
revealed no increase nor maintenance of tumor cell SPARC expression, but an increase in 
stromal SPARC expression in three of the four groups. Additionally, the final serial 
tumor showed stromal SPARC staining similar to that of the human high grade invasive 
carcinoma.  
Importantly, the SPARC antibody used for this study was the same antibody used 
in previous SPARC studies performed in this lab, as described in Larson et al. (2010) and 
Slusser et al. (2016). It is a human-specific antibody; however, it appears to be staining 
the mouse fibroblast cells in the supporting stroma. There is a large degree of SPARC 
sequence and structure homology that has been conserved as species have evolved 
(Brekken and Sage, 2001). Therefore, it is likely that the SPARC antibody is recognizing 
both human and mouse SPARC. Antibody specificity as well as experimental 
methodology can be a complicating factor in studies and result in muddling the literature. 
Tai and Tang (2008) addressed differences in antibody usage resulting in slight 
discrepancies regarding ovarian cancer cell SPARC expression in the literature. This 
same argument can be made for SPARC expression in other cancer types as well, 
reinforcing the use of good, consistent antibodies. 
 It was determined in this study that the stromal SPARC observed in the tumor 
samples was of mouse and not human origin. It is imperative to decipher between tumor 
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cell- and stromal cell-derived SPARC in order to accurately determine expression as well 
as a functional role for SPARC in cancer. As discussed earlier, SPARC has tissue specific 
expression and function (Brekken and Sage, 2001). Therefore, stromal SPARC could be 
supporting tumor growth and progression while tumor cell SPARC expression has an 
inhibitory role. Overall, SPARC expression levels are downregulated in bladder cancer 
cells (Said and Theodorescu, 2013). However, one study proposed an increase in SPARC 
expression within the tumor cells, coinciding with an increase in MMP-2 expression 
(Yamanaka et al., 2001). Importantly, tumors in this study were not devoid of stroma and 
it was not discussed if the SPARC observed was derived from tumor or stroma 
(Yamanaka et al., 2001). Therefore, it is possible that the increase in SPARC expression 
is, in fact, an increase in stromal, rather than tumor cell, SPARC expression associated 
with increasing bladder tumor grade and aggressiveness. 
Interestingly, mechanisms of action for SPARC have been proposed for these 
cancer types; however, the majority of the proposed mechanisms described are attributed 
to functional consequences of changes in SPARC expression within the tumor cells and 
not the stromal cells (Tai and Tang, 2008). Two important roles that have been proposed 
for stromal SPARC are its involvement in matrix modulation as well as dysregulation of 
growth factor functions; both of which can have severely detrimental downstream 
cellular effects (Brekken and Bradshaw, 2010). While the tumor cells themselves may 
show variable expression of SPARC, the supporting stroma appears to be highly positive 
for SPARC expression in pancreatic, ovarian, and bladder cancers (Vaz et al., 2015, 
Brown et al., 1999, Larson, et al., 2010). The results from this study are similar. It is 
possible the variable tumor cell SPARC expression observed is random and hence not 
 144 
 
consistent. It is also possible that stromal-derived SPARC is being internalized by a 
subset of tumor cells and eliciting its effects inside the cell. However, Chlenski et al. 
(2011) determined that internalized SPARC is quickly shuttled back into the extracellular 
matrix. This provides further evidence of a potential role for SPARC in matrix 
modulation and growth factor regulation, ultimately leading to tumor progression. 
Additionally, SPARC has been shown to have limited intracellular roles; 
however, some include: inducing cell cycle arrest via cyclin and inhibitor molecule 
dysregulation, promoting apoptosis via direct interaction with pro-caspase 8, and 
potentially involvement in matrix modulation via intracellular chaperoning of molecules 
important for collagen fibrillogenesis (Mao et al., 2014, Tang and Tai, 2007, Emerson et 
al., 2006, Brekken and Bradshaw, 2010). It is plausible that stromal SPARC is being 
internalized by the bladder tumor cells, as the RT-PCR results did not reveal any 
substantial increase in human SPARC expression. 
The increase in stromal SPARC expression observed in 3 of the 4 groups, along 
with exogenous recombinant SPARC treatment in SPARC-expressing malignant cells, 
indicates a potential tumor-promoting role for stromal SPARC. An important role for 
SPARC is in matrix modulation (Brekken and Bradshaw, 2010). Furthermore, SPARC 
has been shown to be involved in a positive feedback loop with matrix 
metalloproteinases, specifically, MMP-2 and MMP-9 (Arnold et al., 2008). Activation of 
MMP-2 by SPARC has been observed in breast cancer cell lines (Gilles et al., 1998). In 
turn, MMP-2 has been shown to proteolytically cleave SPARC increasing its collagen-
binding affinity (Sasaki et al., 1998). This becomes important for SPARC’s ability to 
modulate the matrix environment. It is possible that the observed increase in stromal 
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SPARC expression in the serial bladder heterotransplant tumors is increasing MMP-2 
activation, as well as other matrix metalloproteinases, thereby increasing SPARC’s 
ability to promote tumor progression and invasion. MMP-2 cleavage of SPARC could 
result in matrix composition changes as well as a decrease in matrix strength promoting 
invasion and migration. Although there were no characteristic features identified by the 
pathologist, from the initial tumor to the final transplant 2 tumor, that indicated disease 
progression; it is possible increases in stromal SPARC expression may indicate early 
signs of bladder urothelial carcinoma progression. Alternatively, increased stromal 
SPARC expression could contribute to changes in the microenvironment increasing 
susceptibility to tumor recurrence. 
Stromal SPARC could also be regulating growth factor interaction with the 
bladder cancer cells. SPARC has been described to interact both directly and indirectly 
with several growth factors including: VEGF, PDGF, FGF, and TGF-β (Brekken and 
Sage, 2001). These growth factors are necessary for normal cell function, making them 
ideal targets for dysregulation contributing to tumor initiation and/or progression. 
Importantly, SPARC has been shown to inhibit PDGF, VEGF, basic (b)FGF, and TGF-β-
stimulated proliferation in various cells (Motamed et al., 2002, Kupprion et al., 1998, 
Sage et al., 1995, Schiemann et al., 2003). Additionally, SPARC was shown to reduce the 
migration of bovine aortic endothelial cells via bFGF (Hasselaar and Sage, 1992). In this 
study, it is possible that tumor cell SPARC is, in fact, contributing to the inhibition of cell 
proliferation via growth factor regulation; therefore, requiring SPARC repression. 
Alternatively, stromal SPARC may be contributing to tumor initiation and progression 
via its feedback mechanism involving TGF-β.  
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Studies show that increased SPARC expression results in increased TGF-β 
expression in mesangial cells and vice versa in dental pulp cells and keratinocytes 
(Francki et al., 1999, 2004, Shiba et al., 1998, Ford et al., 1993). Interestingly, TGF-β has 
been shown to be important for pancreatic ductal adenocarcinoma (PDAC) as well as 
invasive mammary adenocarcinoma progression (Ungefroren et al., 2011). Like SPARC, 
TGF-β plays multiple roles in various cancers (Drabsch and Dijke, 2011, Truty and 
Urrutia, 2007). While all roles are important, here, more relevant roles may include TGF-
β induction of epithelial to mesenchymal transition (EMT) as well as immune evasion. 
Although the bladder tumor cells significantly repress SPARC expression, it is plausible 
that the CAFs in the surrounding stroma show up-regulated TGF-β concomitant with the 
observed increase in stromal SPARC expression, based on various studies suggesting a 
positive feedback loop (Brekken and Sage, 2001). In the stroma, enhanced TGF-β 
expression, via increased SPARC expression, could continue to stimulate fibroblast 
conversion to CAFs as well as promote EMT at the leading edge of the tumor 
(Ungefroren et al., 2011, Drabsch and Dijke, 2011). Additionally, once a cancer has been 
established, TGF-β can promote tumor progression via immune evasion (Flavell et al., 
2010). TGF-β functions as an immunosuppressive molecule in the microenvironment by 
reducing the activity of anti-tumor immune cells such as: natural killer (NK) cells, 
dendritic cells, macrophages, and neutrophils; as well as, recruiting pro-tumorigenic 
immune cells such as: regulatory T cells, alternatively activated M2 macrophages, 
immature dendritic cells, and tumor associated macrophages (TAMS), among others 
(Flavell et al., 2010). This, in conjunction with the physical barrier created from matrix 
modulation by CAFs in the stroma, indicate a potential indirect role for stromal SPARC, 
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via TGF-β upregulation, in contributing to immune evasion and successful tumor 
initiation and progression (Ziani et al., 2018). 
It is possible that, in humans, SPARC expression in the stroma surrounding the 
bladder urothelial carcinoma tumor is contributing to the SPARC repression observed 
within the tumor cells, and, up-regulating TGF-β to promote: tumor cell EMT, CAF 
conversion, as well as immune evasion. This change in the microenvironment could 
ultimately lead to tumor progression and/or increased risk of recurrence, which is a 
significant problem in bladder urothelial carcinoma. Unfortunately, upregulation of 
SPARC in the supporting stroma has been associated with poor patient outcome in a 
variety of cancers (Vaz et al., 2015). Overall, results from this study indicate SPARC 
repression, within the bladder tumor cells. Whether the decrease in SPARC expression is 
needed for initial tumor cell survival and growth is unknown; however, it is clear that 
expression of endogenous SPARC is not needed and/or required for continued tumor cell 
growth and survival. Therefore, with more research, SPARC could be a target of 
diagnostic and/or prognostic value for bladder urothelial carcinoma.
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CHAPTER V 
DISCUSSION 
 This study aimed to determine a role for SPARC in an in vitro model of heavy 
metal cadmium-induced bladder urothelial carcinoma. Bladder cancer has a strong link to 
environmental toxicant exposure (Inamura, 2018), making our in vitro system a relevant 
model to study bladder urothelial carcinoma. Previous long-term, low-dose exposure to 
cadmium, led to UROtsa bladder cell transformation, and ultimately, seven independent 
malignant cell populations (Sens et al., 2004, Somji et al., 2010). This transformation 
resulted in a number of genes showing differential expression compared to the 
untransformed UROtsa parent cell line (Garrett et al., 2014). SPARC showed a strikingly 
significant repression in all seven independent cadmium malignantly transformed cell 
lines (Larson et al., 2010, Garrett et al., 2014). Heterotransplant tumors generated from 
these cell lines along with archived human bladder cancer tumors showed significant 
repression of SPARC within tumor cells (Larson et al., 2010). Heterotransplant tumors 
generated from Cd2+-transformed cells stably transfected with SPARC, still lacked any 
detectable SPARC expression (Slusser et al., 2016). Furthermore, tumors generated from 
the proposed tumor initiating cell subpopulation, Urospheres, showed 5-20% focal 
SPARC expression, which was an increase from the previous tumors; however, still an 
overall decrease in tumor cell SPARC expression (Slusser et al., 2016). This consistent 
repression in: malignant cell lines, heterotransplant tumors, and archived human bladder 
cancer tumors, in conjunction with, literature suggesting SPARC repression in bladder 
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cancer, motivated further research into SPARC expression and function in our model 
system. This study focused on three central hypotheses: 1) SPARC plays a critical role in 
urothelial cell proliferation, migration, attachment, and spreading; 2) Cadmium 
transformation significantly decreases SPARC expression by silencing the promoter early 
in the malignant transformation process; and 3) that in urothelial tumors generated from 
Cd2+-transformed cell lines, SPARC is prohibitive to tumor initiation. 
 Previous studies investigated SPARC’s role in proliferation, migration, and 
invasion of malignantly transformed UROtsa cells (Larson et al., 2010, Slusser et al., 
2016). Results showed no clear cell biological explanation for SPARC’s absence in 
bladder tumors (Larson et al., 2010, Slusser et al., 2016). Chapter II details investigation 
into SPARC’s role in several cell biological processes, focusing mainly on cell 
attachment and spreading. These are both necessary for cell survival and SPARC has 
been implicated to play a role in them (Chen et al., 1997, Bradshaw and Sage, 2001). 
Some studies measure either attachment or spreading (Lee et al., 2017). Several studies 
do measure both attachment and spreading, but the experimental time points extend 
several hours (Sage et al., 1989, Everitt and Sage, 1992, Motamed and Sage, 1998, 
Hudson et al., 2005, Delostrinos et al., 2006, Zhang et al., 2011). Additionally, all of the 
referenced studies added exogenous SPARC to the cell cultures. Our study was unique 
from the aforementioned studies by assessing both attachment and spreading on collagen 
I, in the presence or absence of only cell-derived SPARC, with a single assay during the 
active initial attachment phase. Furthermore, when heterotransplant injections are made 
subdermally, as detailed in chapter IV, the matrix molecule encountered at the highest 
concentration is collagen I. The SPARC binding site on collagen I has been shown to 
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overlap with the cell surface discoidin domain receptor (DDR) and integrin receptor 
binding sites (Giudici et al., 2008); therefore, it is possible that SPARC is competing for 
collagen binding and ultimately interfering with cell attachment. Here, results did not 
show a significant decrease in cell attachment, as was expected. Preliminary results did 
show a decrease in cell attachment to a collagen I matrix; however, subsequent 
experimental troubleshooting required a decrease in the number of cells plated in order to 
accurately and efficiently count and classify cells. Therefore, it is possible that by 
reducing the cell number, the concentration of secreted SPARC was also decreased far 
enough to abrogate its effect on cell attachment. The lack of sufficient SPARC in the 
surrounding media may have resulted in a number of integrin receptor binding sites left 
available on the collagen I fibers, leading to adequate cell attachment. It is also possible 
that the initial cell attachment stimulates SPARC secretion into the matrix; therefore, not 
affecting cell attachment but rather affecting cell spreading. 
Experimental results did show a significant increase in cell spreading in the 
presence of SPARC during the active cell attachment phase. SPARC has been described 
in several systems as a de-adhesive protein, inducing cell rounding by abrogating focal 
adhesions (Bradshaw and Sage, 2001). However, these experiments were performed on 
confluent monolayers and newly attached cells in alternative systems with exogenous 
SPARC added to cultures (Bradshaw and Sage, 2001). One study found increased cell 
spreading of SPARC-transfected murine F9 embryonal carcinoma stem cells when 
cultured in a Ca2+-deficient environment (Everitt and Sage, 1992). Our system does show 
increased cell spreading in SPARC expressing cells; but, there is sufficient calcium 
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present in the medium. Therefore, this is likely not contributing to the results found in 
this study. 
Limited studies have assessed urothelial cell spreading in regards to SPARC 
expression. However, two studies found that exogenous SPARC inhibited spreading of 
urothelial cells (Hudson et al., 2005, Delostrinos et al., 2006, Zhang et al., 2011). Unique 
to our study, cell spreading was analyzed every 15 minutes, up to 1 hour on collagen I; 
and, only endogenous, urothelial cell-derived SPARC was present in cultures. 
Experimental results showed a contradictory role for endogenous SPARC in promoting 
cell spreading of a newly attached cell; that, with siRNA knockdown of SPARC 
expression was abrogated. Integrin α2β1 was found to bind to collagen I fibrils and 
promote cell spreading as well as formation of extended cellular projections of α2β1 - 
transfected Chinese hamster ovary cells and α2β1 - transfected human osteosarcoma Saos-
2 cells (Jokinen et al., 2004). Therefore, SPARC may be preferentially competing with 
alternative integrin and discoidin domain receptors for binding to collagen I, leaving 
available α2β1 integrin binding sites. Furthermore, without the addition of exogenous 
SPARC in the extracellular environment, there may be inadequate competition for 
binding with the integrin-binding sites on collagen I fibrils; ultimately leading to proper 
cell attachment and quicker subsequent spreading. 
Also unique to this study was the analysis methodology utilized for attachment 
and spreading assay quantitation. Several methods have been used to analyze cell 
attachment and spreading, including simple observation quantified using a rounding 
index (RI) by Lane and Sage, 1990. Initial experiments in this study utilized observation 
and a similar classification method. However, the experimental set up made this method 
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extremely time consuming as well as harbored a level of human bias in classification of 
cells. Therefore, implementation of software analysis was necessary to make attachment 
and spreading analysis more efficient and to reduce the human bias associated with 
observational classification. 
Several studies have worked to implement software analysis into experimental 
methods for counting cells as well as analyzing cell morphology (Costa and Yang, 2009, 
Dehlinger et al., 2013, Ambühl et al., 2012, Carpenter et al., 2006, Garvey et al., 2016). 
However, expense and user friendliness were challenges associated with these programs. 
This study implemented the freely available Fiji software for the initial pre-processing of 
attachment and spreading images, which reduced the halo effect using the PHANTAST 
plugin (Jaccard et al., 2014a), and created more contrast between the cells and the 
background. Many of the software analysis programs also had trainable classification 
systems that categorized cells based on morphology (Jaccard et al., 2014b, Jaccard et al., 
2015, Theriault et al., 2012). But, again, user friendliness was an issue. Intriguingly, 
Leica Microsystems, Inc. had a software package, LASX, with analysis capabilities and 
the advantage of being user friendly. However, this software was made for fluorescent 
images rather than gray-scale phase contrast images. The pre-processing performed in 
Fiji allowed the two programs to be used in conjunction resulting in successful 
attachment and spreading analysis. The software classification reduced the impact of 
human bias by using the same trained classifier for every image as well as provided a 
level of consistency throughout the analysis. To the author’s knowledge, this is the first 
study utilizing Leica LASX software for analysis of non-fluorescent images that have 
been pre-processed using Fiji. 
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Overall, it appears that SPARC plays a role in promoting spreading of newly 
attached urothelial and SPARC-transfected urothelial carcinoma cells. This is a potential 
role that is necessary to shut down in order to promote tumor initiation and progression. 
The Cd2+-transformed urothelial carcinoma cells lack any detectable SPARC expression 
(Larson et al., 2010) and the Cd #1 cell line showed delayed cell spreading. Interestingly, 
all cell lines, SPARC expressing and non-SPARC expressing, show no significant 
morphological differences at confluency; with all lines showing an epithelial cell 
morphology (Rossi et al., 2001, Somji et al., 2010, Slusser et al., 2016). Therefore, it is 
possible the non-SPARC expressing cells are using an alternative molecule or molecules, 
such as SPARC family members, to aid in cell spreading; however, this process may not 
be as efficient as in the presence of SPARC. Additionally, the alternative molecules may 
not have as many diverse roles and therefore, may not be as prohibitive to bladder 
urothelial tumor initiation and progression. 
The significant repression found after cadmium transformation of UROtsa cells, 
warranted investigation into the mechanism behind the downregulation of SPARC. 
Previous studies in the lab examined the methylation status of the SPARC promoter as it 
had been described to be hypermethylated in several cancer types (Larson et al., 2010, 
Brekken and Bradshaw, 2010). However, results indicated no significant differences in 
the DNA methylation status of the SPARC promoter between the UROtsa parent cells 
and the Cd2+-transformed cells (Larson et al., 2010). Additionally, previous analysis of 
several miRNAs did not reveal any significant difference in miRNA expression in the 
transformed cell lines that may be contributing to SPARC repression (unpublished data). 
This motivated investigation into an alternative mechanism for regulation of the SPARC 
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promoter, as detailed in Chapter III, with the hypothesis that cadmium transformation 
significantly decreases SPARC expression by silencing the promoter early in the 
malignant transformation process. The decrease in SPARC expression within UROtsa 
parent cells can be observed within the first 24 hours following cadmium exposure and 
continues through the process of cell transformation (Larson et al., 2010). These results 
indicated a role for cadmium in SPARC repression early in the malignant transformation 
process. However, cadmium does not directly bind to DNA, likely making its 
involvement in SPARC downregulation indirect. 
Cadmium has been shown to replace zinc in zinc-finger transcription factors, 
rendering them inactive (Bertin and Averbeck, 2006). Kothinti et al. (2010b) showed that 
human recombinant Sp1 exposed to Cd2+ lost its DNA binding affinity. Further 
experiments showed that Cd2+ replacement of zinc in Sp1 zinc-fingers resulted in 
structural changes with less favorable side chain - DNA base pair interactions; and, that 
there may be preferential targeting of Cd2+ to Zn2+ within unbound Sp1 (Kothinti et al., 
2010b). Preliminary results performed in our lab indicated potential alterations in 
transcription factor expression in the Cd2+-transformed cell lines. Additionally, Sp1 and 
Sp3 zinc-finger transcription factors have been implicated in binding to the SPARC 
promoter activating gene transcription (Chamboredon et al., 2003, Vial et al., 2000, Xu et 
al., 2010). Alternatively, SOX5 transcription factor has been implicated in binding to the 
SPARC promoter inhibiting gene transcription (Huang et al., 2008). Therefore, this study 
focused on alteration of transcription factor binding to the SPARC promoter, induced by 
cadmium malignant transformation. 
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Results from chromatin immunoprecipitation (ChIP) experiments showed Sp1 and 
Sp3 binding to the SPARC promoter in the UROtsa parent cells; however, there did not 
appear to be any binding of these transcription factors to the SPARC promoter in the Cd 
#1 cells. Furthermore, there appeared to be enhanced binding of the SOX5 transcription 
factor to the SPARC promoter in the Cd #1 cells compared to the UROtsa parent cells. 
Preliminary experiments showed downregulation of Sp1 and Sp3 following exposure to 
cadmium (unpublished data). However, mRNA and protein expression analysis in this 
study indicated no significant difference in transcription factor expression between non-
transformed UROtsa parent cells and transformed Cd #1 cells. Transcription factor 
expression is tightly regulated to prevent aberrant gene transcription and abnormal cell 
behavior. Therefore, it is possible that cadmium is initially replacing zinc in the Sp1 and 
Sp3 transcription factors, inactivating them and promoting their degradation. These 
transcription factors have thousands of gene targets and knocking out both of them is 
lethal. Therefore, following transformation, and removal of cadmium, it is likely the cells 
continue to express functional Sp1 and Sp3 transcription factors. However, they may be 
preferentially binding to higher affinity targets. SPARC does not contain a typical TATA 
box and therefore requires co-factors for proper gene transcription (Vizcaíno et al., 2015). 
However, there is a GGA-rich motif that is known to be a binding site for Sp1 and Sp3 
transcription factors (Vial et al., 2000); therefore, SPARC could be a lower order gene 
target for these ubiquitous transcription factors, resulting in its repression. 
Alternatively, cadmium is known to indirectly induce oxidative stress and 
subsequent DNA damage (Rani et al., 2014, Bertin and Averbeck, 2006). SPARC 
promoter may be a target of DNA damage thus resulting in its repression. This could 
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become permanent if the repression is advantageous to the cell’s survival. For example, 
repression of a secreted protein may result in beneficial energy saving for a malignant 
cell requiring extra energy and nutrients for survival. Additionally, as stated earlier, 
SPARC repression inside tumor cells may be advantageous by decreasing SPARC’s pro-
apoptotic activity as well as its regulation of cell cycle progression (Tang and Tai, 2007, 
Said, 2016). In the case of the serial heterotransplant study, SPARC, with potential tumor 
promoting activities, is abundantly found in the supporting stroma which could further 
contribute to its permanent repression within tumor cells.  
The link between cadmium and the SOX5 transcription factor is not as obvious as 
that with Sp1 and Sp3, in part because it is not a zinc-finger transcription factor. Reports 
in the literature have shown that Sp1 recruits chromatin remodeling complexes to the 
promoter region for gene transcription (Li and Davie, 2010). One study found Sp1 co-
localized with Brg-1 ATPase to the SPARC promoter region activating gene transcription 
(Xu et al., 2010). Without Brg-1 ATPase and chromatin remodeling complex recruitment 
to the promoter, SPARC gene transcription was repressed (Xu et al., 2010). Therefore, if 
cadmium is initially replacing zinc in the Sp1 and/or Sp3 transcription factors, they 
cannot bind the DNA. Subsequently, the chromatin remodeling complexes will not be 
associated with the promoter region resulting in gene repression due to inaccessible 
chromatin. Additionally, chromatin accessibility changes, resulting from cadmium 
exposure, may result in preferential availability of SOX5 binding sites on the SPARC 
promoter, further contributing to gene repression. The initial SPARC repression in 
UROtsa parent cells, following cadmium exposure (Larson et al., 2010), may be 
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advantageous; therefore, requiring subsequent mechanisms to aid in the permanent 
SPARC repression observed in the Cd2+-transformed cells. 
Following ChIP experiments, further experimentation assessed SPARC 
expression after siRNA knockdown of Sp1, Sp3, or SOX5 transcription factors. Sp3 
transcription factor showed the most consistent knockdown in both the UROtsa parent 
cells and Cd #1 cells without knockdown in the control samples. Additionally, 
knockdown of Sp3 resulted in a significant reduction of SPARC expression in the 
UROtsa parent cells. Alternatively, SOX5 knockdown resulted in a significant increase in 
SPARC expression in Cd #1 cells. There did appear to be variability in control samples 
that could be the result of stress from transfection. These results indicate potential 
necessary transcription factors for activation of SPARC expression in the UROtsa parent 
cells as well as inhibition of SPARC expression in Cd #1 cells. 
This study addressing cadmium regulation of the endogenous SPARC promoter is 
somewhat separate from the other two studies described here. Our in vitro system 
presented an ideal model to investigate the endogenous SPARC promoter in UROtsa 
parent cells that express SPARC as well as in Cd #1 cells that significantly repress 
SPARC expression. The Cd #1-SPARC transfected cells do express SPARC; however, 
only the SPARC open reading frame was transfected into the cells under the control of 
the strong CMV promoter rather than the endogenous SPARC promoter (Slusser et al., 
2016). This enables a more stable expression of a gene that is significantly repressed, 
otherwise. Therefore, the Cd #1-SPARC cell line could not be used for this study. 
Overall, it was determined that cadmium exposure may be altering transcription factor 
binding to the SPARC promoter; therefore, contributing to SPARC repression. It is clear 
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this repression is happening early in the malignant transformation process; however, the 
exact mechanism remains to be determined. It is likely the significant repression is the 
result of a combination of mechanisms working together; as evidenced by human 
urothelial carcinoma tumors also showing significant repression of SPARC. Further 
research may provide insight into the direct or indirect role cadmium is playing to 
contribute to the permanent repression of SPARC in our model system of cadmium 
induced bladder urothelial carcinoma. 
Chapter IV outlines, in detail, the examination into SPARC’s expression and 
function in bladder urothelial tumor initiation and progression. Previous results from 
Larson et al. (2010) and Slusser et al. (2016) led to the hypothesis that in urothelial 
tumors generated from Cd2+-transformed cell lines, SPARC is prohibitive to tumor 
initiation. The goal for this study was to determine if serially transplanted 
heterotransplant tumors showed an increase in SPARC expression; and, additionally, if 
tumor initiation potential decreased with increased tumor cell SPARC expression. Results 
from the serial heterotransplant study showed an overall repression of human SPARC 
expression within the tumor cells; but, increased mouse SPARC expression in the 
supporting stromal tissue. The expression of SPARC in the stroma of the heterotransplant 
tumors was similar to that observed in Larson et al. (2010). The literature presents 
conflicting results regarding SPARC in cancer. It has been shown to be overexpressed in 
some cancers, including melanomas and gliomas; but, repressed in others, such as 
ovarian, pancreatic, and prostate cancers (Nagarju et al., 2014). This is further 
complicated by the intricate dynamics between tumor and host. Increased SPARC 
expression within supporting stromal cells has been reported to be associated with poor 
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patient prognosis in several cancers (Vaz et al., 2015). Many studies examine tumor 
SPARC expression or stromal SPARC expression; however, few distinguish between the 
two sources, or address both sources of SPARC. It is necessary to consider tumor and 
stromal SPARC to better understand the impact one source versus the other has on 
tumorigenesis and progression. This is especially important because of SPARC’s well 
described tissue-specific expression and proposed function. 
Although there were no characteristic signs of progression observed in this 
experiment, the serial heterotransplant experimental results do suggest an inherent need 
for SPARC to be repressed within tumor cells for tumor initiation and possibly 
progression. The tumor microenvironment has been shown to provide a physical barrier 
between the tumor and the immune system, promoting immune evasion (Ziani et al., 
2018). Therefore, the increased SPARC expression in the surrounding stroma may serve 
to help disguise the tumor with an environment showing SPARC expression similar to 
that of normal tissue promoting immune evasion. Subsequently, the increased SPARC in 
the stroma could be altering the microenvironment in such a way as to promote tumor 
recurrence by matrix modulation and prolonged indirect immune suppression via TGF-β 
regulation. SPARC has been shown to interact with and regulate several extracellular 
matrix molecules (Yan and Sage, 1999), creating a complex web of direct and indirect 
interactions; all of which could contribute to tumor initiation and progression. 
Additional experiments in this study showed that recombinant SPARC added to 
Cd #1-SPARC transfected cell cultures resulted in a decrease in endogenous SPARC 
expression. Interestingly, there was a trend toward a return to baseline expression 
observed in untreated cells, similar to an inverted cytokine response indicating decreased 
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activity due to receptor saturation. These results further show a potential paracrine role 
for SPARC that may contribute to tumor cell repression of SPARC. The concentration of 
recombinant SPARC used may not have been high enough; or, an additional mechanism 
may be necessary to achieve a stronger repression within tumor cells. It is possible that 
the high concentration of SPARC in surrounding stromal cells is enough to elicit a more 
significant repression, as was seen within the serial heterotransplant tumor cells. It is also 
plausible that the high stromal SPARC expression is sufficient for proper and/or 
enhanced tumor cell function, allowing the tumor cells to stop expending energy 
producing and secreting SPARC.  
Reports in the literature suggest that addition of recombinant SPARC to cell 
cultures induces cell rounding and anti-spreading characteristics (Sage et al., 1989, 
Everitt and Sage, 1992, Hudson et al., 2005, Delostrinos et al., 2006). This provides a 
potential link between: the serial heterotransplant, recombinant SPARC, and the cell 
attachment and spreading experiments in this study. It is possible that the increase in 
stromal SPARC expression observed in the serial heterotransplant study is contributing, 
via paracrine action, to the downregulation of SPARC within the tumor cells and 
potentially leading to delayed cell spreading and promotion of tumor initiation and 
progression. Although there did not appear to be any rounding of the Cd #1-SPARC cells 
in response to recombinant SPARC exposure, the concentrations used in this study may 
not have been high enough. Hudson et al. (2005) found rounding of cells at rSPARC 
concentrations of 10 µg/mL or higher. However, as stated earlier, there was a decrease in 
SPARC expression with recombinant SPARC exposure. Furthermore, siRNA knockdown 
of SPARC in Cd #1-SPARC cells resulted in delayed cell spreading and a larger portion 
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of the cell population displaying a rounded or early spreading phenotype. Together, these 
results suggest a potential necessary repression of endogenous SPARC prior to obtaining 
changes in morphology. 
The Cd #1 cells that do not express SPARC, do not show any differences in 
morphology when compared to the UROtsa parent and Cd #1-SPARC transfected cells at 
confluency (Rossi et al., 2001, Somji et al., 2010, Slusser et al., 2016). It is plausible that 
alternative proteins and/or mechanisms are in place to aid in cell attachment and 
spreading; however, slightly delayed from that promoted by SPARC. In the case of the 
serial heterotransplant experiment, the extracellular environment has several components 
for cells to bind to when compared to the in vitro cell attachment and spreading study 
using only collagen I. Therefore, SPARC may also indirectly affect cell spreading 
through regulation of cell interaction with other extracellular matrix molecules. Overall, 
it appears that SPARC is necessary to be shut down within tumor cells for proper tumor 
initiation and progression.  
Although the mechanism for its significant repression remains to be determined; 
the lack of SPARC expression in serially transplanted tumor cells indicates a strong 
tumor suppressor-like role for tumor cell-derived SPARC. Few intracellular roles have 
been proposed for SPARC; however, it is possible that SPARC acts intracellularly within 
bladder urothelial tumor cells to potentially inhibit cell cycle progression and promote 
apoptosis, as described in Said (2016) and Tang and Tai (2007). This could explain the 
low levels of SPARC protein observed in the cell lysate of Cd #1-SPARC cells, and the 
higher levels of secreted SPARC from the same cells. Stromal SPARC may exert a more 
oncogenic activity on the tumor cells via differential regulation of growth factors to 
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promote angiogenesis and immune system evasion as well as matrix modulation to 
promote invasion and metastasis. 
With bladder cancer’s strong link to environmental toxicant exposure, our in vitro 
system is a relevant model to study various characteristics of bladder cancer. A 
significant number of genes were differentially expressed following cadmium malignant 
transformation; however the one gene consistently repressed among the transformed cell 
lines was SPARC (Larson et al., 2010, Garrett et al., 2014). SPARC also shows 
significant repression among the majority of human bladder urothelial tumors (Larson et 
al., 2010, Said, 2016). However, conflicting results are present in the literature due to 
lack of differentiation between tumor cell-derived SPARC and stromal SPARC 
expression, as well as poor antibody quality for specifically recognizing human SPARC. 
Although transgenic mice have been developed that lack SPARC expression and 
it does not appear to be a lethal mutation, the high level of sequence conservation 
throughout evolution points to an important role for this matricellular protein (Brekken 
and Bradshaw, 2010). The differential expression of SPARC in various cancers also 
suggests important tissue-specific roles for SPARC that make it an ideal target to up- or 
downregulate for tumor initiation and progression. However, this variability in expression 
and function also make it a more difficult molecule to target in clinical applications; 
which, is the ultimate goal. Bladder cancer is the most expensive cancer to treat per 
patient lifetime (Kaffenberger et al., 2018, Jung et al., 2018), pointing to a desperate need 
for prognostic and/or diagnostic tools to reduce this burden and increase patient quality of 
life. 
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There is still more research to be done to better understand the role SPARC plays 
in bladder urothelial carcinoma; which, requires differentiation between tumor-derived 
SPARC and stromal SPARC, as well as an understanding of the complex interplay 
between tumor and host. Overall, results from this study determined a potential role for 
SPARC in cadmium-induced bladder urothelial carcinoma that may require suppression 
for proper tumor initiation. Additionally, the observed increase in stromal SPARC 
expression and overall decrease in tumor cell SPARC expression in serial 
heterotransplant tumors, indicates a substantial change in the microenvironment that may 
promote tumor progression as well as prime the microenvironment for subsequent tumor 
recurrence. SPARC is a molecule of considerable interest that with further insight into its 
specific mechanism of action, could be a target for future bladder urothelial carcinoma 
diagnosis or treatment.
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